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Abstract 
 
The high level of diversity exhibited by genes coding for molecules involved in the 
immune system are critically involved with several aspects of human health. The ability 
of the immune system to recognize foreign pathogens or abnormal cells, while tolerating 
itself is achieved through a balance of various components and receptors in the immune 
system. Individual genotypes of immune genes such as HLA and KIR fine-tune this 
balance. Variability in those genes lead to diversity in the response to foreign molecules, 
and can also lead to intolerance to self-molecules in the form of autoimmune responses. 
Several past studies have found HLA and KIR polymorphisms to be associated with 
susceptibility or protection to a range of diseases and hypersensitivity to drugs. HLA has 
also a major role in transplantation, where transplanted tissues need to be as similar as 
possible to avoid rejection. The work described in this thesis contributes towards the 
knowledge of immunogenetic implications in associations with diseases, transplantation 
and adverse reactions to drugs using different bioinformatics approaches. First, it 
provides bioinformatics resources for a better understanding of the impact of 
immunogenetic diversity on human health in the form of two public databases, alongside 
with insights obtained through the analysis of their contents. The KIR and Disease 
Database (KDDB), described in Chapter 2, stores disease associations with KIR genes 
expressed in natural killer cells. The data within KDDB has been analysed to uncover 
trends within studies, in terms of the sets of KIR genes associated with susceptibility to, 
or protection from, auto-immune diseases, infectious diseases, pregnancy complications 
and cancer. The HLA Epitope Frequency Database (EpFreq-DB), described in Chapter 
3, stores population frequencies of HLA epitopes, which are structural units on the 
surface of HLA molecules that have been increasingly associated with improvements in 
transplantation matching. An analysis has been performed to demonstrate global 
differences in the carriage of particular epitopes, and the potential functional 
consequences of using epitope mapping, instead of the more traditional allele matching 
for transplantation scenarios. Lastly, it investigates the molecular mechanisms underlying 
the association HLA polymorphisms with severe hypersensitivity caused by the anti-
retroviral drug nevirapine, using molecular docking approaches. Developments described 
in this thesis contribute to better understanding of the influence of immune variability in 
human health and provides necessary knowledge to advances in personalized medicine.  
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Chapter 1  
Investigations in Immunogenetics 
 
1.1 The human immune system 
The human immune system is a complex system composed of cellular and humoral 
(extracellular macromolecules) components whose primary function is to defend the 
organism against pathogens. Its components and mechanisms are divided in two 
interrelated subsystems. The innate immune system is responsible for an initial and immediate 
response during an encounter with pathogens being able to recognize foreign molecules 
generally present in pathogens and to detect abnormal cells infected by viruses or 
transformed in tumour cells. The adaptive immune system launches a posterior, but more 
effective and specific response, which is also capable of “remembering” an infection, 
being able to quickly release the more effective response in case of re-infection. Although 
the primary function of the immune system is fighting foreign pathogens, it also interacts 
with other physiological mechanisms, such as pregnancy, and can be influenced by 
various other factors such as sleep and diet. 
A characteristic of the human immune system is the remarkable genetic variability, 
innately present in germline genes or acquired by somatic recombination, of key 
molecules participating in the detection of invading microorganisms. This high molecular 
diversity is essential for the capability of the immune system to react and adapt its 
response to a wide range of ever evolving pathogens. The high number of immunogenetic 
polymorphisms maintained in the human population results in significant differences in 
the genetic makeup of immune genes between individuals, generating a consequent inter-
individual variability in the manifestation of the immune system response against various 
microorganisms or tumours. Some of this variation can also lead to malfunctions of the 
immune response and cause autoimmune diseases, where the mechanisms that prevent 
the organism to react against itself get disrupted. Inter-individual difference of immune 
genes is also a crucial factor to be assessed prior to transplantation procedures to avoid 
elicitation of immune responses caused by antigens expressed by immune genes which 
are different from the ones possessed by the patient.
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Although the immune system is conventionally subdivided in innate and adaptive 
immune systems, all the cells participating in the immune system are leukocytes originated 
from progenitor stem cells in the bone marrow. After maturing into diverse cell types, 
they migrate to peripheral tissues or circulate in the blood stream and lymphatic system 
to exert functions related to innate, adaptive or both systems. Leukocytes such as 
macrophages, basophils, neutrophils, eosinophils, mast cells and natural killer cell 
lymphocytes are a part of the innate immune system, while antigen specific B and T 
lymphocytes are part of the adaptive immune system. Another leukocyte, the dendritic 
cell, is considered to be a cell that interfaces the innate and adaptive immune systems, 
since its main function is to activate T cells by presenting them pathogen derived peptides 
and providing signals necessary for activation (Figure 1.1) [1]. 
 
 
Figure 1.1: Components of the human immune system and the integration of innate and adaptive 
systems, from [2]. 
 
1.1.1 Innate Immune System 
The innate immune system, also known as non-specific immune system, is the first 
line of defence against pathogens. It is composed of physical barriers, such as the 
epithelial surface, and of leukocytes and humoral molecules capable of recognizing 
generic patterns present in microorganisms. Regarding its cellular components, 
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phagocytes, such as macrophages, neutrophils, and dendritic cells, detect the presence of 
pathogens using pattern recognition receptors (PRRs), which are receptors that can 
recognize conserved molecular sequences commonly shared by pathogens. Those 
receptors are expressed by fixed genes innately encoded in the genome, differing from B 
and T cell receptors of the adaptive immune system, whose genes undergo multiple 
somatic genetic rearrangements to achieve an extremely high diversity, and therefore 
recognize and adapt a specific immune response [2]. PRR activation leads to the release 
of inflammatory mediators, resulting in the clinical symptoms of inflammation such as 
increased sensitivity of pain receptors and vasodilation in the inflammation site (redness). 
Those mediators also attract more immune cells to the inflammation site, especially 
phagocytes, which is also facilitated by the increased blood flow [1]. 
Phagocytes engulf and digest microorganisms into smaller amino acid sequences 
called peptides, which are then presented as antigens to cells of the adaptive immune 
system. Another name for phagocytes is antigen-presenting cells (APC), since this 
function is a link for the activation of the adaptive immune response. Through this 
mechanism, APCs educate lymphocytes from both the adaptive and innate immune 
system about specific infections, mainly from extracellular origin [3]. Although various 
leukocytes can perform this function, dendritic cells are specialized APCs. Their distinct 
morphological and functional characteristics gives them unique roles essential for 
stimulating, regulating and enhancing other cells of the immune system [4]. 
While the phagocytes are responsible for neutralizing microorganisms outside cells 
and warn the adaptive immune system, another group of leukocytes in the innate immune 
system, natural killer (NK) cells, are responsible for eliminating cells that have been 
compromised by intracellular pathogens, and are also able to eliminate tumour cells. 
Humoral defences include the lipopolysaccharide (LPS) binding protein, which plays a 
role in the mechanism for PRRs recognition, and the molecules composing the 
complement system whose function is, through various pathways, releasing a biochemical 
cascade resulting in the destruction of the microorganism [2]. 
 
1.1.2 Adaptive Immune System 
The components of the adaptive immune system function to deliver a highly specific 
immune response against pathogens, further developing an immunological memory, 
4 
 
allowing its quick activation in case of a reinfection. Activation of this system is dependent 
of antigen exposure, which is one of the characteristics distinguishing it from the innate 
immune system. Despite its high efficacy, the adaptive immune system has a delayed 
response, taking up to 5 days for proliferation and differentiation into effector cells able 
to deliver a response [2]. In evolutionary terms, the adaptive immune system is more 
recent than the innate immune system, since it is only present in vertebrates [5]. 
T lymphocytes or T cells are mainly responsible for cellular immune responses while 
B lymphocytes or B cells are responsible for humoral immune response through the 
production of antigen-specific antibodies, also called immunoglobulins. Different from 
cell receptors of the innate immune system encoded from germline genes, T and B cell 
receptors (TCRs and BCRs) undergo a type of somatic gene recombination during their 
maturation in the bone marrow, which is referred as V(D)J recombination. Receptors are 
built by random assembly of V, D and J gene fragments, resulting in a hugely diverse 
receptor repertoire that enables those cells to recognize antigens from the vast amount 
of possible invading pathogens [6]. After acquiring their receptors, lymphocytes capable 
of reacting against self-molecules are eliminated, a maturation stage that occurs in the 
thymus for T cells and in the bone marrow for B cells. Immunocompetent cells then 
migrate to lymphoid tissues as naïve cells, ready to be exposed to antigens, causing it to 
proliferate by clonal expansion and differentiate into effector T cells or antibody-
producing plasma B cells. TCRs interact with antigens in the form of peptides presented 
by cells through molecules of the major histocompatibility complex (MHC), while BCRs 
interact with their cognate antigens outside cells [1]. 
T cells are subdivided into helper and cytotoxic T cells, according to their different 
functions and the presence of distinguished TCR co-receptors (CD4 and CD8, 
respectively). These co-receptors determine the type of MHC molecule that the TCR can 
bind. Helper T cells or CD4+ T cells interact with MHC class II molecules present in 
APCs while cytotoxic T cells or CD8+ T cells interact with MHC class I molecules 
present in almost all cells [7]. Those differences are related to the fact that CD4+ T cells 
are mainly involved in the stimulation of immune mechanisms against microorganisms 
that have undergone phagocytosis by APCs while the function of CD8+ T cells is to 
eliminate cells that have been infected by pathogens. While cytotoxic T cells destroy 
infected cells presenting foreign peptides, helper T cells are responsible for releasing 
molecular signals, called cytokines, which mediate the activity of other cells, including 
cells of the innate immune system. 
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The activation of B cells via interaction of their BCRs to a cognate antigen initiates 
the humoral portion of the adaptive immune system. When activated, they differentiate 
to plasma B cells whose function is to secret immunoglobulins which are structurally 
similar to the BCR of the activated B cell. Immunoglobulins bind directly to invading 
microorganisms, coating their surfaces in order to neutralize them, i.e. prevent them from 
infecting cells. This antibody coating, referred as opsonisation, also facilitates their 
capture by phagocytes and is involved in pathways for activation of proteins of the 
complement system [1]. 
 
1.1.3 Immunoglobulins: Humoral effectors of the adaptive 
immune system 
TCRs, immunoglobulins and BCRs are members of the immunoglobulin superfamily 
(IgSF) sharing mechanisms to increase diversity, such as V(D)J recombination, and 
structural similarities, being composed of a variable region (V) related to antigen 
recognition, and a constant region (C) related to activating of immune responses. 
Distinctively, immunoglobulins display an additional mechanism to increase their 
diversity. After gene rearrangement they undergo somatic hypermutation, consisting of 
point mutations in V regions that contribute to the increasing affinity of immunoglobulins 
during the course of the infection [1]. All these mechanisms make immunoglobulins 
highly specific to their targets. The understanding of the mechanisms governing the 
immunoglobulin specificity was essential to the development of structural based strategies 
to improve tissue transplantation, discussed in Chapter 3 of this thesis. 
Immunoglobulins are Y-shaped molecules composed of two heavy (H) chains and 
two light (L) chains connected by disulphide bonds, where both H and L chains are equal. 
They are identical to BCRs from their originating cells, except for a small portion of the 
COOH-terminus of the H chain connecting it to the B cell membrane. The V region 
comprises of the N-terminal variable domains of the L and H chains (VL and VH, 
respectively), while the C region comprises of L and H chain conserved domains (CL and 
CH, respectively (Figure 1.2) [1]. 
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Figure 1.2: Immunoglobulin structure from different perspectives. (A) Highlight of 
immunoglobulin L and H chains. (B) Description of C and V immunoglobulin sub regions, 
according to L and H chains. (C) Indication of the Fab and Fc portions generated by proteolytic 
cleavage (Adapted from [1]). 
 
V domains of both L and H chains contain three regions with a distinctive higher 
variability called hypervariable regions (HV) - HV1, HV2 and HV3, where HV3 is the 
most variable region. Those HV regions are located close to each other in the antigen 
binding site of the immunoglobulin, and are commonly referred as complementarity-
determining regions (CDRs), as their surface structure matches the antigen surface [1]. 
Thus, both chains contain three CDRs (CDR-L1, -L2, -L3 pairing with CDR-H1, -H2 
and -H3, respectively) where the total of six CDRs are brought together in each antigen 
binding site of the immunoglobulin, conferring its specificity (Figure 1.3) [8]. 
Immunoglobulin CDRs are encoded by recombinant V, D and J genes in distinct loci 
specific to L and H chains. While both CDR1 and CDR2 are singularly encoded by V 
gene segments in L and H loci, CDR3 displays increased variability by being encoded by 
combinations of V, D and J segments (CDR-L3 from V and J segments and CDR-H3 
from V, D and J segments). Variability is especially increased in CDR-H3, since H chain 
locus have the additional polygenic D segment, greatly increasing the number of possible 
specificities generated in comparison to other CDRs. Furthermore, N-nucleotides (non-
template encoded) flanking both sides of the D segment are randomly added by the TdT 
enzyme [8]. Those characteristics make CDR-H3 the most variable CDR and the 
dominant region on the determination of immunoglobulin specificity and affinity, while 
others CDRs do not variate as much and their structure is limited to a small set of main-
chain conformations referred as canonical structures [9]. 
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Figure 1.3: Complementary Determining Regions (CDR) loops in an antigen-binding site. CDR-
H1, -H2 and -H3 are located in the antibody heavy chain, and L1, L2 and L3 are located in the 
antibody light chain. The centrally located CDR-H3 confers specificity to the antibody, while 
interactions with other CDRs are secondary (Adapted from [8]). 
 
Nevertheless, it has been shown that among the 50 HV amino acid residues in the 
immunoglobulin V region, small numbers of residues make contact with the protein 
antigen, interfacing around 15-22 antigenic amino acid residues [10]. This antigen contact 
surface is the structural definition of an epitope. An antigenic molecule can carry several 
epitopes, consisting of small immunogenic sub regions displaying non-self protein 
conformations. The epitope complementary region in the immunoglobulin is called 
paratope [8]. An epitope within a protein can be formed by non-linear amino acids 
structurally together due to protein folding, originating conformational or discontinuous 
epitopes. The opposite case are continuous or linear epitopes, where the epitope is 
comprised of amino acids linear sequence in the polypeptide chain [1].  
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Knowledge of general epitope structural conformations (linear and non-linear) 
recognized by CDR-H3 allowed for prediction of HLA epitopes that could play a role in 
antibody-mediated transplant rejection. Areas over the surface of an HLA molecule 
containing polymorphic residues that are within predicted area recognized by CDR-H3 
were defined as functional units important for matching in transplantation, providing new 
alternatives for current DNA-based matching. Definition of HLA epitopes is discussed 
in more detail in Chapter 3 of this thesis. 
 
1.1.4 Natural Killer Cells: Lymphocytes of the innate 
immune system 
Despite being categorized as part of the innate immune system since they do not 
require exposure to foreign antigens and their receptors do not undergo somatic 
recombination, NK cells are lymphocytes originated from progenitor cells common to T 
and B lymphocytes. Initially considered to be primitive lymphocytes, it has been suggested 
they have co-evolved alongside lymphocytes of the adaptive immune system as a response 
to pathogens that downregulate MHC class I molecules to evade from cytotoxic T cells 
[11-13]. Although NK cells were discovered as a result of their ability to target and kill 
tumour cell lines that expressed little or no HLA class I molecules [14]. It is now known 
that the killing function in NK cells is dependent on a mixture of activating and inhibitory 
receptors present on the membrane and the interaction with their respective MHC ligands 
[15]. 
Normal cells express a high quantity of MHC class I molecules on their surface while 
low or absent MHC class I expression are a sign of infection or neoplastic transformation. 
Equipped with a complex of receptors that monitor ligand expression in cells, NK cells 
are capable of identifying and destroying cells with abnormal levels of MHC class I 
expression, a scenario also referred as “missing-self”. In summary, NK cell interaction 
with other cells, also referred as NK synapse has the following stages: i) interaction of 
receptors with respective ligands in target cell; ii) integration of signals from bound 
receptors; iii) NK cell remains inactivated or becomes activated; iv) if activated, NK cell 
destroys the target cell by releasing cytotoxic granules and v) release of cytokines that 
modulate activity of other cells. Several receptor families in NK cells recognize MHC 
class I ligands, and some have the function to send inhibitory signals that prevent NK 
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cell activation. In the presence of insufficient inhibitory signals, NK cells are activated by 
the interaction of activating receptors with activating ligands [16]. 
Inhibitory signals are released via phosphorylation of a tyrosine residue in the 
immunoreceptor tyrosine-based inhibitory motif (ITIM) cytoplasmic domain, present in 
all NK inhibitory receptors, which then leads to recruitment of phosphatases through 
their SH2-domains that act preventing NK cell activation. Signalling by activating 
receptors occurs via phosphorylation of a tyrosine residue in the immunoreceptor 
tyrosine-based activating motif (ITAM), present in NK cell adapter proteins associated 
with NK cell activating receptors. Tyrosine kinases are then recruited to initiate a cascade 
of events leading to Ca2+ influx, degranulation, and transcription of cytokine production 
[11]. 
Receptors families in NK cells recognizing MHC class I or related ligands include C-
type lectins-like group (CD94/NKG2), killer-cell immunoglobulin-like receptors (KIR) 
in humans and Ly49 in mice and LILR. Despite most of the NK cell receptors binding 
MHC class I related molecules, several receptors bind non-HLA ligands, for example, 
CD16 binds IgG, triggering an activating response, and NKp30, NKp44 and NKp46 are 
activating receptors that bind molecules expressed by pathogens and self-ligands. Among 
those receptors, KIRs are the most variable family. They are expressed by a variety of 
KIR genes, resulting in several molecular variants of KIR receptors that, despite being 
similar, can perform different functions (inhibitory or activating), however most KIRs 
have inhibitory function [17-21]. 
Further discoveries after the initial description of NK cell physiology led to updates 
in the “missing-self” hypothesis (Figure 1.4).  The initial hypothesis stated that NK cells 
are activated when encountering cells lacking MHC class I ligands. Nowadays it is known 
that NK cells can also be activated by cells overexpressing activating ligands with no 
MHC class I downregulation. Furthermore, cells that naturally lack MHC class I ligands, 
like erythrocytes, also lack activating ligands for NK cells and do not elicit an activating 
response on those cells [11]. Variability of both NK receptors and their respective ligands 
in target cells also represents a factor interfering in the determination of NK cell 
activation. Due to the extensive polymorphism on some NK cell receptor genes, 
individuals display variable receptor-ligand repertoires therefore having variable balances 
of potential inhibitory and activating signals. This variability can also produce a 
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deleterious effect in situations where an excess of activating signals due to a more 
“activating” combination of receptors results in autoimmune diseases [22]. 
 
 
Figure 1.4: Mechanisms determining NK cell activation according to an updated version of the 
“missing-self”. The classical definition of this hypothesis states that NK cells becomes activated 
when targeting cells missing MHC class I molecules. Updates on this hypothesis includes other 
possible scenarios. Erythrocytes are examples of cells which do not express MHC class I ligands, 
but do not lead to NK cells activation as it lacks activating receptors (A). Cells that in normal 
conditions express MHC class I lead to inhibitory signals on NK cells (B), but infection or tumour 
transformation can lead to downregulation of MHC class I and expression of activating ligands 
(C). Some cells normally express both MHC class I and activating ligands, and can overexpress 
activating ligands in unhealthy situations with no changes in MHC class I expression, shifting the 
balance of signals towards NK cell activation (D). Variability in individual NK cell receptors-
ligands repertoire also influences the balance of signals and thus the sensitivity of NK cells [11]. 
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NK cells also participate in mechanisms related to pregnancy. Uterine NK (uNK) 
cells are the most abundant leukocytes in the uterus, and regulate the invasion of the 
trophoblast into the uterine wall and the transformation of maternal arteries in high 
conductance vessels [23]. Similarly, different receptor combinations influence this 
mechanism, in this case mainly due to interaction with paternal ligands present in the 
trophoblast. Excessive inhibition of uNK cell receptors by trophoblast ligands have been 
suggested to impair transformation of maternal arteries, leading to pregnancy disruption 
[24]. 
Knowledge of the mechanism of NK cell activation, relying on its receptor repertoire, 
combined with target cell ligands can also be used for therapeutic strategies. Using 
allogeneic NK cells for cancer immunotherapy is one strategy that takes advantage of 
imbalances on NK cell receptor signals, where differences in KIR receptors and MHC 
ligands between recipients and donors cause NK cells to be more or less aggressive 
against tumour cells in the recipient [25]. In transplant settings, NK cells can influence 
the outcome both positively and negatively. For bone marrow transplants, they play an 
important role on preventing cancer relapse by targeting tumour cells, but they can also 
participate on immune responses against the host [26]. In solid organ transplantation, 
they can be involved on graft chronic rejection [27]. 
Since the polygenic and polymorphic nature of KIR receptors produces a high 
genotype diversity in populations compared to other NK cell receptors, they have been 
implicated in shaping individual response to infections and tumours, in the outcome of 
transplantation, and in the occurrence of autoimmune diseases and pregnancy 
complications. Furthermore, different KIR receptors display different levels of affinity to 
their ligands, which is also influenced by ligand polymorphisms, i.e. different MHC alleles 
[24]. The influence of human KIR variability in disease development is investigated in 
this thesis (Chapter 2). 
 
1.2 Genetics of the immune system 
Genetic polymorphism refers to nucleotide differences in one or more positions in the 
DNA sequence between individuals. The sole term polymorphism can also refer to their 
phenotypic variants, i.e. their expressed proteins. Sometimes gene polymorphisms are 
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referred as alleles, which are alternative genetic variants that can be present at a position 
(or locus, plural loci) in the chromosome. The allele definition is similar to genetic 
polymorphism, the difference being that the term allele is inferring chromosome diploidy, 
i.e. the fact the humans have chromosome pairs, each one inherited from one of the 
parents, and therefore a double set of each gene in a particular locus, termed genotype. Thus 
it is possible for individuals to express two different alleles of a polymorphic gene 
(heterozygosity). 
Part of the ability of the human immune system to identify and react against a broad 
range of constantly evolving pathogens that can infect the organism is interrelated with 
the extensive diversity displayed by a set of immune gene families. The Human Leukocyte 
Antigen (HLA) and the Killer-cell Immunoglobulin-like Receptors (KIR) gene families 
present an outstandingly high variability and express key components related to 
monitoring for the presence of non-self peptides or abnormal ligand expression on the 
cell surface, respectively. Both exhibit elevated number of polymorphisms, HLA being 
situated in the most polymorphic locus in the human genomic, while KIR also varies in 
haplotype gene content. The consequent variability of immunogenetic profile in 
populations and the functional implications of the molecules expressed by those genes 
makes them frequent targets in disease association studies investigating the correlation of 
immune gene polymorphisms with the observation of different disease outcomes, i.e. a 
higher susceptibility or protection against different disease types. 
A set of genetic polymorphisms inherited together on a region of a single 
chromosome, from a single parent, are called haplotypes. For a given chromosomal region, 
individuals have a set of two haplotypes (one on each chromosome), and the combination 
of the polymorphisms in both haplotypes is also referred as genotype. The HLA gene 
complex is located in the chromosome 6, while KIR gene complex is located in the 
chromosome 19. Therefore, genes in each of those gene families respectively are linked 
in the same chromosome, resulting in different haplotypes with variable frequencies in 
populations. 
 
1.2.1 Population Genetics 
Study of genetic polymorphism frequencies in populations is a component of 
population genetics research. The investigation of genetic frequencies is important for 
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understanding evolutionary biology, population dynamics, and also disease association 
studies. Several population genetics measures are commonly used in HLA and KIR 
population and disease association studies. A common one is allele frequency which consists 
of the percentage of an allele polymorphism in a population chromosome pool. Since 
individuals have two chromosomes, they can carry one or two copies of the allele. 
Therefore, the allele frequency reflects the proportion of the allele in all chromosomes in the 
population. This is different from another measure referred as carrier frequency, which is 
the percentage of individuals in the population carrying a polymorphism, disregarding 
zygosity (heterozygous or homozygous). Carrier frequency is commonly used in KIR gene 
studies, due to their variable gene content of KIR haplotypes (presence / absence) making 
it difficult to determine their zygosity. 
Regarding genotype information, an individual can have two copies of the same allele 
(homozygous) or different alleles in each chromosome (heterozygous). The genotype frequencies 
for a locus consists of the percentage of genotypes from individuals in a population, 
homozygous and heterozygous. For a biallelic locus, i.e. a locus containing two 
polymorphisms (A and a), three genotype frequencies (AA, Aa and aa) can be estimated. 
Genotype frequency can also denote the frequencies of multi loci genotypes, where all 
genotypes in a population correspond to the pairwise combination of all existing 
haplotypes in that population. In this case, the equivalent of the allele frequency would 
be the haplotype frequency. 
 
Hardy-Weinberg Equilibrium 
Genotype frequencies can be estimated according to probabilistic proportions based 
on the population allele frequencies, which are referred as Hardy-Weinberg proportions. 
If the observed genotype frequencies in a population are statistically equivalent to the 
expected by Hardy-Weinberg proportions (HWP), the population is in Hardy-Weinberg 
equilibrium (HWE) [28]. Although HWE can be affected by natural selection and 
population events, shifts in HWE are often indicative of problems with population 
sampling or typing methods [29]. HWP is based on the probabilities of the alleles in a 
population to be homozygous or heterozygous. Using again a biallelic locus as example, 
A and a alleles have p and q frequencies, respectively, in a population. According to 
probabilistic theory, p2 and q2 are the expected frequency of homozygotes (AA and aa), 
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while 2pq is the expected frequency of heterozygotes (Aa). This logic yields the general 
HWP formula: 
p2 + 2pq + q2 = 1 
HWP can also be applied for estimating other mathematical variables in populations. 
For example, a formula derived from HWP, sometimes referred as Bernstein’s formula, 
is used to estimate gene frequencies from carrier frequencies, which is useful for KIR 
studies [29]. In this thesis, another calculation derived from HWP has been applied to 
estimate HLA epitopes frequencies, described in Chapter 3. 
 
Linkage Disequilibrium 
Haplotypes are also expected to be proportionally balanced or in linkage equilibrium. 
Linkage disequilibrium can be caused by factors such as recombination rate and genetic 
linkage, i.e. their simultaneous presence in the same chromosome [28]. Tightly linked loci 
are more likely to be in linkage disequilibrium, as they have a higher chance of being 
inherited together [30]. HLA genes have a very high genetic linkage, being clustered on a 
relatively small region of chromosome 6, and therefore display high linkage disequilibrium 
among themselves. The same is true for KIR genes, clustered on a on chromosome 19. 
If natural selection acts on a single locus in highly linked gene families, its frequency is 
increased together with other closely linked loci in the haplotype, even if they are neutral 
regarding selection [29,31]. This phenomenon represents a challenge for genetic studies 
to identify the locus (or loci) actually being selected or being associated with a particular 
condition. Studies associating genetic variants with traits or diseases tend to report all 
statistically significant associations found. Some of the genetic variants associated may 
not be directly influencing the investigated condition, but show statistical significance by 
being in linkage disequilibrium with an actual causative variant. Since both HLA and KIR 
gene families display high degree of genetic linkage, it is necessary to take linkage 
disequilibrium into account before drawing definite conclusions from genetic association 
studies of those gene families [32]. 
 
Haplotype Frequency Estimation 
To assess the effects of linkage disequilibrium in population genetic studies it is 
necessary to acquire haplotype frequencies of the studied loci, but most genetic studies 
15 
 
rely on DNA typing techniques that only provides genotype information, which is not 
enough to determine what polymorphisms are linked in the same chromosome. This is 
because most techniques rely on generating information on relatively short sequences of 
DNA (either by direct sequence or PCR), up to a few kb in length. As a result, phasing 
between alleles from different loci cannot be easily achieved, due to the typical presence 
of identical sequences in-between on both chromosomes typed. One method to obtain 
haplotypes is to obtain genotype data from the individuals’ parents, but this is often 
impractical. It is possible, however, to use statistical methods to estimate the haplotypes 
and their frequencies in a population based on population genotype data. There are 
several computational methods for achieving this task, including some software packages 
designed specifically for either HLA or KIR gene families. For the level of polymorphism 
exhibited by those gene families, maximum likelihood methods using the expectation 
maximization (EM) algorithm are mostly used [32]. These methods are reasonably 
effective for large populations, say > 1000 individuals, working on the likely co-
occurrence of the same alleles in different individuals, but start to break down for low 
frequency haplotypes in smaller populations, as there is simply no signal with which to 
work. A module for haplotype and linkage disequilibrium estimation from HLA 
genotypes using this method is present in PyPop (www.pypop.org), which is a software 
package containing an array of tools designed for population genetics analysis of highly 
polymorphic multi loci genetic data [33]. 
 
1.3 The Major Histocompatibility Complex (MHC) 
The major histocompatibility complex (MHC) is a genomic region of approximately 
4 Mb, located at the 6p21.3 region of the human chromosome 6. It contains more than 
200 closely linked genes, performing various functions, mostly related to the immune 
system [34]. It is by far the most polymorphic region in the human genome, where many 
of its genes exhibit thousands of known allelic variants. As shown in Figure 1.5, the 
complex is divided into three regions (class I, class II and class III). MHC class I and class 
II regions are mostly composed of HLA genes while the class III region, located between 
class I and II regions, is composed of non-HLA genes with immune-related functions. 
The twenty one highly polymorphic genes of the HLA gene complex have been constant 
subjects of interest in diverse fields of study. Besides influencing disease susceptibility and 
immune reactions such as adverse drug reactions, their variability also makes them 
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important assets in genetic studies investigating human population origins and dynamics, 
and a problem in organ and cell transplantation as differences in donor and patient HLA 
profiles can lead to immune mediated tissue rejection. 
 
 
Figure 1.5: Location of MHC in chromosome 6 and genetic organization of class I, class II and 
class III regions. HLA genes are located in class I (HLA-A, -B, -C, -E, -F and -G) and class II 
(HLA-DR, -DQ, -DP and -DM) regions [Adapted from [35]]. 
 
1.3.1 Human Leucocyte Antigens (HLA) 
The HLA gene complex is located within the MHC region. HLA class I (HLA-A, -B, 
-C, -E, -F and -G) and class II (HLA-DM, -DO, -DP, -DQ and -DR) genes are 
codominant, and translate for cell surface molecules responsible for antigen presentation 
to T cells. HLA class I genes are expressed in almost all cells, and their main function is 
to present peptides from intracellular microorganisms to cytotoxic (CD8+) T cells. HLA 
class II genes are mainly expressed in APCs, such as macrophages and dendritic cells, and 
their main function is to present peptides that have been phagocytized by APCs to helper 
(CD4+) T cells [35,36]. 
HLA class I molecules are composed of a heavy α-chain encoded by HLA class I 
genes, a light chain called β2-microglobulin (β2M) and a short bound peptide (Figure 1.6). 
Human β2M is an extracellular molecule encoded by a conserved gene on the 
chromosome 15. The α-chain is composed by different domains encoded by specific 
exons of HLA class I genes. The leader peptide is encoded by exon 1, the α1, α2 and α3 
extracellular domains are encoded by exon 2, 3 and 4, respectively, the transmembrane 
portion is encoded by exon 5, the cytoplasmic tail is encoded by exons 6 and 7, and exon 
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8 is the 3’ untranslated region (UTR). Despite sharing domain structure similarity with 
HLA class I and having analogous function, HLA class II molecules are composed of 
two transmembrane chains (α chain and a β chain), both encoded by HLA class II genes, 
and a bound peptide (Figure 1.6). Similarly to HLA class I molecules, each exon encodes 
for specific portions of each chain, but HLA class II genes encode for only two 
extracellular domains (α1 and α2 for α chains, β1 and β2 for β chains) from exons 2 and 
3, respectively. Thus, each HLA class II molecules is composed of four extracellular 
domains [36]. 
 
 
Figure 1.6: Structure of the HLA Class I and Class II molecules [37].  
 
Membrane distal domains of HLA class I and class II molecules (α1 and α2 for class 
I, α1 and β1 for class II) form a groove where the peptide is tightly bound. This peptide-
binding groove (PBG) consists of a sheet of N-terminal β-pleated strands forming the 
“floor” of the groove, and COOH-terminal α-helices forming its “walls”. The top of the 
molecule comprising the peptide and α-helices is the surface that interacts with TCRs and 
other receptors. HLA class I peptides contain generally 8 to 10 amino acids, while HLA 
class II accommodates larger peptides usually from 12 to 24 amino acids as its PBG has 
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system cells (e.g. B and T lymphocytes, macrophages and dendritic cells) (Klein & Sato 
2000a).  
 
The main function of the HLA Class I molecule is to present antigens to cytotoxic T 
lymphocytes (CD8+ T cells) which can eradicate cells typically infected by viruses. In 
contrast, HLA Class II molecules present peptides to T helper cells (CD4+ T cells) 
which, although they cannot directly eliminate infected cells, play an important role in 
the activation of other immune cells.  
 
Based on the molecular structure, the HLA Class I molecule is for ed by two 
polypeptides chains (α and β) containing a total of five domains: two peptide-binding 
domains (α1 and α2), one immunoglobulin-like domain (α3), a lateral β2-microglobulin 
gene (β2m), the transmembrane region (TM) and the cytoplasmic tail (Figure 1.2). The 
structure of the class II is composed of two mirror peptides with four domains each: a 
peptide-binding domain (α1 or β1), the immunoglobulin-like domain (α2 or β2), the 
transmembrane region and the cytoplasmic tail in each of the chains.  
 
 
Figure 1.2: Structure of the HLA Class I and Class II molecules. 
(Klein & Sato 2000a) 
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open ends, allowing peptides to hang out of the PBG. HLA class I PBG fully surrounds 
the peptide, limiting its size, and each extremity of the peptide is pinned to opposite ends 
of the PBG, mainly by hydrogen bonds. Every HLA molecule expressed in the molecular 
surface has a bound peptide originated from cellular degradation products. In healthy 
cells, the peptide source is from normal cellular components (self-peptides). In infected 
cells, some of the peptides are derived from pathogens [36]. 
Although thousands of different peptides can be bound to HLA molecules, they are 
not randomly selected, as subsites or pockets (Figure 1.7) of the PBG display preference 
for certain residues in specific positions of the peptide sequence, called peptide-binding 
motifs. Most polymorphic residues of HLA class I molecules are located within those 
pockets, influencing their size, shape and charge. Therefore, different HLA types have 
variable peptide sequence preference. While HLA class I pockets, mainly located in PBG 
extremities, primarily influence peptide affinity, HLA class II peptide affinity is 
determined by conserved residues centrally located in the PBG, resulting in lower peptide 
selectivity by HLA class II molecules. Therefore, polymorphisms within HLA class II 
PBG are mainly located in complementary pockets secondary to peptide affinity. 
 
 
Figure 1.7: Illustration of HLA pockets and binding peptide residues in HLA-B*27 [38]. 
 
In HLA class I molecules most of the polymorphic differences in DNA sequence are 
in exons 2 and 3, coding for the most external domains (α1 and α2) located on the top of 
molecule. Hundreds of different alleles are known for HLA-A, -B and -C, while other 
HLA class I genes are monomorphic or display little polymorphism. Polymorphic 
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differences in HLA class II molecules can derive from both chains, depending on the 
isoform. HLA-DR α-chain (HLA-DRA) is monomorphic, while its β-chain (HLA-DRB) 
is polymorphic, being the most variable HLA class II isoform. HLA-DRB is a polygenic 
segment with variable gene content (HLA-DRB1, -DRB3, -DRB4 and -DRB5), where 
HLA-DRB1 is a highly polymorphic gene present in all haplotypes while other HLA-
DRB genes can be present or not. In contrast, both chains of HLA-DP and HLA-DQ 
are polymorphic, while HLA-DM and HLA-DO show little polymorphism [36]. 
 
HLA nomenclature and resolution levels 
 
 
Figure 1.8: Structure of HLA nomenclature. 
(Source: http://hla.alleles.org/nomenclature/naming.html) 
 
HLA genes can be typed at different levels of resolution depending on the typing 
technique employed. Antibody-based serological typing yields low resolution allele 
definitions while DNA-based typing methods generates allele typing at higher resolutions. 
The resolution by which an allele has been typed can be identified by its nomenclature 
(Figure 1.8). The HLA nomenclature also provides information regarding protein 
expression. HLA allele names start with a prefix referring to the gene name. An asterisk 
separates the prefix from the rest of the nomenclature, which consists of up to four sets 
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Figure 1.3: Structure of the nomenclature for HLA alleles. 
(Reprinted with permission of S.G.E. Marsh) 
Source: http://hla.alleles.org/nomenclature/naming.html 
 
The notation used to define the DNA sequence variant consists of 2-4 levels (Fields) 
which are separated by a colon (:) as shown in Figure 1.3. Level 1 (Field 1) encodes the 
HLA allele family which usually corresponds to the antigen group (e.g. A*02), level 2 
(Field 2) defines the DNA sequence variant at protein level which is typically given in a 
consecutive numerical order (e.g. A*02:101), level 3 (Field 3) is used to describe a 
synonymous DNA substitution3 within the coding region (i.e. A*02:101:01 and A*02:101:02 
alleles both encod  for Arginine at codon 163 which is located in exon 3 in the 
sequence, howeve , nucleotide sequences of these two alleles corre p nd to CGG and
AGG respectively) and level 4 (Field 4) is used for those alleles that present a difference 
in the non-coding region4 of the sequence (e.g. A*02:101:01:02) [For more details on HLA 
allele nomenclature see (Marsh et al. 2010)].  
 
Additionally, several suffixes are used in the HLA nomenclature to indicate special 
characteristics of the allele indicating whether the allele is not expressed (N), whether 
the allele has shown a low expression on the surface of the cell (L), whether the 
                                                 
3 A synonymous substitution is the replacement of one nucleotide in which the change does not affect the 
amino acid produced. E.g. CGG and AGG both encode the amino acid Arginine. 
4 The non-coding region is the part of the DNA sequence that does not encode for protein sequences. 
20 
 
of numbers called fields and a suffix that is present in some allele names. Fields are 
separated by colons, and represent different HLA resolution levels. The first field refers 
to the allele serological antigen designation. The second field corresponds to alleles 
differing in the amino acid sequence, but part of the same serological group. The third 
field classifies alleles with differences in the nucleotide sequence, but no difference in the 
protein sequence (synonymous substitutions). The last field is used to distinguish alleles 
that only display sequence differences in introns or untranslated regions. Some allele 
names can also contain a suffix, consisting of a single letter (‘N’, ‘L’, ‘S’, ‘C’, ‘A’ or ‘Q’) 
that refers to peculiarities in the allele expression. The suffix ‘L’ indicates ‘Low’ cell 
surface expression in comparison to normal levels of allele expression. The ‘S’ suffix 
indicates a soluble ‘Secreted’ molecule not present on the cell surface. The ‘C’ suffix 
designates alleles expressing ‘Cytoplasmic’ proteins not present on the cell surface. The 
‘A’ suffix indicates an ‘Aberrant’ expression, in cases where it is not known if the protein 
is expressed. The ‘Q’ suffix refers to ‘Questionable’, in cases where there is evidence that 
the mutation observed in the allele affects protein expression [39]. 
High resolution HLA typing methods can sometimes generate ambiguous HLA types. 
DNA sequence-based methods are often restricted to exons 2 and 3 (for HLA Class I 
genes), or exon 2 only (for HLA class II), since those exons encode for major 
determinants of the peptide-binding region specificity, containing most of the 
polymorphic positions. Differences between two alleles located outside the genotyped 
exons generates allele ambiguity. Another type of ambiguity referred as genotypic 
ambiguity occurs when it is not possible to distinguish between different heterozygous 
allele combinations without haplotype information. Since unambiguous HLA typing is 
limited to specialized laboratories, statistical methods using HLA frequency data from 
world populations are used for solving ambiguous HLA data [40]. 
 
HLA evolution and diversity 
It is believed that the remarkable diversity displayed by HLA is an evolutionary 
response to various infectious diseases which have exerted a balancing selective pressure, 
favouring diversity in those loci and heterozygote excess in populations. This hypothesis 
is supported by the fact that most polymorphisms are observed within the ‘peptide-
binding site’ (or antigen recognition site) region. Where polymorphism exists (in 
individuals or populations), a wider range of antigens can be recognized, suggesting also 
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that individuals heterozygote for HLA loci are more adapted to survive in pathogen-rich 
environments [41]. Due to the high number of HLA polymorphisms, most individuals 
are heterozygous for HLA genes, thus expressing six kinds of HLA class I molecules plus 
six or more kinds of class II molecules. Diversity of HLA genes is associated with antigen 
presenting functions, increasing the range of possible peptides to be presented, and also 
shaping the interaction strength between MHC and T cells. Thus, heterozygous 
individuals have more options of PBG shapes, increasing the range of possible peptides 
to be presented. Furthermore, other immune-related molecules also contribute to shaping 
HLA diversity. HLA class I molecules are known to interact KIR receptors, which are 
also very diverse. Although KIR genes are not linked genetically to the HLA complex, 
being on a different chromosome, it is suggested that both may have co-evolved due to 
certain combinations of HLA-KIR molecules causing complications in pregnancy [42,43]. 
The rapid evolution of human HLA genes generates extensive allele differences 
across populations. Those population specific alleles are often derived from more widely 
distributed alleles, differing only by small sequence segments that can be found in other 
alleles [44]. Besides making HLA genes a material for the study of the history of 
populations, this characteristic influences all other HLA related analysis due to how those 
genes can be genotyped. HLA typing in lower resolution levels do not cover the whole 
HLA gene sequence and may omit those population specific differences. Therefore, 
results from HLA association studies using low resolution typing methods may not be 
replicated in other populations if the causative molecular region in only distinguished by 
high resolution typing. 
 
HLA association with human pathologies 
Because of their immune function and their high level of polymorphism, HLA genes 
are obvious targets for disease association studies. They have been shown to influence 
individual susceptibility to several pathologies, mostly infectious and autoimmune 
diseases [35,45]. They have also been linked to complex diseases [46-48], neurological 
disorders [49-51] and adverse reaction to drugs [52]. Since the expressed HLA protein 
plays a role in various pathways of the immune response, different immunological 
mechanisms can be the underlying cause of those associations. HLA variants associated 
with those pathologies usually vary across different populations due not only to their 
diverse HLA allele pool and allele frequencies, but also due to variable environmental 
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pressures exerted in different populations [41]. It is also important to note that HLA may 
be associated with a pathology in conjunction with other genes. A classic case is the 
epistatic interaction between HLA class I and KIR genes, and several combinations of 
their variants have been linked to various disease types. 
 
1.4 Killer-cell Immunoglobulin-like Receptors (KIR) 
The KIR gene cluster is located in the leukocyte receptor complex (LRC) at position 
19q13.4 of the human chromosome 19 [17,18]. To date, sixteen KIR genes have been 
identified, coding for receptors with activating (KIR2DS1, KIR2DS2, KIR2DS3, 
KIR2DS4, KIR2DS5A/B and KIR3DS1) or inhibitory (KIR2DL1, KIR2DL2, KIR2DL3, 
KIR2DL5A, KIR2DL5B, KIR3DL1, KIR3DL2 and KIR3DL3) function, with KIR2DL4 
appearing to have both functions. Two pseudogenes KIR2DP1 and KIR3DP1 have also 
been identified [53]. KIR receptors are transmembrane glycoproteins members part of 
the IgSF, constituted of two (KIR2D) or three (KIR3D) Ig-like domains, a 
transmembrane region, and a cytoplasmic tail. Structurally, the activating and inhibitory 
functions of KIR are related to the length of their cytoplasmic tail that can be short (S) 
or long (L), distinguished in their nomenclature [53]. Long cytoplasmic tails contain one 
or two ITIM sequences, and short cytoplasmic tails have no ITIM sequence. KIR 
receptors with short cytoplasmic tails have a lysine in the transmembrane region, which 
is important for the receptor to interact with the DAP12 adapter protein that plays a role 
in NK cell activation [19]. 
Despite having distinct functions and variable ligand affinity, KIR receptors are 
structurally similar (Figure 1.9). They have a rapid evolutionary rate due to their close 
positions in the genome and their high sequence similarity, a consequence from gene 
duplications and conversions [54]. One example is the conversion of the inhibitory 
KIR2DL2 into the activating KIR2DS2, where two ITIMs are present in KIR2DL2, 
while in KIR2DS2 a stop codon in its cytoplasmic domain precedes the ITIMs, which 
are non-translated [11]. Variation in KIR loci can result from different gene and/or allele 
content of an individual [55], giving rise to haplotype diversity and leading to a very large 
number of different genotypes that have been observed (presence/absence of KIR 
genes). Its polygenic nature and haplotype gene content variation represents a challenge 
for genotyping KIR genes while discriminating zygosity information. Most KIR 
genotyping tests performed by laboratories are only able to reveal presence or absence of 
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KIR genes in populations, from where carrier frequencies can be calculated by direct 
count and gene frequencies need to be estimated using Bernstein’s formula [29]. 
 
 
Figure 1.9: Comparison of KIR receptor structures, highlighting their domain organization, length 
of cytoplasmic tail and presence of ITIM sequences [19]. 
 
 
 
Figure 1.10. KIR haplotypes and their gene content variability. Haplotype A is generally non-
variable in its gene content, while the B haplotype contains one or more of the genes encoding 
activating KIRs (KIR2DS1/2/3/5 and KIR3DS1) and the genes encoding inhibitory KIRs 
(KIR2DL5A/B and KIR2DL2) [Adapted from [24]]. 
 
The KIR genes KIR2DL4, KIR3DL2, KIR3DL3 and KIR3DP1 are present in nearly 
all individuals with a few exceptions [56], and are commonly known as ‘framework’ genes. 
The frequencies of inhibitory and activating genes vary in different populations, as 
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reviewed in [56]. A 24-kilobase band using HindIII digestion and Southern blot analysis 
distinguishes the haplotypes, termed A and B that make up the genotype [57]. 
The A haplotype is generally non-variable in its gene content – framework genes plus 
KIR2DL1, KIR2DL3, KIR2DS4 and KIR3DL1, although occasionally one of these genes 
may be missing [56]. In contrast, the B haplotype contains one or more of the genes 
encoding activating KIRs (KIR2DS1/2/3/5 and KIR3DS1) and the genes encoding 
inhibitory KIRs (KIR2DL5A/B and KIR2DL2) (Figure 1.10). In B haplotypes variability 
is created by both the presence/absence of a gene and by allelic variation, in contrast, A 
haplotypes owe much of their variability to allelic variation [56]. 
According to the Allele Frequencies Net Database (AFND), a public database storing 
population variability of immune genes developed in our research group, more than 
approximately 600 KIR genotypes have been identified in worldwide populations [58]. 
Regarding allelic variability, 907 KIR alleles have been reported according to the last 
release of IPD-KIR (Release 2.7.0) [59], a public database storing KIR gene nomenclature 
and sequences following standards of the KIR Nomenclature Committee [60]. B 
haplotypes tend to be more prevalent in non-Caucasian populations, such as Australian 
Aborigines and Asian Indians, whereas in Caucasian populations approximately 55% will 
have one and 30% two A haplotypes [61,62]. It is thought that populations with higher 
frequencies of B haplotypes are those under strong pressure from infectious diseases. 
Such extensive diversity among modern populations may indicate that geographically 
distinct diseases have exerted recent or perhaps on-going selection on KIR repertoires. 
From a practical viewpoint, this makes the choice of controls very important for all 
disease association studies. Additionally, it points to the possibility of finding population 
restricted associations of specific KIR polymorphisms with diseases. 
The population HLA allele pool also plays a role in shaping the population diversity 
of KIR alleles and haplotypes, since most of the KIR receptors function by recognizing 
MHC class I ligands (Table 1.1). Different KIR receptors recognize specific motifs of 
HLA class I molecules. The affinity strength of those interactions is variable depending 
of both KIR and HLA genes and / or alleles involved [63]. KIR2DL1 and KIR2DL2/L3 
recognize motifs majorly present in HLA-C alleles. KIR2DL1 binds HLA-C epitopes 
distinguished by the presence of a lysine in position 80 (C2 epitope or HLA-C2) while 
KIR2DL2 and KIR2DL3, which are alleles from the same gene, bind HLA-C and some 
HLA-B epitopes containing an asparagine in position 80 (C1 epitope or HLA-C1) [63]. 
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KIR3DL1 binds HLA-B and some HLA-A possessing the Bw4 public epitope. HLA-B 
alleles can be categorized in HLA-Bw4 and HLA-Bw6 for containing the serological 
defined Bw4 and Bw6 epitopes, respectively. Those cross-reactive epitopes are defined 
by specific amino acid motifs in the 77-83 positions in the α1 domain of HLA-B (and 
some HLA-A containing Bw4 epitopes), but only Bw4 epitopes are known to be 
recognized by KIR3DL1 (Table 1.2) [64]. KIR3DL2 receptors bind to HLA-A*03 and 
HLA-A*11 allotypes, however this receptor is shows a weak inhibitory ability and an 
interaction dependent on the peptide bound to the HLA molecule [65]. 
 
Table 1.1: KIR molecules and their respective ligands, signalling and function [66]. 
KIR Ligand Signalling Function 
2DL1 HLA-C2Lys80 ITIM Inhibitory 
2DS1 HLA-C2Lys80 (weak) DAP12 Activating 
2DL2 HLA-C1Asn80 ITIM Inhibitory 
2DL3 HLA-C1Asn80 ITIM Inhibitory 
2DS2 HLA-C1Asn80 (weak) DAP12 Activating 
2DL4 HLA-G ? Both 
2DL5 ? ITIM Inhibitory 
2DS3 ? DAP12 Activating 
2DS4 ? DAP12 Activating 
2DS5 ? DAP12 Activating 
3DL1 HLA-Bw4 ITIM Inhibitory 
3DS1 ? DAP12 Activating 
3DL2 HLA-A (weak) ITIM Inhibitory 
3DL3 ? ITIM Inhibitory 
 
 
While ligands for most of the inhibitory receptors are well defined, little is known 
about ligands for activating KIR receptors. Despite some activating KIRs having been 
shown to bind MHC class I ligands, those interactions are significantly weaker and their 
relevance is not fully understood. Distinctively, while KIR receptor interactions with 
ligands usually lead to either an inhibitory or activating signal, KIR2DL4 performs both 
functions, showing however a weak inhibitory potential [67]. It binds the non-classical 
HLA-G ligand in soluble form inducing activating signalling. Additionally, HLA-G 
expression is restricted to trophoblast cells in the foetus, suggesting its role in NK cell 
vascular remodelling during pregnancy [68]. 
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Table 1.2: KIR-ligands in HLA- and HLA-B. HLA-C alleles are of the C1 or C2 group while most 
HLA-B alleles are Bw4 or Bw6, according to their motifs [59]. 
 
 
 
KIR associations with human pathologies 
KIR genes are also frequent subjects of disease association studies due to their 
variability and function. Different types of pathologies such as infectious diseases, 
autoimmune diseases, tumour development and pregnancy complications have been 
associated with KIR genes, reflecting their roles in diverse physiological mechanisms 
involving NK cells. Those disease associations are also influenced by KIR and HLA genes 
epistasis, since the majority of KIR receptors function by binding to specific types of 
MHC class I molecules. Therefore, in most cases, an outcome associated with single KIR 
genes or KIR gene combinations is dependent of MHC class I genotypes, considerably 
increasing the complexity of these genetic investigations. Investigation of the associations 
between KIR genes and diseases is the focus of Chapter 2. 
The resulting effect from different KIR/HLA genotypes is a consequence of the 
combinations of signals they are capable of generate. The balance of NK cell signals shifts 
towards activation or inhibition according to the individual proportion of activating or 
inhibitory KIR-ligand combinations. Genotypes promoting increased NK cell activation 
or inhibition are associated with different outcomes, being able to mutually protect or 
increase susceptibility against different diseases. For example, while increased activation 
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is associated with protection against various viral infections, it also increases the risk of 
autoimmune diseases, indicating there is a fine balance between efficient NK cell 
activation and improper activation leading to autoimmune reactions [24,69]. 
 
1.5 HLA matching in transplantation 
The identification of the MHC locus resulted from early works attempting tissue 
transplantation in inbred mice strains, which recognized that the histocompatibility 
necessary to avoid transplant rejection was determined by matching donor and recipient 
with similar MHC [36]. From that point on, tissue transplantation developed into an 
established medical procedure accompanied by the necessity of MHC compatibility 
between donor and patient, although some organs are more affected by MHC mismatches 
than others. In bone marrow, and to a slightly lesser extent in kidney, transplantation 
knowledge of highly polymorphic HLA class I and class II genes in both donors and 
patients is essential for ensuring transplant success since mismatches on those genes can 
lead to tissue rejection through diverse pathways of the immunological system. The more 
similar are HLA polymorphisms from donor and patient, the better the prognostic and 
survival of the transplanted graft. Nevertheless, due to advances in immunosuppressive 
therapy some level of HLA mismatch can be accepted depending on the transplanted 
graft, however accompanied by undesired side effects due to its non-specific action, 
increasing risk of cancer and infection [70]. 
 
1.5.1 Mechanisms of transplant rejection 
Rejection of solid organ transplants can be triggered by different mechanisms of the 
immune response and therefore vary regarding clinical manifestations and time of onset. 
Acute rejection occurs days to weeks after the transplant due mainly to the adaptive immune 
response from T cells recognizing alloreactive MHC molecules causing tissue damage. 
Since T cells have memory properties that speed up the immunological response when 
re-encountering antigens, any further attempts to transplant grafts from the same donor 
lead to accelerated rejection. Some individuals may have pre-existing alloantibodies against 
HLA or ABO group antigens due to sensitization via previous transplants, blood 
transfusion or pregnancy. If these are donor-specific antibodies (DSA), which can 
recognize alloantigens in the transplanted graft, a fast type of rejection named hyperacute 
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rejection occurs within minutes to hours. This antibody-mediated response (AMR) is 
characterized by reactions against vascular endothelial cells triggering blood clotting and 
complement cascades. Chronic rejection occurs months to years after the transplant, and it 
is characterized by gradual deterioration of the graft mediated by both cellular and 
humoral mechanisms (T cells and AMR). A higher number of permissible HLA 
mismatches is associated with shorter graft survival due to a faster progression of chronic 
rejection mechanisms [1]. 
T cell mediated allorecognition can occur directly or indirectly. Direct allorecogniton 
takes place when donor APCs within the graft presenting donor peptides activate 
recipient T cells and lead to acute rejection. Indirect allorecognition occurs when patient 
APCs present peptides originated from donor molecules (MHC or non-MHC), and it has 
been mostly associated with chronic rejection [71]. AMR is also a mechanism contributing 
for chronic rejection through de novo DSA development. Individuals with no pre-existing 
DSA can still receive a HLA mismatched transplant, which could then lead to post-
transplant DSA development and chronic rejection even with the administration of 
immunosuppressive therapy [72]. 
HLA matching have different importance depending on the transplanted organ. Liver 
and corneal transplants, for example, suffer little influence from HLA mismatches. In 
contrast, HLA matching is crucial for kidney and even more so for bone marrow 
transplantation. For allogeneic hematopoietic stem cell transplantation (HSCT) from 
bone marrow, polymorphic HLA class I and II loci should be as close as possible in donor 
and recipient, having strict policies with limited degree of mismatch acceptability. HLA 
mismatches in this type of transplantation leads transplanted donor cells to recognize 
HLA antigens which are not part of the donor HLA type [73]. Despite being less strict 
than bone marrow transplants, HLA matching is essential for renal transplants and 
sensitized patients that have developed anti-HLA antibodies represent a challenge in 
finding suitable donors. 
 
1.5.2 HLA matching for renal transplants 
Renal transplant is recommended for patients with end-stage renal disease, being the 
most commonly performed type of solid organ transplant, which can be sourced from 
living or deceased donors [74]. For the chance of receiving a kidney from a deceased 
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donor, patients are allocated onto waiting lists, along with information regarding their 
ABO blood group, HLA class I (at least HLA-A and -B) and class II (at least HLA-DRB1) 
type, and the presence of anti-HLA antibodies [75]. In the UK, this data is managed by 
the NHS Blood and Transplant (NHSBT) recipient registry. When a potential deceased 
organ donor with a consent for organ donation is identified, the NHSBT receives 
information regarding donor’s ABO blood group and HLA type. Patients in waiting lists 
with compatible ABO blood group and absence of anti-HLA DSA are then considered 
potential recipients [70]. 
Sensitization to HLA constitutes a major impediment for a patient to receive a kidney 
since pre-existing antibodies can react against donor antigens causing hyperacute 
rejection. Performing donor-recipient crossmatch, a test that determines if the patient has 
alloantibodies reacting against donor leukocytes, is crucial prior to renal transplant 
procedures. Time on transplant waiting lists for sensitized patients is significantly longer 
than for non-sensitized patients, being even more difficult for highly sensitized patients. 
The extent to which a recipient is sensitized can be described using calculated panel 
reactive antibodies (cPRA), giving the percentage of a donor panel that is reactive to a 
patient’s serum, i.e. yields a positive crossmatch, using the donor panel HLA type as a 
parameter. For highly sensitized patients with >80% cPRA, finding a negative crossmatch 
is so challenging that they tend to accumulate on transplant waiting lists [76], being the 
reason why they are prioritized in registries matching ranking systems [77]. Additionally, 
the presence of anti-HLA antibodies in sensitized patients with mismatched transplants 
reduces graft survival to an extent proportional to the degree of sensitization [78]. 
Among other factors, ranking potential recipients in the waiting list is based on the 
degree of HLA mismatches particularly at the HLA-DR, -B, and -A loci, comprising from 
0 to 6 possible HLA mismatches due to the codominance of those biallelic loci [79]. 
Lower numbers of HLA mismatches are associated with lower rates of acute rejection 
and longer graft survival [80]. The use of immunosuppressive therapy helps preventing 
acute rejection episodes and enables the transplant, despite doing little to prevent chronic 
rejection which affects long-term survival of the graft. Nevertheless, acute rejection still 
occurs in nearly 10-20% of recipients within a year of transplantation [70]. 
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1.6 Immunogenetic databases 
This section briefly presents important web-based bioinformatics databases that are 
used throughout this thesis, and in the case of the Allele Frequency Net Database 
(AFND) adapted, in various contexts in Chapter 2-4. A wider summary beyond the 
databases presented in is contained within [31]. 
 
1.6.1 IMGT/HLA and the Immuno Polymorphism 
Database (IPD) 
The international ImMunoGeneTics information system® (IMGT®) [81] integrates 
various informatics tools related to various components of the immune system, such as 
genetic, proteomic, structural data from various organisms as a resulting effort from the 
HLA Informatics Group in collaboration with the European Bioinformatics Institute. 
Their sub-databases IMGT/HLA and the IPD/KIR [59] store information regarding 
human HLA and KIR, respectively, and were relevant for the analyses performed in the 
present thesis. 
The IMGT/HLA database maintains reported sequences of human MHC 
polymorphic loci in all available resolutions, and it is the official repository for the WHO 
Nomenclature Committee that determines HLA allele nomenclatures for newly released 
sequences. Clinical HLA typing laboratories for hospitals and donor registries, 
commercial organizations, and large-scale genome sequencing projects are the data source 
for IMGT/HLA. A high standard in data quality is achieved by the strict acceptance 
criteria for submission of novel sequences. Similar standards are employed in the 
IPD/KIR database, which is the official repository for KIR polymorphisms, following 
standards determined by the KIR Nomenclature Committee.  The IPD/KIR is part of a 
parent database named Immuno Polymorphisms Database (IPD), characterized by the 
storage of non-HLA immunogenetic data. IMGT® data can be also cross-referenced in 
the International Nucleotide Sequence Database Collaboration (INSDC), consisting of 
DNA DataBank of Japan (DDBJ) (Japan), GenBank (USA), and the EMBL-European 
Nucleotide Archive (ENA) (UK). 
Both IMGT/HLA and IPD/KIR platforms also provide tools for several types of 
analysis, such as allele metadata including previous nomenclatures, multi loci sequence 
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alignment of HLA and KIR alleles for both nucleotide and polypeptide sequences, 
sequence similarity search tools (FASTA and BLAST), and bulk data download of all 
versions released through ftp in custom formats. The IMGT/HLA also provides a listing 
of ambiguous allele combinations which are identical over exons 2 and 3 for HLA class I 
and exon 2 for HLA class II. 
IPD-IMGT/HLA URL: https://www.ebi.ac.uk/ipd/imgt/hla/ 
IPD-KIR URL: https://www.ebi.ac.uk/ipd/kir/ 
 
1.6.2 Allele Frequency Net Database (AFND) 
To capture population diversity of HLA and other immune genes, the Allele 
Frequency Net Database (AFND) [44] was created as an online repository for the storage 
of immune gene frequencies in different populations across the world. AFND is co-
developed by my supervisors Profs Middleton and Jones. As mentioned throughout this 
chapter, immunogenetic population variability influences several clinical and research 
fields such as associations with diseases, histocompatibility, pharmacogenetics, 
anthropological and evolutionary studies. Therefore, this repository provides invaluable 
information for a broad range of analyses in diverse research fields, containing more than 
a thousand populations from more than 10 million healthy individuals. AFND was 
initially created to store frequencies of immune gene polymorphisms, including 
polymorphic HLA and KIR loci, and has been in constant development with the addition 
of specialized data types and new tools, where some of the new developments are part of 
this thesis results. 
AFND data is sourced from peer-reviewed publications, from populations analysed 
by HLA working groups and committees, populations from national registries and 
individual laboratories. The data to be included is verified and standardized following the 
criteria for data quality before being publicized in the website. These criteria include 
correct designation of population characteristics and their geographical locations, 
validation of frequency data, and compliance with official allele nomenclatures. New 
AFND developments and investigations as part of this thesis involved the use of HLA 
and KIR frequency and genotype data previously stored in the database. Those 
developments providing specialized tools in clinical and research fields have been 
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described in the latest AFND update published in the Nucleic Acids Research journal in 
2015 during the course of this PhD, and are described in detail in chapters 2 and 3.  
AFND URL: http://allelefrequencies.net 
 
1.7 Research Aims 
 
The overall aim of the thesis is to use bioinformatics approaches to understand how 
genetic polymorphisms in immune genes (HLA and KIR) manifest in different outcomes 
in important clinical scenarios. Three scenarios were examined using three different 
bioinformatics techniques. First, associations between KIR genes and disease risk (largely 
auto-immune and infectious and disease risk were examined via literature mining 
alongside the generation of a new public database (Chapter 2). Second, the structural 
polymorphism of HLA and relationship to antibody-mediated transplant rejection was 
investigated using adapted population genetics techniques (Chapter 3). Third, HLA 
associations with adverse drug reactions were examined, using a particular case study of 
nevirapine, and the technique of in silico docking (Chapter 4). Chapter 5 presents brief 
discussion and summarises the overall results.  
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Chapter 2  
A database for curating the associations 
between killer-cell immunoglobulin-like 
receptors and diseases in worldwide 
populations 
 
2.1 Abstract 
The killer cell-immunoglobulin-like receptors (KIR) play a fundamental role in the 
innate immune system, through their interactions with human leukocyte antigen (HLA) 
molecules, leading to the modulation of activity in natural killer (NK) cells, mainly related 
to killing cells infected by pathogens. KIR genes are hugely polymorphic both in the 
number of genes an individual carry and in the number of alleles identified. This chapter 
describes the development of a database named KIR and Diseases Database (KDDB), 
capturing a large quantity of data derived from publications in which KIR genes, alleles, 
genotypes and/or haplotypes have been associated with infectious diseases (e.g. hepatitis 
C, HIV, malaria), autoimmune disorders (e.g. type I diabetes, rheumatoid arthritis), cancer 
and pregnancy-related complications. KDDB has been developed as part of the Allele 
Frequency Net Database (AFND, http://www.allelefrequencies.net), a larger platform 
which captures worldwide frequencies of alleles, genes and haplotypes for several immune 
genes, including KIR genes, in healthy populations, covering over four million 
individuals. KDDB has been created through an extensive manual curation effort, 
extracting data on more than a thousand KIR-disease records, comprising about a 
hundred different diseases. Furthermore, an overview analysis of KDDB showed a trend 
for association of activating KIR genes with autoimmune diseases. Published in two peer-
reviewed journals, KDDB has been providing a new resource for understanding KIR and 
disease associations. Database URL: http://www.allelefrequencies.net/diseases/ 
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2.2 Introduction 
The human leukocyte antigen (HLA) and killer-cell immunoglobulin-like receptors 
(KIR) gene families have been implicated in many disease association studies, due to their 
immune function and their high variability between individuals and populations. It has 
been suggested that variability presented by these genes is correlated with the observation 
of different disease outcomes, i.e. a higher susceptibility or protection against diseases in 
some individuals. Differences in their genetic compositions lead to individual variability 
in the immune response, fine tuning its effectiveness. While most HLA genes are broadly 
expressed in cells and are involved in multiple pathways of the cell-mediated adaptive 
immune response [36,82], KIR genes are mostly expressed in natural killer (NK) cells, 
modulating  its activation during a NK cell synapse [83]. 
NK cells are bone marrow derived lymphocytes that play an active role in the innate 
immune system by interacting with HLA class I molecules to kill pathogen infected cells 
[12]. Initially, NK cells were discovered as a result of their ability to target and kill tumour 
cell lines that expressed little or no HLA class I molecules, a mechanism defined as 
“missing-self” [14]. It is now known that more complex scenarios can modulate NK cell 
activation, which is dependent on a mixture of activating and inhibitory receptors present 
on the membrane and the interaction with a variety of ligands in target cells, including 
HLA ligands [15]. 
KIR receptors are the most polymorphic receptors in NK cells, and are able to 
contribute to its activation or inhibition. Expressed by a gene cluster in the chromosome 
19, their variability relates not only to their polymorphisms (allelic variants of a single 
gene), but also to the different combinations of KIR genes composing haplotypes [17-
21]. This variable gene and/or allele content of an individual [55], gives rise to a very large 
number of different genotypes that have been observed (presence/absence of KIR 
genes). To collect allele, haplotype and genotype frequencies of several immune genes in 
different healthy human populations, the Allele Frequency Net Database (AFND) was 
developed [84]. AFND stores large sets of data regarding HLA, KIR major 
histocompatibility complex class I chain related (MIC) and cytokine gene polymorphisms, 
and has shown to be frequently used in the immunogenetics field, being currently cited 
in more than 600 publications. To date, 594 different KIR genotypes in 18,981 individuals 
from 157 populations have been reported to AFND.  
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Different disease types, mainly of autoimmune and infectious nature, have been 
associated with KIR genetic variants. Reported results include associations with single 
genes (or single alleles) to associations with groups of genes and full genotypes 
[24,69,82,85]. A disease association is defined as a statistically significant association 
between a genetic element (gene, allele, genotype etc.) with a given disease outcome, either 
positive or negative i.e. the genetic profile makes the disease more likely/severe or less 
likely/severe than the control population. Due to the number of existing KIR genes and 
haplotypes, studies test for multiple associations with KIR varying in complexity, 
especially when attempting to investigate a synergic effect of combinations of genes. 
Furthermore, another level of complexity is added when information about HLA ligands 
is included. As such, the development of a database to store data regarding disease 
associations with those genes is a necessary step towards a more effective comprehension 
of such complex data. 
The work described in the present chapter produced two publications in two peer-
reviewed journals. The most relevant was published in 2013 by the Database journal, 
consisting of a detailed description of KDDB development similarly as presented in this 
chapter [86] (Appendix A). This publication was part of a special issue devoted to the 
International Society of Biocuration, and has been presented in the 6th International 
Biocuration Conference in the same year of publication. Contribution to this work from 
colleagues included as co-authors mostly consisted of data extraction from selected 
research papers to be included in KDDB, while planning, structuring and developing 
KDDB, as well as supervising the curation process, were majorly my contribution to the 
present work. Later, two manuscripts published in Transfusion Medicine and 
Hemotherapy journal (2014) [87] and in the Nucleic Acids Research journal (2015) [44] 
describing the latest updates in AFND include a summarized KDDB description 
(Appendix A). I am first author of the aforementioned publications, with a shared first 
authorship in the latter. KDDB development was also published (non-peer reviewed) in 
both European Federation for Immunogenetics (EFI) and American Society for 
Histocompatibility and Immunogenetics (ASHI) newsletters in 2014 (Appendix A). 
This chapter describes the creation of the KIR and Disease Database (KDDB) from 
data curation process to database development, and demonstrates its utility to facilitate 
meta-analyses and trend identification by exploring whether there is evidence that the 
presence of activating KIR genes are significantly associated with susceptibility to auto-
immune disease or protection from infectious disease or with and vice-versa. 
36 
 
2.3 Methods 
 
2.3.1 Data curation 
The first step towards creation of KDDB was the collection and extraction of data 
from peer-reviewed publications, according to the workflow shown in Figure 2.1. 
Published KIR and disease association studies were extracted from the HuGE Navigator 
(version 2.0) [88], which is a web-based tool enabling searches of the scientific literature 
for studies on genetic associations with diseases. The HuGE Navigator makes use of the 
MeSH (Medical Subject Headings) terminology, which contains standardised keywords 
associated with clinically-related published studies. In KDDB, we loaded MeSH terms 
that describe specific diseases with which associations have been found. Manual curation 
was performed to extract relevant data from retrieved studies. A set of consistent rules 
were applied to ensure that different curators extracted data in the same way (Figure 2.1). 
All studies identified based on the relevant MeSH terms were analysed and inserted into 
KDDB unless they did not fulfill one of the following criteria (also shown on Figure 2.1): 
(i) the article was not written in English, since we do not have the capability to translate 
articles at present (ii) the study design was not based on a gene frequency comparison 
between two samples with different clinical outcomes (future updates to KDDB will 
attempt to include more complex study designs), (iii) the article identified by the HuGE 
Navigator was not in fact related to KIR (i.e. misidentified), (iv) the study was not related 
to a disease specifically, but to transplantation outcomes. Studies associating 
transplantation outcomes and KIR have heterogeneous designs - some studies associate 
KIR-ligand matches/mismatches based on recipient and donor samples, and others 
correlate the risk of relapse with KIR combinations. These study designs are under 
evaluation to ascertain if they can either fit the existing KDDB schema, or will be stored 
in a different database schema in the future. A data validation pipeline was created to 
ensure that quantitative data and metadata had been correctly extracted from each 
publication, involving two curators reviewing the same source publication to reduce the 
chance for misinterpretation or copy-paste errors.
37 
 
 
Figure 2.1: The data curation pipeline, the types of data that were extracted from each publication and the submission workflow developed within KDDB. 
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2.3.2 Implementation 
The back-end of the database was developed using a Microsoft SQL Server relational 
database schema. The organization and relationship of core information stored in KDDB 
is described by the entity-relationship diagram presented in Figure 2.2. Three main 
relational entities were identified as common for all curated article: ‘Study’ comprises data 
regarding the study profile usually having single values, such as literature identifiers 
(PubMed ID or pmid), population data and sample sizes; ‘Disease’ provides additional 
classification of disease type and MeSH information, and it is a separate entity since a 
study can be associated with more than one disease classification; ‘Association’ comprises 
data regarding associations reported by individual studies; and ‘Country’ and ‘Continent’ 
stores standard geographic information used throughout AFND. 
 
 
Figure 2.2: Entity-relationship diagram of KDDB schema. 
 
Users can connect to the database using the most common web browsers. The web 
interface of KDDB has been created to allow users to query the database, retrieve data 
and submit new data sets. For that purpose, interactive web pages for querying and 
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submitting data were developed using the Active Server Pages (ASP) scripting 
environment and JavaScript language. The graphical display was designed using 
HyperText Markup Language (HTML) and Cascading Style Sheets (CSS), ensuring that 
the page will be viewable in most used web browsers. The data submission pipeline will 
be an important feature for future updates to KDDB, since we recognise the benefits of 
obtaining community input, including unpublished data sets. 
In order to submit studies to KDDB, a submission form pipeline was developed 
which can be accessed through the AFND homepage by the menu “Submissions” and 
the submenu “Add KIR and disease association study” (Figure 2.3). This web form 
consists of four steps. The first step captures summary information about the study 
including the number of patients and controls. Information is also captured on the 
geographic location of the population, the ethnicity and the bibliographic reference. The 
second step captures the disease association data – the genes, alleles, haplotypes, KIR-
HLA ligands, etc., the disease name, the frequency of patients and controls exhibiting the 
given genetic profile and the results of the statistical test. The third step (optional) allows 
users to upload anonymised raw data (the KIR genetic profile of every individual in the 
study). The fourth step allows users to review their data and submit. The submission 
pipeline is publicly available for users to submit their own studies, including unpublished 
data or studies missed in the curation process. 
 
2.3.3 KDDB Data Analysis 
Descriptive analyses of the frequency and distribution of studies associating diseases 
to KIR genes were performed in a subset of the associations captured by KDDB 
containing only: i) associations with the presence of single KIR genes (including 
associations with combinations of KIR and HLA ligands); ii) associations with complete 
information regarding the association direction (susceptibility / protection) and iii) 
associations with a specific disease term, excluding studies associating multiple diseases 
of different types (Appendix B). The exclusion of KIR combinations was implemented 
to avoid associations with low statistical power due to multiple comparisons, while the 
remaining criteria was implemented for simplicity. 
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Figure 2.3: Screenshots of the data submission pipeline within KDDB. The arrows indicate the flow of the user interaction with the submission pipeline.
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To investigate trends for activating or inhibitory KIR genes to be more frequently 
reported associated to susceptibility or protection to different disease types, the number 
of associations reported for KIR genes (individually or grouped by activating and 
inhibitory function) was compared between susceptibility and protection groups of each 
disease type using the Fisher’s exact test based on a 2×2 contingency table. Analysis 
grouping by gene function excluded 2DL4 and pseudogenes. Since there are only two 
neurological studies, this disease type was not included in statistical analysis. 
Undetermined studies were also not included in descriptive analysis due to their variable 
aetiology. All statistical analyses were performed using R statistical packages [89] within 
RStudio integrated development environment (IDE) [90]. 
 
2.4 Results 
 
2.4.1 Website organization 
The KIR and Diseases Database is part of Allele Frequencies Net Database (AFND), 
and can be accessed through the AFND homepage (http://www.allelefrequencies.net/) 
using the menu “KIR” and the submenu “KIR and disease associations” (Figure 2.4) or 
via a direct URL access at http://www.allelefrequencies.net/diseases/, both options 
opening the KDDB homepage (Figure 2.5). The website interface allows the user to query 
and retrieve KIR and disease associations applying a collection of filters. The user can 
restrict the search by gene or allele, country of origin of studied samples, continent of 
origin of studied samples or studied disease. Those filters can be applied alone or used in 
combination (Figure 2.6). 
Results from a query are retrieved in a table format, with each row being a different 
disease association with KIR (Figure 2.6). In each row, the following information is 
displayed: (i) row number, (ii) the associated MeSH term, (iii) the country of origin of the 
sample, (iv) the associated KIR profile, (v) the sample size and gene frequencies for 
controls and patients, (vi) odds ratio value, (vii) p-value and (viii) statistical method 
employed in comparisons. A link is provided, by clicking on the population name, to 
show the demographic information on the disease and corresponding control 
populations. As for normal populations in AFND, individual KIR gene frequencies or 
haplotype frequencies can be plotted on world maps. This enables a user to interpret 
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disease association risks for KIR profiles in a geographic, ethnic group or individual 
population-based context. 
 
 
 
 
Figure 2.4: KDDB can be accessed through the AFND homepage 
(http://www.allelefrequencies.net/) using the menu “KIR” and the submenu “KIR and disease 
associations”. 
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Figure 2.5: KDDB homepage providing links for querying the database and to submit new 
studies.  
 
 
Figure 2.6: The query interface within KDDB, showing the additional detail about a given 
association study retrieved by following the hyperlink. 
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2.4.2 KDDB Content and Geographical Distribution 
In the initial literature search performed alongside KDDB development, 159 articles 
remained after applying the exclusion criteria detailed in Figure 2.1. From all the articles, 
a total of 1027 KIR disease-associations were captured from 113 articles. A set of 46 
articles were removed at this stage due to studies lacking mandatory data/metadata or the 
numerical data were inaccessible, for example displayed only on charts. The genetic 
associations identified in this data compilation included those with single KIR genes, 
profiles of combined KIR genes and / or HLA class I ligands, and full KIR genotypes. 
In total, 70 unique diseases have been associated with KIR across the studies in the 
present database. From these studies, a total of 1027 KIR records were inserted into 
KDDB, of which 496 are statistically significant KIR-disease associations. 
After the initial curation, a total of 139 additional articles were included in KDDB by 
further instances of literature search and data curation, comprising a total of 427 
associations, where 26 diseases distinct from the previous data collection were added, 
summing to a total of 96 distinct diseases investigated by studies stored in KDDB. As 
shown in Figure 2.7, KIR studies associated with autoimmune and infectious diseases are 
the majority, accounting for 34% (89) and 32% (84), respectively, followed by cancer 
studies with 15% (41), pregnancy complications with 8% (21) and neurological conditions 
with 1% (2). The remaining 10% (26) of the studies investigated diseases or conditions 
with undetermined caused or not fitting the previous categories (e.g. multifactorial 
diseases), but known to have an immune component related to its manifestation. Some 
studies were associated to multiple disease types, and were included in more than one 
disease type category. 
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Figure 2.7: (A) Percentage of studies stored in KDDB classified by disease type. (B) Percentage 
of studies stored in KDDB classified by continent. Multi-centric studies or articles not clearly 
mentioning geographical origin of samples were not included.  
 
KIR and disease studies have a wide geographical distribution, but most of the studies 
are from Europe (42%), followed by Asia (25%) and North America (13%) (Figure 2.7). 
Studies investigating infectious diseases have a relatively even distribution compared to 
autoimmune disease studies, the latter group being concentrated in certain geographical 
regions, being completely absent in Africa, except for Tunisia in North Africa. Some 
countries such as Japan, and several countries in the Eastern and Northern portion of 
Europe, including all Scandinavian countries, have reported autoimmune, but no 
infectious disease studies. Argentina, the north of Brazil in South America, and most 
countries in Africa and Southeast Asia have only reported KIR studies with infectious 
diseases. Other disease types have an even global distribution, except for the absence of 
cancer studies in Africa (Figures 2.8 and 2.9). 
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Figure 2.8: Geographical distribution of KIR studies according to the disease type investigated. 
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Figure 2.9: Geographical distribution of KIR studies investigating autoimmune and infectious diseases.
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2.4.3 Descriptive analysis of KDDB data 
The following analyses were performed using a subset of the associations present in 
KDDB selected according to criteria described in Methods section. From associations 
reported in studies, autoimmune and infectious diseases have been associated with all 
activating (2DS1, 2DS2, 2DS3, 2DS4, 2DS5 and 3DS1) and inhibitory genes (2DL1, 
2DL2, 2DL3, 2DL5, 3DL1 and 3DL2) for both susceptibility and protection effects. For 
other disease types, some KIR genes have not been associated with either effect (Table 
2.1), but also a lower number of studies have been published for those disease types. 
Regarding the number of studies finding associations with each KIR gene, Figure 2.10 
shows there is variability in the frequency of reported associations according to 
susceptibility and protection to disease types. Some trends are noticeable for autoimmune 
diseases, where 2DS1, 2DS2, 3DS1 and 2DL2 appear to have been more frequently 
reported associated with susceptibility than to protection to this disease type, while 3DL1 
is more frequently reported associated with its protection. Furthermore, the highest 
number of reported associations by disease type was 2DS1 association with susceptibility 
to autoimmune diseases, accounting for 29% of the autoimmune disease studies included 
in this analysis, followed by 2DL2 in 28% of the studies (Table 2.1). 
For infectious diseases, three activating KIR genes are mostly reported associated 
with susceptibility (2DS1, 2DS2 and 2DS3), while the other activating KIR genes (2DS4, 
2DS5 and 3DS1) have been mostly associated with protection, where 2DS3 and 3DS1 
show higher differences between frequencies of susceptibility and protection reported 
associations. Regarding other disease types, a trend for higher frequency of reported 
associations of 2DL1 with protection to cancer can be observed. Despite the trends 
observed, statistical analysis comparing the number of reported associations with each 
KIR gene against all other associations for susceptibility and protection groups, found 
only 3DL1 for autoimmune diseases and 2DL1 for cancer to be statistically significant 
(Table 2.1) (P = 0.04 and P = 0.02, respectively). 
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Table 2.1: Comparison of KIR gene associations with susceptibility and protection to diseases reported in multiple association studies found in the literature, 
grouped by disease type. 
KIR genes Autoimmune 
(Studies = 58) 
Cancer 
(Studies = 23) 
Infectious 
(Studies = 51) 
Pregnancy 
(Studies = 7) 
Neurological 
(Studies = 2) 
Activating S P P-Value S P P-Value S P P-Value S P P-Value S P P-Value 
2DS1 17 (0.29) 7 (0.12) 0.91 5 (0.22) 0 (0.0) 1.00 7 (0.14) 3 (0.06) 0.96 2 (0.29) 1 (0.14) 0.88 1 (0.5) 0 (0.0) - 
2DS2 14 (0.24) 7 (0.12) 0.79 3 (0.13) 2 (0.09) 0.78 6 (0.12) 4 (0.08) 0.86 3 (0.43) 0 (0.0) 1.00 1 (0.5) 0 (0.0) - 
2DS3 4 (0.07) 4 (0.07) 0.38 3 (0.13) 1 (0.04) 0.93 9 (0.18) 3 (0.06) 0.99 1 (0.14) 0 (0.0) 1.00 0 (0.0) 0 (0.0) - 
2DS4 5 (0.09) 1 (0.02) 0.95 2 (0.09) 2 (0.09) 0.64 3 (0.06) 4 (0.08) 0.53 0 (0.0) 2 (0.29) 0.21 1 (0.5) 0 (0.0) - 
2DS5 3 (0.05) 3 (0.05) 0.44 3 (0.13) 0 (0.0) 1.00 4 (0.08) 6 (0.12) 0.40 2 (0.29) 1 (0.14) 0.88 1 (0.5) 0 (0.0) - 
3DS1 11 (0.19) 3 (0.05) 0.96 4 (0.17) 2 (0.09) 0.87 3 (0.06) 8 (0.16) 0.12 2 (0.29) 0 (0.0) 1.00 1 (0.5) 0 (0.0) - 
Total Activating 54 25 0.04* 20 7 0.004* 32 28 0.21 10 4 0.04* 5 0 - 
Inhibitory                
2DL1 8 (0.14) 7 (0.12) 0.36 1 (0.04) 7 (0.3) 0.02* 2 (0.04) 2 (0.04) 0.71 0 (0.0) 2 (0.29) 0.21 0 (0.0) 0 (0.0) - 
2DL2 16 (0.28) 10 (0.17) 0.61 4 (0.17) 4 (0.17) 0.57 7 (0.14) 10 (0.2) 0.34 0 (0.0) 1 (0.14) 0.48 0 (0.0) 0 (0.0) - 
2DL3 7 (0.12) 7 (0.12) 0.28 2 (0.09) 4 (0.17) 0.27 9 (0.18) 14 (0.27) 0.21 0 (0.0) 0 (0.0) 1.00 0 (0.0) 0 (0.0) - 
2DL5 8 (0.14) 5 (0.09) 0.63 1 (0.04) 2 (0.09) 0.45 5 (0.1) 3 (0.06) 0.88 1 (0.14) 1 (0.14) 0.74 1 (0.5) 0 (0.0) - 
3DL1 4 (0.07) 8 (0.14) 0.04* 4 (0.17) 4 (0.17) 0.57 4 (0.08) 5 (0.1) 0.53 0 (0.0) 1 (0.14) 0.48 1 (0.5) 2 (1) - 
3DL2 1 (0.02) 1 (0.02) 0.63 0 (0.0) 0 (0.0) 1.00 1 (0.02) 1 (0.02) 0.76 0 (0.0) 0 (0.0) 1.00 0 (0.0) 0 (0.0) - 
Total Inhibitory 44 38 - 12 21 - 28 35 - 1 5 - 2 2 - 
2DL4 0 (0.0) 0 (0.0) 1.00 0 (0.0) 0 (0.0) 1.00 0 (0.0) 0 (0.0) 1.00 0 (0.0) 1 (0.14) 0.48 0 (0.0) 0 (0.0) - 
2DP1 1 (0.02) 3 (0.05) 1.00 0 (0.0) 0 (0.0) 1.00 0 (0.0) 0 (0.0) 1.00 0 (0.0) 1 (0.14) 1.00 0 (0.0) 0 (0.0) - 
3DP1 2 (0.03) 0 (0.0) 1.00 0 (0.0) 0 (0.0) 1.00 0 (0.0) 0 (0.0) 1.00 0 (0.0) 0 (0.0) 1.00 0 (0.0) 0 (0.0) - 
‘Studies’ = Number of studies found in the literature for the respective disease type. ‘S’ = Susceptibility; ‘P’ = Protection. ‘Pregnancy’ refers to pregnancy complications. 
The frequency reported between parenthesis is the number of associations reported divided by ‘Studies’. 2DL4 has been shown to have both functions (Inhibitory / 
Activating), and 2DP1 and 3DP1 are pseudogenes. * P-values < 0.05, i.e. statistically significant differences between the number of susceptibility and protection KIR gene 
associations found in the literature related to different disease types. Statistical analysis was not performed for ‘Neurological’ studies due to the low number of studies 
available. 
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Figure 2.10: Distribution of individual KIR gene associations with susceptibility or protection to 
disease types. The y-axis is the count of the number of studies reporting a statistically significant 
association of the given gene with a given disease belonging to one of the disease classifications, 
either making individuals more susceptible (green) or more protected (red) under the four general 
headings. The KIR genes have been divided into those understood to be “activating” (left panel) 
and “inhibitory” (right panel). 
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Figure 2.11: Distribution of KIR genes associations with susceptibility or protection to disease 
types according to their function. The y-axis is the count of the number of studies reporting a 
statistically significant association of an activating or inhibitory KIR gene with a given disease 
belonging to one of the disease classifications, either making individuals more susceptible (green) 
or more protected (red) under the four general headings. 
 
Grouping genes by function also shows variability in the frequency of reported KIR 
gene associations with susceptibility and protection to disease types (Figure 2.11). For 
autoimmune diseases, cancer and pregnancy complications, enrichment of activating KIR 
gene associations with susceptibility to these disease classifications can be observed. An 
opposite trend of inhibitory KIR gene associations with protection is observed only in 
relation to cancer and pregnancy complications, but not for autoimmune diseases. For 
infectious diseases, only a slight difference is observable between the compared groups. 
Statistical analysis comparing the number of reported associations with KIR genes 
grouped by function between susceptibility and protection groups, found enrichment of 
activating KIR genes in susceptibility associations to autoimmune diseases, cancer and 
pregnancy complications to be statistically significant (Table 2.1, P = 0.04, P = 0.004 and 
P = 0.04, respectively). 
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For a detailed analysis of the diseases involved in the previously mentioned analysis, 
an overview of the proportions of activating KIR gene associations with susceptibility to 
individual diseases belonging to autoimmune, cancer and pregnancy complications 
disease classifications is shown in Figure 2.12, revealing a wide range of autoimmune 
diseases and cancer types covered by those disease types. Diabetes mellitus type 1 
accounts for the larger proportion of the associations of activating KIRs with 
susceptibility to autoimmune diseases (approximately 26%), while acute lymphoblastic 
leukaemia and colorectal neoplasms accounts for the larger proportion of the associations 
of activating KIRs with susceptibility to tumours (45% and 25%, respectively). In 
contrast, associations of those genes with susceptibility to pregnancy complications are 
all related to recurrent (70%) and spontaneous (30%) miscarriage. 
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Figure 2.12: Proportion of reported KIR associations associated with susceptibility to diseases belonging to autoimmune, cancer and pregnancy 
complications classifications of disease types. 
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Figure 2.13: Clustered heatmap of KIR gene frequencies across populations in AFND. KIR genes 
belonging to A haplotypes (major branch on the right side of the x-axis) show higher frequencies 
in populations comprising mostly inhibitory KIR genes, while KIR genes exclusive to B 
haplotypes (major branch at the left side of the x-axis) show lower and most variable frequencies, 
containing mostly activating KIR genes. The closer KIR genes are clustered, the higher the chance 
they have strong linkage disequilibrium. 
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Since certain KIR genes have strong linkage disequilibrium, a clustered heatmap was 
generated for KIR gene frequencies across populations present in AFND to investigate 
KIR genes clustered together that can be influencing disease associations with KIR genes 
(Figure 2.13). KIR genes from the less variable A haplotype show generally higher 
frequencies in populations and contain mostly inhibitory KIR genes, while KIR genes 
from B haplotypes show lower and most variable frequencies, containing mostly 
activating KIR genes. Among B haplotype genes, strong linkage disequilibrium between 
two centromeric KIR genes (2DS2 and 2DL2) and between two telomeric KIR genes 
(2DS1 and 3DS1) are evidenced by their clustering, showing very similar gene frequencies 
across populations. 
 
2.5 Discussion 
An overview of the studies included in KDDB identified about a hundred distinct 
diseases of diverse nature associated with KIR genes, suggesting NK cell involvement in 
underlying mechanisms of several biological pathways. They have a wide world 
distribution, however most of the studies originate from developed countries. Most of 
the disease types associated with KIR seem to have an even geographical distribution, 
except for autoimmune diseases. This differential distribution of KIR studies with 
autoimmune diseases is in accordance with the ‘hygiene hypothesis’, stating that a lower 
incidence of infectious diseases in a population, due to economic development or climate, 
is correlated with the increasing incidence of autoimmune and allergic diseases [91]. 
However, differences may also be due to socio-economic factors in developing countries 
affecting access to health care and research development [92,93]. 
An individual NK cell simultaneously expresses distinct KIR receptors according to 
the individual KIR genotype, where the resulting profile contributes to the modulation 
of NK cell activity. In summary, the characteristics from each individual KIR genes that 
may affect their combined effect on NK cell activation are: i) KIR function, which can 
be activating, inhibitory or both, ii) their ligand specificity and iii) structural differences 
affecting binding to ligands, existing between KIR receptors with similar function, or 
between polymorphisms of a specific KIR gene. 
Utilizing disease association studies within KDDB, an explorative analysis of reported 
statistically significant KIR and disease associations was performed, focusing on the 
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investigation of trends related to KIR gene function for different disease type 
classifications (autoimmune diseases, infectious diseases, cancer and pregnancy 
complications) and comparison between the association effect (susceptibility or 
protection). Reported KIR gene associations with susceptibility to autoimmune diseases, 
cancer and pregnancy complications show enrichment of activating KIRs, where more 
studies have reported association between susceptibility to those disease types and 
activating genes than one would expect by chance (Table 2.1). For autoimmune diseases 
and cancer, those associations cover a range of disorders, while only miscarriage (habitual 
and spontaneous) is covered by the pregnancy complications category. 
Nevertheless, only miscarriage and pre-eclampsia have been associated with KIR 
genes, and the enrichment of activating KIR associations with susceptibility to 
miscarriage found in the present study suggests a potential role of these genes in 
miscarriage occurrence, but not in pre-eclampsia. Uterine NK (uNK) have a specialized 
function during trophoblast invasion in pregnancy, however the mechanisms involving 
activation of uNK cells are not fully understood [23]. It has been shown that both 
excessive activation and inhibition of uNK cells interacting with trophoblast cells 
correlate with birth weight and foetus mortality [94]. Additionally, despite the potential 
role of KIR2DL4 recognizing HLA-G ligand with restricted expression in foetal 
trophoblast cells, only one study in KDDB found an association of this gene with pre-
eclampsia. It should be noted, however, that the number of studies investigating KIR and 
pregnancy complications in the present analysis is limited. 
It has been suggested that KIR profiles leading to lower inhibition and higher 
activation would be beneficial in infections and at the same time constitute a risk to 
autoimmunity and cancers that have an inflammatory component [24]. Present results 
support the hypothesis of a relationship between enrichment of activating KIR gene 
associations and susceptibility to autoimmune and cancer, but did not indicate clear 
relationships with protection to infectious diseases. 
Most of the studies associating KIR and infectious diseases involve 2DL2 (20%) and 
2DL3 (27%) conferring protection effect, but the frequency of studies associating the 
same genes with susceptibility to infectious diseases are similar (18% and 14%, 
respectively). A possible explanation for those inhibitory genes to be associated with both 
susceptibility and protection against infections could be due to their function in 
recognizing HLA ligands. Interactions between KIR and HLA-C ligands C1 (recognized 
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by 2DL2 and 2DL3) and C2 (recognized by 2DL1) appear to be the dominant 
mechanisms controlling NK cell activation [95]. These receptors have also been shown 
to recognize peptides in HLA ligands, although with a much broader specificity compared 
to TCR receptors from T cells [95]. While 2DL1 shows a consistent high frequency across 
populations, 2DL2 and 2DL3 frequencies are relatively more variable (Figure 2.13), being 
more likely for them to be contributing to the variability of NK cell response to infections. 
The data present in KDDB could in theory also be used in more robust systematic 
review and meta-analysis methods specific to observational studies. A systematic review 
consists of locating individual studies investigating a common research question, while 
reviewing their methods and results regarding their eligibility and methodological quality. 
A meta-analysis consists of a statistical analysis of the resulting data typically derived from 
a systematic review, generating a new result from the overall pooled dataset. Additionally, 
meta-analysis methods include assessment of publication bias and heterogeneity among 
studies (i.e. different magnitudes or different directions across results) [96]. 
However, there are limitations to the application of meta-analysis methods in KIR 
and disease studies due to the variability and complexity of KIR genes. Genetic variability 
among populations acts a confounder factor in meta-analyses, requiring stratification of 
the reviewed pooled dataset by ethnicity or application of multivariate analysis [97,98]. 
Furthermore, combinations of multiple KIR genes within haplotypes interacting with 
variable ligands could influence disease outcome, whereas most KIR studies compare 
only individual KIR genes between case and control groups. KIR and disease meta-
analyses that have been published to date investigate the effect of individual KIR genes 
in specific diseases [99-104]. These studies also stratify populations by ethnicity, using 
broad ethnical classifications, such as ‘Asian’, ‘Caucasian’ and ‘Black’, which have been 
the subject of debate in the immunogenetic field [105]. The data in KDDB, even when 
examining one particular disease, tends to split across different ethnic groups, which 
should not be pooled for a meta-analysis. As such, traditional meta-analysis methods 
might be appropriate for a selection of diseases covered in KDDB, for which there are 
multiple studies on the same ethnic group e.g. type I diabetes, but these methods would 
have to be used with caution if there are doubts that other environmental factors were 
not well matched in different studies. Additional studies investigating combinations of 
KIR genes and their interactions with HLA ligands may be necessary to perform meta-
analyses capable of covering the effect of multiple KIR and HLA genes in diseases, 
beyond what is currently captured by KDDB. 
58 
 
The first release of KDDB included only data identified by the HuGE Navigator. 
Since HuGE Navigator does not retrieve all studies, additional search strategies, for 
example via Pubmed and Web of Knowledge, have been employed to locate studies 
missed in the first pass curation process. Studies that do not fit into the simple model of 
a case-control disease association study have been excluded from the curation process. 
Capturing more complex stratification studies is possible in KDDB, but will necessitate 
either some loss of granularity of the data, or the development of a much more complex 
schema and display interface. Another limitation of KDDB is that many disease studies, 
especially those that do not find statistically significant associations, are not published and 
there is a risk that resources such as KDDB could suffer from publication bias. The web 
form for data submission allows researchers to submit their data, even if it is unpublished 
or does not contain a statistically significant association. 
Other tools in AFND also allow uploading of anonymised raw data (individual KIR 
type and HLA ligands) to enable improved quality control measures (such as validation 
of frequency calculations) and to enable advanced analyses of the data. For example, 
having the individual data available will allow analyses such as looking at disease 
associations in the centromeric or the telomeric regions and evaluating the influence of 
LD in different populations. 
 
2.6 Conclusions 
Over the last ten years of existence, AFND has provided the immunogenetics and 
histocompatibility community with an online repository for the examination of immune 
gene frequencies in different healthy populations. Development of KDDB aims to cover 
disease studies that have been associated with KIR genes and to include studies in which 
no significant association has been found, to avoid publication bias. Analysis of KDDB 
content provided insights on the relationship of KIR functionality with different disease 
classifications, showing an enrichment of activating KIR genes reported associated with 
susceptibility to autoimmune diseases, tumour development and miscarriage. Future work 
regarding database development will consist of improvements to KDDB interface to 
facilitate data retrieval and database reorganization for accommodation of study types not 
fitting the current schema. Additional data in other sections of AFND connecting to data 
in KDDB are also envisioned, since KIR gene frequencies, genotyping data and LD data 
are important assets for investigating KIR associations. Finally, KDDB facilitates meta-
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analyses and data re-use to understand the underlying function of KIR genes in a variety 
of disease processes, and has the potential to fill the existing gap in literature from 
publication bias. 
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Chapter 3  
HLA epitope matching in world 
populations 
 
3.1 Abstract 
The presence of anti-HLA donor-specific antibodies (DSA) in transplant patients is 
a crucial factor related to rejection. These antibodies target specific regions of HLA 
proteins that are different from the transplant patient’s HLA proteins – referred to as 
HLA epitopes. Current efforts in HLA matching for transplantation often attempt to 
minimise the number of allele-level mismatches. Each allele is distinct from others based 
on any non-synonimous variation considering the whole DNA sequence at any position. 
However, HLA comparison on a sequence level does not reflect protein structure 
similarity as an immunological target, since individuals with different HLA genotypes may 
be able to carry the same set of HLA epitopes. A matching strategy based solely on HLA 
allele nomenclature ignores those cases, even though they may not elicit an anti-HLA 
DSA response. Similar to allele frequencies, understanding HLA epitope frequencies in 
world populations could be important information for estimating the probability of 
finding a suitable donor in a given geographical region or human population. The first 
aim of this chapter is to describe the development of the HLA Epitope Frequency 
Database (HLA-EpiDB) as a new feature of AFND, being publicly accessible for users. 
HLA-EpiDB was generated by mapping HLA epitopes definitions to 
genotype/haplotype data stored in AFND to generate population-level HLA epitope 
frequencies. The second aim of this chapter is to present an explorative analysis of the 
use of HLA epitope definitions in alloreactivity profile matching using single antigen bead 
(SAB) profiles from sensitized patients. Comparisons between alloreactivity profile 
matching using HLA epitopes and high resolution HLA allele matching reveals that 
differences in matching proportions obtained using both methods are influenced by 
current limitations in both SAB assays and HLA epitope definitions. Despite these 
analyses suggesting that optimization of alloreactivity matching requires improvements in 
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both methods, it also highlights a potential use of HLA epitope definitions in increasing 
the granularity from SAB assay results. A better understanding of HLA epitopes can 
contribute to reducing the chance of positive crossmatch in sensitised patients, while 
knowledge of HLA epitope frequencies help transplant clinicians and the 
immunogenetics research community to better understand and determine HLA mismatch 
acceptability across worldwide populations. Database URL: 
http://allelefrequencies.net/hlaepitopes/ 
 
3.2 Introduction 
Early transplantation studies using tumours in mice led to the establishment of the 
tissue compatibility concept, where the major histocompatibility complex (MHC) was 
recognized as a genetic region containing genes to be matched prior to transplantation 
[106]. Within the MHC region, the HLA gene complex contains the most relevant genes 
for tissue compatibility due to their extensive variability and broad expression in tissues, 
as differences in HLA gene type between donor and recipient can lead to rejection of the 
transplanted tissue triggered by an immune response against non-self molecules. HLA 
class I and class II molecules play a key role in the adaptive immune response, being 
responsible for antigen presentation to cytotoxic (CD8+) and helper (CD4+) T cells, 
respectively. While HLA class I molecules are ubiquitous expressed in cells, HLA class II 
expression is mostly restricted to APCs [36]. 
“Classical” HLA class I (HLA-A, -B and -C) and class II (HLA-DRB, HLA-DP and 
HLA-DQ) are the most polymorphic HLA loci, and therefore considerably important in 
transplantation. According to IMGT/HLA database release 3.29.0.1, 12,544 alleles have 
been described for “classical” HLA class I loci and 4,622 alleles have been described for 
“classical” HLA class II [107]. Most of the variation between alleles is observed within 
the peptide-binding site (or antigen recognition site) region, as selective pressures from a 
pathogen-rich environment favouring the maintenance of diverse HLA molecules that 
can present multiple peptide “shapes” [41]. 
However, all this necessary variability for defending the organism against pathogens 
represents a problem in the unnatural transplantation scenario. A transplant of a foreign 
tissue (allograft) containing molecules not present in the recipient triggers cellular and 
humoral alloimmune responses targeting non-self molecules present in the allograft. The 
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extent of HLA mismatching between donor and recipient is correlated with the risk of 
rejection and graft loss, but HLA matching requirements vary according to different 
transplant types [108]. Haematopoietic stem cell transplantation (HSCT) has the strictest 
matching requirements, needing high resolution (two field allele nomenclature) matching 
for most ‘classical’ HLA loci [109]. For logistical purposes, renal transplants only use low 
resolution (one field allele nomenclature) matching for HLA-A, -B and -DR loci and 
absence of anti-HLA DSA [73] (see Chapter 1 for more details on HLA allele resolution 
levels). The presence of anti-HLA DSA pre-transplant is associated with hyperacute 
rejection – an immediate immune reaction against the transplanted organ – while DSA 
formed post-transplant are associated with acute and chronic antibody-mediated rejection 
(AMR) – characterized by acute or chronic tissue injury with microvascular inflammation 
[108,110,111]. 
 
3.2.1 Anti-HLA Alloantibody Detection 
A patient with anti-HLA DSA, or a ‘sensitized’ patient, has had previous contact with 
non-self HLA molecules through previous transplants, pregnancy or blood transfusion 
[108]. Some patients are considered ‘highly sensitized’, having developed antibodies 
against most HLA antigens, being extremely challenging for them to find a suitable donor 
[112]. The level of sensitization in patients is defined by the PRA measure, consisting in 
the proportion of the population to which a patient will react due to pre-existing 
alloantibodies. In 2006, more than 15,000 patients on the waiting list for renal 
transplantation in the United States were reported sensitized (defined as PRA > 20%) 
and nearly 50% of those patients had a PRA > 80% [113]. 
 Detection of those alloantibodies was initially performed using cell-based assays 
containing lymphocyte cell panels, but introduction of solid-phase assays using purified 
or recombinant HLA class I and class II molecules improved the sensitivity and specificity 
of anti-HLA antibody detection [114]. A commonly used solid-phase assay uses 
multiplexed single antigen beads (SAB) coated with single HLA antigens and flow 
cytometry technology to detect binding of human IgG antibody (Luminex®) [115]. SAB 
assays can detect alloantibodies against class I (HLA-A, -B and -C) and class II molecules 
(HLA-DR, HLA-DQ and HLA-DP), with different degrees of resolution and allele 
coverage. 
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SAB assay results report the mean fluorescence intensity (MFI) which is a semi-
quantitative estimation of the antibody level. Despite also being used to monitor antibody 
levels in patients especially post-transplant [116], SAB results are mainly interpreted 
qualitatively through the definition of an MFI cut-off value. Beads containing HLA types 
showing MFI values above the cut-off value are considered positive for the presence of 
alloantibodies against the HLA antigens present on a giving bead. This cut-off value varies 
across transplant laboratories since there is no consensus regarding adequate thresholds. 
Therefore, laboratories define the cut-off value based on the MFI levels observed in 
relevant controls and laboratory experience from clinical results obtained over time, 
falling usually in the range of 1000-2000 MFI [117]. 
Ultimately, interpretation of MFI values from SAB assays should be analysed 
individually in conjunction with patient history. MFI values can be affected by several 
factors related to the SAB assay, to the patient serum, or to characteristics specific to 
some HLA epitopes recognized by patient’s antibodies, such as epitope sharing, affecting 
its antigenicity. Different HLA types on different beads share common HLA epitopes 
leading a specific anti-HLA antibody to bind on multiple beads resulting in reduction of 
the MFI levels reported for single beads [118]. 
In the transplant scenario, the humoral immune system sees each HLA type as a 
collection of HLA epitopes capable of being recognized by alloantibodies, where 
mismatched epitopes between HLA types from donor and patient result in antibody 
response. This rationale is leading clinicians and researchers to look at HLA matching 
from a structural perspective, using HLA epitopes as units to be matched. 
 
3.2.2 HLA Epitopes and Structural Matching 
In solid organ transplantation, the production of anti-HLA DSA will occur due to B 
cell recognition of non-self HLA epitopes. The HLA molecule surface with its multiple 
polymorphic amino acids represents a collection of possible HLA epitopes to elicit 
antibody production, if mismatched. Despite laboratory identification of several HLA 
epitopes [119], current experimental findings depend on the limited availability of 
monospecific alloantibodies capable of recognizing HLA epitopes [120]. Filling this gap, 
knowledge of epitope-paratope interaction using protein structure crystallographic 
models allowed for in silico determination of HLA epitopes [121]. 
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The total epitope surface interfacing an antibody paratope is around 15-22 residues, 
with a contact area of 650-900 Å radius, but the specificity of an epitope is associated 
with a smaller region of 3-3.5 Å radius. Referred as ‘functional’ HLA epitopes, this 
epitope area mainly comprises of polymorphic amino acids interfacing the centrally 
located complementary determining region (CDR) H3 loop, which is the loop mostly 
associated with antibody specificity (Figure 1.3, Chapter 1). Exposed mismatched 
polymorphisms in the HLA molecule surface within the ‘functional’ epitope area are seen 
to be responsible for eliciting an antibody response (Figure 3.1). This set of polymorphic 
amino acids (or ‘eplets’) consist of the functional units defining an HLA epitope to be 
compared in HLA epitope matching. 
 
 
Figure 3.1: Polymorphic residues on HLA-A, -B and -C molecules. On the α-heavy chain, residues 
in yellow are polymorphic and residues in pink are conserved. In blue, the β2-microglobulin that 
is responsible for anchoring the HLA molecule in the membrane [122]  
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Several HLA epitopes are shared among different HLA alleles and across different 
HLA loci, a reflex of evolutionary mechanisms such as convergent evolution and gene 
recombination acting on the HLA gene family [36]. This characteristic is the main reason 
why some individuals become ‘highly sensitized’ if they are immunized against an epitope 
shared by many HLA alleles appearing at a high frequency in populations. Nevertheless, 
the extent of shared epitopes between HLA alleles and loci raises the possibility of HLA 
epitope compatibility between mismatched HLA types (Figure 3.2). Furthermore, HLA 
epitope matching enables a quantitative analysis based on the number of mismatched 
epitopes. Different HLA type comparisons having the same number of allele mismatches 
can show different numbers of HLA epitope mismatches (also referred as ‘epitope load’). 
Since a higher number of HLA epitope mismatches have been correlated with an 
increased risk of rejection, [122,123] information on the number of epitope mismatches 
could help patients who are unable to find a ‘match’ to minimize their risk of rejection. 
 
 
Figure 3.2: Single HLA-A antigen mismatch representing an acceptable mismatch from an HLA 
epitope perspective (Donor: A*32 / Patient: A*01). Despite nine epitopes in A*32 that are not 
present in A*01, they are configure as shared self-epitopes present in other HLA antigens from 
patient.  
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A list of HLA epitope definitions is maintained by the HLA Epitope Registry 
(http://www.epregistry.com.br/) [120] (Figure 3.3), with a nomenclature system based 
on positions and abbreviated names of polymorphic residues composing the ‘eplets’ of 
each HLA epitope. Some of the listed HLA epitopes have antibody reactivity evidence 
(‘provisional’ or ‘confirmed’), while others have only been predicted in silico. The database 
also provides the HLA alleles mapped to each epitope, including a selection for 
Luminex® SAB alleles only. Using the aforementioned HLA epitope definitions, an 
epitope matching algorithm called HLA Matchmaker has been developed [124] to 
determine epitope mismatches in HLA types from patients and donors, and also to 
identify epitopes belonging to reactive HLA alleles in SAB assays possibly being 
recognized by alloantibodies. 
 
 
Figure 3.3: Screenshot of the HLA Epitope Registry database, showing a subset of class I epitopes 
and HLA alleles where they are present, subdivided in a category containing only alleles present 
in Luminex® SAB and another category including alleles absent in SAB assays. 
 
Originally, HLA Matchmaker was distributed as a spreadsheet file, but due to the 
difficulty to use the tool in a clinical environment because of its time-consuming analysis 
of alloantibodies, EpVix was conceived as a web-based version of HLA MatchMaker with 
a more user-friendly interface [125] (Figure 3.4). For alloantibody analysis, EpVix takes 
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the patient’s HLA type and SAB assay result as input, as well as the chosen MFI cut-off 
value. All epitopes present in the patient’s HLA type are flagged as self-epitopes. 
Reactivity to epitopes present in HLA alleles below the cut-off value is considered 
negative. Finally, the remaining epitopes present only in HLA alleles above the cut-off 
values are considered potential epitopes being targeted by alloantibodies, as in practice it 
is possible that only some of the remaining epitopes may be alloantibody targets. For 
example, an output from EpVix may show a common epitope related to all HLA alleles 
above the cut-off, suggesting the possibility that only that epitope has caused the patient 
immunization against all reactive HLA types in the SAB assay. In these situations, 
knowledge of the HLA types causing the immunization event helps verifying actual 
reactive epitopes. 
 
 
Figure 3.4: Screenshot of EpVix [125] option for epitope analysis of alloreactive antibody SAB 
profiles generating all possible reactive epitopes, with additional options to manipulate the MFI 
cut-off value and interactively highlight epitopes shared by different alleles. 
 
HLA matchmaker has been mostly applied to HLA mismatch acceptability for 
sensitized patients by minimizing epitope mismatches as an attempt to improve overall 
survival of the transplanted organ [126,127]. The Eurotransplant organisation, a program 
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to facilitate donor selection and cross-border exchange of donor organs, has incorporated 
epitope matching for highly sensitized patients [123]. 
With the investigation of HLA epitopes starting to be part of the routine of transplant 
laboratories and an added factor in donor selection programs, it is also necessary to gather 
knowledge of the worldwide distribution of HLA epitopes for improving matching 
algorithms using HLA epitope data. A population HLA epitope frequency is the 
percentage of the population possessing a given epitope (phenotypic frequency) that can 
be expressed by distinct HLA genes or alleles. Similar to how HLA allele and haplotype 
population frequencies are currently used in donor search algorithms [128,129], HLA 
epitope frequencies from populations can be used for development of epitope-based 
donor selection strategies. 
EpFreq-DB database, described in this chapter, has been developed as a new 
repository within the Allele Frequency Net Database (AFND) aiming to fill this 
knowledge gap by storing worldwide HLA epitope frequencies originated from HLA 
population genotype data. A short description of EpFreq-DB has been reported in two 
manuscripts published in Transfusion Medicine and Hemotherapy journal (2014) [87] and 
in the Nucleic Acids Research journal (2015) [58] describing the latest updates in AFND 
(Appendix A). Furthermore, the generated HLA epitope population data was used to 
explore the applicability of HLA epitopes in alloantibody reactivity analysis in sensitized 
patients by comparing the matching likelihoods based on alloreactive HLA epitopes to 
likelihoods based on alloreactive HLA antigens from SAB assay results. 
 
3.3 Methods 
 
3.3.1 HLA Epitope Definitions 
The HLA epitopes nomenclature and definitions used in EpFreq-DB are according 
to the first release of the HLA Epitope Registry [120]. Each epitope definition 
corresponds to single or multiple polymorphic residues within the molecular 
conformation of a ‘functional’ epitope, sometimes including specific self-residues that 
were shown to be necessary for immunogenicity of certain epitopes. A mixture of 
positions and amino acid letter abbreviations from their definitions are used to compose 
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unique nomenclatures to each HLA epitope. In the present study only epitopes belonging 
to HLA class I were considered, and data associated to each epitope was extracted. HLA 
class II epitopes have not been included since limited genotype data for HLA class II is 
available, being mostly HLA-DRB1 typing. For determining HLA class II epitope 
frequencies in the HLA-DRB locus, data regarding HLA-DRB3, -DRB4 and -DRB5 is 
necessary since there are shared epitopes between those genes, otherwise inaccurate 
estimates of epitope frequencies would be generated. The latest release of HLA Epitope 
Registry has updated epitope definitions partially different from the first release. The 
epitope matching analyses in the present study use epitope definitions from the latest 
version, while definitions in EpFreq-DB will be updated at a later stage. 
 
3.3.2 HLA Population Data 
HLA raw genotyping data and haplotype frequency data from AFND were used for 
calculating epitope frequencies, but only HLA raw genotyping data was used to generate 
HLA epitope profiles for matching analysis. All datasets have alleles at high resolution, 
i.e. with an HLA nomenclature of at least two fields (e.g. A*01:01). Although AFND has 
a vast amount of HLA allele frequency data, only haplotype frequency data was 
considered suitable for calculating epitope frequencies. Estimation of HLA epitope 
frequencies from allele frequencies was attempted based on probability theory, but results 
differed from estimations made using HLA genotypes. Frequencies from epitopes 
present simultaneously in different loci are influenced by population linkage 
disequilibrium in the HLA loci, and estimating their frequencies from allele frequencies 
with no LD data led to considerable variation between observed and expected frequencies 
(data not shown). In total, 30 populations have been included in EpFreq-DB, 16 
consisting of raw genotyping data and 14 consisting of haplotype frequencies. Regarding 
their geographic distribution, 20% belong to Africa, 23% from Asia, 33% from Europe, 
20% are from North America and 3% are from Oceania. 
 
3.3.3 Epitope Frequency Calculation 
HLA epitope frequencies were obtained from HLA raw genotyping data and HLA 
haplotype frequencies. Frequency calculation from HLA raw genotyping data was 
performed according to following steps. First, HLA epitope individual profiles were 
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generated by listing distinct epitopes mapping to alleles in individual HLA genotypes. 
Second, the frequency of each epitope mapped in a population was obtained by direct 
counting. Since HLA genotyping data is generally not publicly available, it is also desirable 
being able to use HLA haplotype frequency data for obtaining epitope frequencies. For 
this purpose, the logic from Hardy-Weinberg proportions (HWP) equation – a 
mathematical concept commonly used in population genetics studies to estimate expected 
genotype frequencies in a population [130] – was applied to HLA haplotype frequencies 
(Figures 3.5 and 3.6). 
 
 
Figure 3.5: Comparison of the variables used in the application of HWP for biallelic loci or HLA 
epitopes. (A) The HWP equation and highlights the components p2 and 2pq. (B) A detailed 
description of the variables originated from HWP equation in a usual biallelic loci scenario. (C) 
Application of HWP variables in the epitope scenario, where HLA allele variants are divided in 
two groups: a “homozygote” frequency group corresponding to the percentage of individuals 
containing epitope-related alleles / haplotypes in one locus for both chromosomes, and a 
“heterozygote” frequency group corresponding to the percentage of individuals containing 
epitope-related alleles / haplotype in one locus and in only one chromosome. 
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Figure 3.6: Example of all the steps involved in the calculation of population frequency of 65GK 
and 66K epitopes in England North West population, using both types of entry data (HLA raw 
data and allele/haplotype frequencies). In the raw data box, the alleles having a 66K epitope are 
outlined in red and the alleles having a 65GK epitope are filled in yellow. 
 
For any given biallelic locus, HWP equation can be applied to estimate its expected 
genotype frequencies (p2, 2pq and q2 frequencies) using population frequencies from both 
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alleles (p and q) (Figure 3.5). Applying the probability theory logic behind HWP, all HLA 
haplotypes in a population were classified in two categories according to the presence and 
absence of a given epitope. Similar to biallelic loci, the frequency of both categories 
represented p and q variables (p = epitope is present in the haplotype, q = epitope is absent 
in the haplotype). Lastly, the epitope frequency can be extracted from HWP equation as 
the percentage of individuals in a population possessing the epitope in any of their 
haplotypes (Epitope frequency = p2 + 2pq). An example showing the application of both 
methods is summarized in Figure 3.6. Perl scripts were developed to perform the HLA 
epitope frequency calculations. Additional hierarchical clustering analysis of epitope 
frequencies distribution was performed using R Statistical Programming Language [89]. 
 
3.3.4 EpFreq-DB Implementation 
The back-end of EpFreq-DB database was developed using a Microsoft SQL Server 
relational database schema. The organization and relationship of core information stored 
in the database is described by the entity-relationship diagram presented in Figure 3.7. 
HLA epitopes and their respective characteristics were defined as the following relational 
entities in the database schema: ‘Epitope’ containing epitope names according to HLA 
Epitope Registry database, ‘Polypeptide’ containing structural mapping of epitopes 
(position and amino acid), ‘Allele’ mapping their polymorphisms, ‘Locus’ mapping their 
genetic locations, and ‘Population’ and ‘Frequency’ containing geographical information 
of populations and their epitope frequencies. 
Users can connect to the database using the most common web browsers. A web 
interface for EpFreq-DB has been created to allow users to query the database, being 
linked to the Allele Frequency Net Database and following a similar web design. For that 
purpose, interactive web pages for querying data were developed using the Active Server 
Pages (ASP) scripting environment and JavaScript language. The graphical display was 
designed using HyperText Markup Language (HTML) and Cascading Style Sheets (CSS), 
ensuring that the page will be viewable in most used web browsers. 
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Figure 3.7: Entity-relationship diagram of EpFreq-DB schema. 
 
3.3.5 HLA epitope alloreactivity analysis 
An analysis comparing HLA epitope matching to traditional HLA allele matching 
regarding sensitization by anti-HLA DSA was performed using scripts developed in 
Python programming language. In summary, alloantibody profiles from SAB assay results 
from three patients were analysed in EpVix for determination of HLA epitopes possibly 
recognized by detected alloantibodies. Then, the percentage of individuals in each 
population not possessing any of those epitopes was then compared to the percentage of 
individuals not having the HLA types considered reactive in SAB assay results. The details 
involved in each step of this analysis are described hereafter. 
 
HLA epitope profiles from populations 
Available HLA raw genotype data from AFND populations was converted into HLA 
epitope profiles, i.e. a list containing all distinct HLA epitopes belonging to each 
individual’s HLA genotype from each population was generated. Only HLA class I types 
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(HLA-A, -B and -C) were converted. Table 3.1 shows detailed information from 
populations, including geographical information, HLA genes typed and sample size. 
Several populations do not have HLA typing data for all class II genes, such as those 
associated to renal transplant requiring only HLA-A, -B and -DRB1. Since some epitopes 
can be simultaneously originated from more than one locus, selection of HLA epitopes 
composing profiles of each population was made in accordance to HLA genes typed. If 
an epitope is expressed by alleles part of a HLA gene not typed in a population, the 
epitope is excluded from the conversion, even if it can be present in other genes with 
typing information available. As an example, if a population does not have HLA-C typing 
information, epitopes that can be expressed by HLA-C alleles are excluded, even if they 
are unique to HLA-C alleles, or are also present in HLA-A and / or HLA-B alleles. This 
same logic has been also applied when obtaining epitope frequencies. This step prevents 
inaccurate estimates regarding the likelihood of finding an individual with a given epitope 
in the population due to its undetectable presence in non-typed HLA loci. 
 
Table 3.1: Populations having HLA raw genotyping data used to generate epitope profiles. 
Population Continent Typed Loci N 
Ireland Northern Europe A, B, C 1000 
England North West Europe A, B, C 298 
Netherlands UMCU Europe A, B, C 64 
Malaysia Peninsular Malay South-East Asia A, B, C 951 
Portugal Azores Terceira Island Europe A, B, C 130 
Malaysia Peninsular Chinese South-East Asia A, B, C 194 
New Zealand Polynesians with Full Ancestry Oceania A, B, C 21 
New Zealand Polynesians with Admixed History Oceania A, B, C 27 
New Zealand Maori with Full Ancestry Oceania A, B, C 46 
New Zealand Maori with Admixed History Oceania A, B, C 105 
Malaysia Kedah Kensiu South-East Asia A, B 21 
Hong Kong Chinese BMDR South-East Asia A, B, C 7795 
Hong Kong Chinese cord blood registry South-East Asia A, B 3892 
Albania DKMS Europe A, B, C 146 
Austria DKMS Europe A, B, C 854 
Belarus DKMS Europe A, B, C 42 
Belgium DKMS Europe A, B, C 199 
Bosnia DKMS Europe A, B, C 399 
Bulgaria DKMS Europe A, B, C 149 
Croatia DKMS Europe A, B, C 801 
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Czech DKMS Europe A, B, C 310 
Denmark DKMS Europe A, B, C 69 
Estonia DKMS Europe A, B, C 21 
Faroe DKMS Europe A, B, C 64 
Finland DKMS Europe A, B, C 64 
France DKMS Europe A, B, C 530 
Greece DKMS Europe A, B, C 749 
Hungary DKMS Europe A, B, C 256 
Ireland DKMS Europe A, B, C 57 
Italy DKMS Europe A, B, C 2224 
Latvia DKMS Europe A, B, C 33 
Lithuania DKMS Europe A, B, C 66 
Luxemburg DKMS Europe A, B, C 118 
Macedonia DKMS Europe A, B, C 87 
Montenegro DKMS Europe A, B, C 45 
Nederlands DKMS Europe A, B, C 583 
Norway DKMS Europe A, B, C 24 
Poland DKMS Europe A, B, C 3250 
Portugal DKMS Europe A, B, C 429 
Romania DKMS Europe A, B, C 552 
Russia DKMS Europe A, B, C 2227 
Serbia DKMS Europe A, B, C 283 
Slovakia DKMS Europe A, B, C 70 
Slovenia DKMS Europe A, B, C 130 
Spain DKMS Europe A, B, C 627 
Sweden DKMS Europe A, B, C 62 
Swizterland DKMS Europe A, B, C 266 
Ukraine DKMS Europe A, B, C 269 
UK DKMS Europe A, B, C 419 
 
 
Identification of HLA epitopes specific to anti-HLA alloantibodies 
HLA alloantibody profiles pre-loaded as sample data in EpVix tool from three 
patients were used as the input dataset matched against populations. The profiles were in 
Luminex® SAB assay format and showed variable levels of sensitization (Table 3.2). 
Establishment of reactive HLA alleles and epitopes was based on two MFI cut-off values: 
2000 and 4000. The lower MFI cut-off value is currently used by the Transplant 
Immunology laboratory in the Royal Liverpool University Hospital (Middleton, D., 
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personal communication), being also a common choice among other laboratories. A 
higher MFI cut-off value was also applied to evaluate its effect, since the selection of 2000 
as “standard” cut-off is based on relatively arbitrary criteria. Reactive HLA alleles from 
all three patients were converted to epitopes using the HLA Matchmaker algorithm on 
EpVix, generating a total of two epitope datasets per patient (one dataset for each MFI 
cut-off value). 
 
Minimum HLA epitope sets 
In HLA epitope sets derived from EpVix, there is the possibility that not all listed 
epitopes are causing alloreactivity. For example, in case an epitope is common to all HLA 
alleles considered reactive, there is a chance that the patient’s anti-HLA alloantibodies are 
only specific to that epitope. To evaluate the effect of selecting only a subset of epitopes 
capable of explaining all reactive HLA types, epitope lists generated by EpVix were 
reduced to the minimum epitope set common to the maximum number of reactive HLA 
types (Figure 3.8). Both minimum and full epitope sets were included in the analysis. 
 
Figure 3.8: Algorithm to determine minimum HLA epitope set capable of explaining reactive 
alleles in Luminex® SAB assays. HLA epitopes were ranked in descending order according to the 
number of alleles they were related to in EpVix analyses. Iterations through the ranked list selected 
epitopes in the list order until all alleles have corresponding epitopes in the selected list. Additional 
steps were added to check for ties among epitopes with equal rank and similar ability to explain 
reactivity.  
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HLA allele and epitope ‘negative’ matching in populations 
A data pipeline was developed in Python programming language using alloantibody 
reactivity profiles (for both epitopes and alleles) as input to be matched against HLA 
population data (epitope profiles and genotypes). Input epitope sets were also adapted to 
the matched populations according to their typed HLA genes. If an epitope is present in 
a HLA gene that has not been typed for a population, the epitope is excluded from the 
input set being matched against that specific population. Output values from the data 
pipeline correspond to the percentage of the population possessing none of the items in 
the input set (HLA alleles or epitopes), i.e. individuals not displaying putative units 
causing alloreactivity in patients (‘negative matching’). 
 
3.4 Results and Discussion 
 
3.4.1 Validation of HLA epitope frequencies estimated 
from HLA haplotype frequencies 
To validate the calculation of HLA epitope frequencies from haplotype frequencies, 
the method was applied on haplotype frequencies generated from HLA raw genotyping 
data using PyPop software [33]. A comparison of HLA epitope frequencies obtained from 
generated haplotype frequencies against observed epitope frequencies calculated directly 
from raw genotype data were performed for populations in EpFreq-DB with available 
raw data. Figure 3.9 compares epitope frequencies calculated from raw genotyping data 
to obtained haplotype frequency data for 30 populations with sample size greater than 
100, showing similar frequencies for both groups (for detailed comparison for individual 
populations, see Appendix C). 
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Figure 3.9: Correlation between HLA epitope frequencies calculated from HLA raw data and 
HLA haplotype frequency data for populations with sample size greater than 100. Each point 
corresponds to the population frequencies of a distinct HLA epitope calculated using HLA raw 
genotype data (x-axis) and HLA haplotype frequency data (y-axis), where different colours 
represent different populations. The observed distribution of the points shows that there is little 
variation between HLA epitope frequencies calculated using either data sources, for populations 
with sample size of at least 100 (for detailed comparison for individual populations, see Appendix 
C). 
 
1.1.1 Website organization 
The EpFreq-DB database is part of Allele Frequencies Net Database (AFND), and can 
be accessed through the AFND homepage (http://www.allelefrequencies.net/) using the 
menu “HLA Epitopes” and the submenu “HLA Epitopes - ABC” or via a direct URL 
access at http://www.allelefrequencies.net/hlaepitopes/, both options directing to 
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EpFreq-DB query page (Figure 3.10). The website interface allows the user to retrieve 
population HLA epitope frequencies applying a collection of data filters through different 
view modes. Retrieved data in the query page can be filtered by: i) one or more specific 
populations through a drop-down list to select one specific population or a textbox to 
select more than one population, ii) one or more specific HLA epitopes by also a drop-
down list and textbox for selection, iii) demographic information (country, continent, 
ethnicity and sample size), iv) HLA loci from where HLA epitopes are expressed 
(including multiple loci combinations), v) amino acid position range in the polypeptide 
sequence, and vi) HLA alleles or a complete HLA genotype, retrieving data from all 
epitopes present in HLA alleles. It is also possible to sort results by populations or epitope 
names in alphabetical order or in descending order from the highest frequencies (Figure 
3.10). 
The default display of any retrieved data consists of a list showing population epitope 
frequencies per row, along with additional demographic and molecular data related to the 
population and HLA epitope, respectively. Results can be display in alternative views: i) 
a printer-friendly view similar to the default view, but with less formatting elements, ii) a 
grid view, showing results in a table format with populations as columns and epitopes as 
rows, and iii) a heatmap view, which is the grid view with cells displaying colours with 
their intensity varying according to the frequency value (Figure 3.11). Utilization of the 
grid or heatmap view in combination with filtering HLA epitopes present in specific 
alleles or genotype are particularly interesting for identification of populations where a set 
of epitopes can be found at the desired frequency: higher frequency when searching for 
individuals with similar epitope profiles of a patient with known HLA genotype, and 
lower frequencies when searching for individuals not having reactive epitopes to 
alloantibodies.  
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Figure 3.10: EpFreq-DB query page. Several filters for performing a specific search are available 
at the top of the page. A search can also be performed using no filters selected. In this example, 
‘HLA genotype’ filters were selected (highlighted in green). The resulting epitope frequencies for 
each population in the database will contain only epitopes present in the specified genotype. 
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Figure 3.11: ‘Heatmap’ view of EpFreq-DB query results. The lighter the colours the higher the 
frequencies, and vice-versa. 
 
3.4.2 Worldwide HLA epitope frequency distribution 
Although the database web interface produces a heatmap view of world HLA epitope 
frequencies, a similar analysis was performed with the addition of hierarchical clustering 
analysis regarding the similarity of populations according to epitope frequencies and 
grouping of epitopes with similar frequencies in all populations. Only HLA-A and HLA-
B epitopes were included in this analysis, since some populations do not have HLA-C 
data available. Figure 3.12 shows that epitopes have different degrees of variability across 
populations, where some epitopes are highly frequent in all populations, while others are 
consistently rare. It is also possible to identify some epitopes dominant in specific 
geographic regions in comparison to others.  
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Figure 3.12: Heatmap of HLA-A and -B epitope frequencies in world populations. Lighter areas 
in yellow represent higher frequencies, while darker areas represent lower frequencies. Areas in 
red have intermediate frequencies. 
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Epitope frequencies in EpFreq-DB are current linked to HLA Epitope Registry 
database, where each HLA epitope row provides a URL link to EpFreq-DB query page 
specific to that epitope. With the incorporation of HLA epitope matching in transplant 
programs, information of their population frequencies is necessary for donor search 
strategies and for assessing the impact of alloreactive epitopes on patient’s matching 
likelihood in specific populations, with the potential to improve patients’ chances of 
finding a match in transplant programs implementing cross-border exchange of deceased 
donor organs. 
 
3.4.3 HLA allele and epitope matching of alloreactivity 
profiles 
To evaluate the impact of the use of HLA epitopes in alloreactivity profiles from 
sensitized patients, explorative analysis of alloreactivity profile matching comparing HLA 
epitopes and high resolution HLA allele matching was performed. EpVix uses the HLA 
MatchMaker algorithm to generates a list containing all possible alloreactive epitopes 
based on Luminex® SAB assay results. Alloreactivity profiles from patient samples 
present on EpVix with 2000 and 4000 MFI cut-off values are described in Table 3.2. 
Since it may be possible that not all epitopes identified in EpVix are actual 
alloantibody targets, a list containing the minimum set of epitopes capable of explaining 
the reactive alleles from SAB assays were generated for each patient. Except for a few 
populations, there is no difference between the matching likelihoods obtained by both 
epitope sets (full and minimum epitope sets) (Figure 3.13). Differences higher than 10% 
between those two groups were observed only for three Asian populations (Figure 3.14). 
This result shows existence of non-random association between epitopes. Those selected 
as the minimum epitope sets are by definition the more highly frequent epitopes, serving 
in practice as markers highly linked to other epitopes in the full set. Following on from 
this result, the later analyses will only include the full epitope set to avoid influence of 
differences observed in outlier populations. 
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Table 3.2: HLA epitope analysis of three alloreactivity profiles from EpVix, using 2000 and 4000 MFI cut-off values. 
Allele MFI HLA Epitopes (MFI cut-off 2000) HLA Epitopes (MFI cut-off 4000) 
Patient 1 (cPRA 55.86%) 
A*02:01 10368 62GE 62GK2 94TV 107W 144TKH 145KHA 62GK2 94TV 107W 144TKH 145KHA 
A*02:06 9257 62GE 62GK2 94TV 107W 144TKH 145KHA 62GK2 94TV 107W 144TKH 145KHA 
A*02:03 8100 62GE 62GK2 94TV 107W 144TKH 145HT 62GK2 94TV 107W 144TKH 145HT 
A*68:01 7961 144TKH 145KHA 245VA 144TKH 145KHA 245VA 
A*69:01 7488 94TV 107W 144TKH 145KHA 94TV 107W 144TKH 145KHA 
A*68:02 6598 11SM 144TKH 145KHA 245VA 11SM 144TKH 145KHA 245VA 
B*57:03 4405 62GE 62GRN 97V None 
B*57:01 3613 62GE 62GRN 97V  
A*29:01 2990 102HV  
A*24:03 2365 None  
A*30:02 2228 76EG  
B*58:01 
 
2158 62GE 62GRN  
Patient 2 (cPRA 69.99%) 
A*03:01 21730 62QE 62QE+151H 62QE+s56G 66NAQ 66NV 71QS 97I 113YR 161D 
275EL 
62QE 62QE+151H 62QE+s56G 66NAQ 66NV 71QS 97I 113YR 161D 
275EL 
A*32:01 21218 62QE 62QE+s56G 66NAH 66NV 76ESI 113YQ 245AS 62QE 62QE+s56G 66NAH 66NV 76ESI 113YQ 245AS 
A*31:01 21163 9T 56R 62QE 66NAH 66NV 73ID 113YQ 245AS 9T 56R 62QE 66NAH 66NV 73ID 113YQ 245AS 
A*30:01 20812 17RS 56R 62QE 66NAQ 66NV 71QS 97I 152RW 275EL 17RS 56R 62QE 66NAQ 66NV 71QS 97I 152RW 275EL 
A*74:01 20600 62QE 62QE+s56G 66NAH 66NV 113YQ 245AS 62QE 62QE+s56G 66NAH 66NV 113YQ 245AS 
A*68:02 20409 11SM 62RNR 62RR 62RRN 63NN 66NAQ 66NV 71QS 245VA 11SM 62RNR 63NN 66NAQ 66NV 71QS 245VA 
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A*29:01 19818 9T 62LQ 66NAQ 66NV 71QS 73TDA 76ANT 77NGT 102HV 113YR 
245AS 
9T 62LQ 66NAQ 66NV 71QS 73TDA 76ANT 77NGT 102HV 113YR 
245AS 
A*30:02 19801 17RS 56R 62QE 66NAH 66NV 76EG 77NGT 97I 152RR 275EL 17RS 56R 62QE 66NAH 66NV 76EG 77NGT 97I 152RR 275EL 
A*34:02 19634 62RNR 62RR 62RRN 63NN 66NAQ 66NV 71QS 97I 113YR 145RT 245AS 62RNR 63NN 66NAQ 66NV 71QS 97I 113YR 145RT 245AS 
A*33:01 19567 9T 62RNR 62RR 62RRN 63NN 66NAH 66NV 73ID 113YQ 186R 245AS 9T 62RNR 63NN 66NAH 66NV 73ID 113YQ 186R 245AS 
A*66:02 19199 62RNR 62RR 62RRN 63NN 66NAQ 66NV 71QS 113YQ 145RT 245AS 62RNR 63NN 66NAQ 66NV 71QS 113YQ 145RT 245AS 
A*33:03 19183 9T 62RNR 62RR 62RRN 63NN 66NAH 66NV 73ID 113YQ 186R 245AS 9T 62RNR 63NN 66NAH 66NV 73ID 113YQ 186R 245AS 
A*11:01 19138 62QE 62QE+151H 62QE+s56G 66NAQ 66NV 71QS 97I 113YR 151AHA 
152HA 163R 163RW 275EL 
62QE 62QE+151H 62QE+s56G 66NAQ 66NV 71QS 97I 113YR 
151AHA 152HA 163R 163RW 275EL 
A*66:01 19102 62RNR 62RR 62RRN 63NN 66NAQ 66NV 71QS 113YQ 145RT 163R 
163RW 245AS 
62RNR 63NN 66NAQ 66NV 71QS 113YQ 145RT 163R 163RW 245AS 
A*11:02 19088 62QE 62QE+151H 62QE+s56G 66NAQ 66NV 71QS 97I 113YR 151AHA 
152HA 163R 163RW 275EL 
62QE 62QE+151H 62QE+s56G 66NAQ 66NV 71QS 97I 113YR 
151AHA 152HA 163R 163RW 275EL 
A*68:01 19027 62RNR 62RR 62RRN 63NN 66NAQ 66NV 71QS 113YR 245VA 62RNR 63NN 66NAQ 66NV 71QS 113YR 245VA 
A*25:01 19021 62RNR 62RR 62RRN 63NN 66NAH 66NV 76ESI 113YQ 145RT 163R 
163RW 245AS 
62RNR 63NN 66NAH 66NV 76ESI 113YQ 145RT 163R 163RW 245AS 
A*29:02 18835 9T 62LQ 66NAQ 66NV 71QS 73TDA 76ANT 77NGT 113YR 245AS 9T 62LQ 66NAQ 66NV 71QS 73TDA 76ANT 77NGT 113YR 245AS 
A*69:01 18063 62RNR 62RR 62RRN 63NN 66NAQ 66NV 71QS 62RNR 63NN 66NAQ 66NV 71QS 
A*26:01 17195 62RNR 62RR 62RRN 63NN 66NAH 66NV 73TDA 76ANT 77NGT 
113YQ 145RT 163R 163RW 245AS 
62RNR 63NN 66NAH 66NV 73TDA 76ANT 77NGT 113YQ 145RT 
163R 163RW 245AS 
A*43:01 14771 62LQ 66NAH 66NV 73TDA 76ANT 77NGT 113YQ 145RT 163R 163RW 
245AS 
62LQ 66NAH 66NV 73TDA 76ANT 77NGT 113YQ 145RT 163R 163RW 
245AS 
A*80:01 12467 56E4 66NAH 66NV 76ANT 77NGT 97I 113YR 152RR 56E4 66NAH 66NV 76ANT 77NGT 97I 113YR 152RR 
A*01:01 4440 44KM3 62QE 62QE+151H 62QE+s56G 66NAH 73TDA 76ANT 77NGT 
97I 113YR 152HA 163R 163RG 275EL 
44KM3 62QE 62QE+151H 62QE+s56G 66NAH 73TDA 76ANT 
77NGT 97I 113YR 152HA 163R 163RG 275EL 
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A*36:01 4382 44KM3 62QE 62QE+151H 62QE+s56G 66NAH 73TDA 76ANT 77NGT 
97I 113YR 152HA 275EL 
44KM3 62QE 62QE+151H 62QE+s56G 66NAH 73TDA 76ANT 
77NGT 97I 113YR 152HA 275EL 
A*34:01 4015 62RNR 62RR 66RKQ 71QS 113YQ 145RT 245AS 62RNR 66RKQ 71QS 113YQ 145RT 245AS 
B*15:16 2495 62RER 62RR 62RRN  
B*44:03 
 
2071 None  
Patient 3 (cPRA 54.23%) 
B*37:01 12794 None None 
B*57:01 11036 62GE 62GRN 97V 62GE 62GRN 97V 
B*57:03 10812 62GE 62GRN 97V 62GE 62GRN 97V 
B*58:01 8634 62GE 62GRN 62GE 62GRN 
A*02:03 7274 62GE 62GK2 145HT 62GE 62GK2 145HT 
A*02:01 7104 62GE 62GK2 62GE 62GK2 
A*02:06 6743 62GE 62GK2 62GE 62GK2 
B*08:01 2210 None   
Highlighted epitopes compose the minimum epitope set that can explain the reactions observed with each SAB HLA antigen. 
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Figure 3.13: Correlation between epitope matching percentages in populations obtained using 
‘minimum’ and ‘full’ epitope sets as input. The epitopes within those sets are not present in the 
respective patients (non-self). According to their SAB assay results and the HLA epitope logic, 
anti-HLA antibodies present in patients could be targeting some or all epitopes in the ‘full’ set. 
Thus, matched donors are the ones not having any of the epitopes in the analysed epitope set 
(‘negative’ matching). While the ‘full’ epitope set contains all non-self epitopes present in reactive 
HLA alleles, the ‘minimum’ epitope set contain the minimum set of non-self epitopes that could 
explain the observed reactivity. Each point in the plot represents the frequencies of individuals in 
a population not having the input epitope sets (‘minimum’ set: x-axis, ‘full’ set: y-axis) that could 
be donor candidates for each patient (three patients at MFI cut-offs of 2000 and 4000). Although 
it is expected by probability that smaller sets would yield higher ‘negative’ matching percentages, 
the plot shows that for the vast majority of the populations there was no difference in matching 
‘minimum’ and ‘full’ epitope sets. 
 
Comparison between population matching percentages obtained using allele and 
epitope sets generated by EpVix as input is shown in Figures 3.15 and 3.16. It can be 
noted that for most patients and the respective MFI cut-offs used, frequencies of matched 
individuals across populations are higher for alleles than epitopes, except for patient 3, 
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but only when combined to a 2000 cut-off value. Increasing the MFI cut-off removes the 
B*08:01 allele from the allele input set, for which the EpVix algorithm did not identify 
any possible reactive epitope. Higher allele matching frequencies in some populations for 
some patient / MFI cut-off combinations can be explained by the fact that HLA alleles 
included in SAB assays correspond to a subset of the existing alleles in populations, 
whereas alleles not included in those assays contain shared epitopes identified by EpVix. 
 
 
Figure 3.14: Dotchart of populations showing any difference in matching likelihoods between 
minimum and full epitope sets. Most differences are lower than 2%, except for one Chinese 
population and Malaysian populations showing differences higher than 10% for patient 1 and 2, 
respectively. 
 
To ascertain the explanation for the aforementioned results, the same previously 
described matching analysis was performed including HLA alleles not part of Luminex® 
SAB assays that contain reactive epitopes identified (Figures 3.15 and 3.16). The higher 
allele matching frequencies previously identified were then eliminated upon the inclusion 
of non-SAB alleles, confirming our predictions. This result also highlights that alleles 
present in SAB assays may not sufficiently represent allele diversity in populations (Figure 
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3.17). Inclusion of non-SAB alleles also generates a slight increase in the quantity of 
epitope matching frequencies higher than allele matching frequencies. These differences 
are due to some alleles above the declared MFI cut-off not having any associated epitope 
defined as reactive by the HLA Matchmaker algorithm (Table 3.2). 
 
Figure 3.15: Correlations between population matching percentages obtained using allele and 
epitope sets as input. Each point in the plot represents the frequencies of individuals in the 
population not having the input sets (epitope set: x-axis, allele set: y-axis) in a population, for one 
of the three patients at a given MFI cut-off (2000 or 4000). In the panel on the left, alleles from 
input set include only Luminex® SAB alleles, while panel on the right includes alleles not present 
in the assay. 
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Figure 3.16: Point plot of epitope matching frequencies minus allele matching frequencies in 
populations, categorized by patients / MFI cut-off combinations. In the panel on the left, alleles 
from input set include only Luminex® SAB alleles, while panel on the right includes alleles not 
present in the assay. 
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Figure 3.17: Dot chart showing only populations where Luminex® allele matching frequencies 
are higher than epitope matching frequencies. For these populations, SAB assays do not 
sufficiently represent their allele diversity, with higher discrepancies being observed in Malaysian 
populations. 
 
The reason why some alleles in EpVix output show no related epitope identified as 
reactive is due to the logic of its algorithm, where self-epitopes or epitopes belonging to 
any allele below the MFI cut-off value are not flagged as reactive epitopes. This is the 
case for B*08:01 and other alleles found reactive in SAB assays, but more pronounced 
differences were observed due for B*08:01 in patient 3 at a 2000 cut-off due to its high 
frequency in the populations investigated [58]. Therefore, inconsistencies in HLA epitope 
definitions and / or SAB assays could be limiting factors in the optimization of 
transplantation matching towards increasing chances of finding a match. The difficult 
interpretation of MFI values along with several factors that can lead to false-positive or 
false-negative results are a source of controversy on the reliability of SAB assays 
[116,117,131]. 
A further challenge in the interpretation of HLA epitope data is that the logic behind 
HLA Matchmaker epitopes defined in silico may not completely reflect the in vivo epitope 
interactions with alloantibodies. HLA Matchmaker reports on the knowledge of HLA 
polymorphisms, and general definitions regarding what is known about antibody-antigen 
interactions, to infer HLA epitopes that could be reactive in mismatched transplanted 
organs. Polymorphic residues exposed on the HLA surface within an area consisting of a 
few residues that are believed to bind CDR-H3, and to be centrally located within the 
epitope (so-called functional epitope), are considered the relevant units (‘eplets’) to be 
compared between donors and recipients. On the other hand, traditional in silico B cell 
epitope prediction tools, mainly used in vaccine development, utilize different approaches 
to infer epitopes. These tools take into account physicochemical properties such as 
hydrophilicity, flexibility, polarity, and exposed surface, and spatial characteristics of the 
3D structure of proteins to determinate surface accessibility [132]. Despite extensive 
research in this field, in silico B cell epitope prediction methods are far from reliable and 
are currently an unsolved problem [133-135], indicating that antibody-antigen interactions 
are much more complex than what it is currently known and that inferences used by HLA 
Matchmaker algorithm may be oversimplifying the mechanism of alloreactivity. 
92 
 
It has been suggested that predicting B cell epitopes should be accompanied by 
knowledge of binding antibodies [134], and the latest prediction tools have been 
addressing this issue by incorporating antibody data related to its sequence and / or 
structure [136]. In this sense, HLA Matchmaker algorithm also misses specific antibody 
information, since the determination of molecular surface areas over the HLA molecule 
corresponding to the paratope of a patient’s antibody is not based on human anti-HLA 
alloantibodies, but uses similar models available on PDB to infer that information [10]. 
Recent studies have been challenging the paradigm of epitope-paratope interaction 
through CDRs and the pivotal importance of CDR-H3. With the growing number of new 
antibodies being characterized, it has been shown that epitope-paratope interactions are 
not exclusively influenced by CDRs, and also that not always CDR-H3 plays a dominant 
role in the specificity of the interaction [134]. This represents another limitation in the 
HLA Matchmaker algorithm, since HLA epitopes are majorly defined based on CDR-H3 
complementarity. Besides, it has been demonstrated that residues outside the area 
predicted to interface CDR-H3 are critical for the reactivity of some HLA epitopes [137]. 
Finally, HLA epitope matching differs from traditional HLA allele matching by 
generating subunits containing polymorphic residues from HLA molecules which are 
configured according to general definitions regarding epitope interactions with CDR-H3. 
However, since current understanding regarding antigen-antibody interactions have not 
been reliable for epitope prediction, the parameters used to define ‘eplets’ would also 
inherit this knowledge gap. Further studies characterizing antigen-antibody interactions 
in humoral HLA alloreactivity are necessary for improving prediction of HLA epitopes. 
 
3.5 Conclusion 
The HLA Matchmaker algorithm has been setting the standards for HLA epitopes 
matching based on the structural concept of a functional epitope containing relevant 
polymorphisms that can potentially elicit an antibody immunological response. With the 
increasing interest in this field, EpFreq-DB provides a public database with HLA epitope 
frequency data for several worldwide populations. Nevertheless, since a new release of 
HLA epitope registry has changed some HLA epitope definitions, EpFreq-DB is being 
updated accordingly and an upgrade will be released at a later stage. Worldwide epitope 
distribution described in the present study shows that several epitopes are almost always 
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present or absent across all investigated populations, narrowing a subset of epitopes with 
higher variability to be more relevant for transplant matching. 
A comparative analysis of alloreactivity profile matching using HLA epitopes and 
high resolution HLA allele matching highlights current limitations in both SAB assays 
and HLA epitope definitions. It should be noted that this analysis is limited by a small 
patient sample size, and additional investigations using a larger number of patients are 
needed to confirm the present findings. 
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Chapter 4  
Structural basis of the association of 
HLA-C*04:01 with nevirapine adverse 
drug reactions 
 
4.1 Abstract 
HIV patients being treated with nevirapine are at risk of developing adverse drug 
reactions, ranging from mild to severe hepatic and skin reactions. These T cell mediated 
‘off-target’ reactions have been shown to be associated with certain human leukocyte 
antigen (HLA) alleles in patients being treated with particular drugs. Previous studies have 
reported associations of HLA-C*04:01 with nevirapine hypersensitivity in African 
populations, including a genome-wide association study (GWAS) reporting an association 
to a SNP encoding a substitution at residue Glu49 of HLA-C*04:01. A putative role of 
this residue in causing nevirapine-induced hypersensitivity had been suggested due to the 
fact that this residue is nearly unique to HLA-C*04 alleles. To investigate this hypothesis, 
molecular docking of nevirapine and 12-hydroxy-nevirapine metabolite (a break-down 
product of nevirapine that could be involved in the adverse reaction) with HLA-C*04:01 
was undertaken to determine the possible effect of the residue substitution on nevirapine 
binding. The data suggest that none of the predicted modes of nevirapine docking 
conformation interact with residue Glu49, which is located on the periphery of the 
peptide binding domain. The putative docking site with the highest predicted affinity 
highlights an interaction between nevirapine and residues Ser9 and Phe99 in the B pocket, 
which are almost unique to C*04:01, with the exception of relatively rare alleles C*04:07 
and C*14:02. While none of the predicted modes interacted with residue 49, docking 
results suggest that binding of either nevirapine or 12-hydroxy-nevirapine around the 
centre of the peptide-binding regions is likely to be important in the mechanism of the 
immune-mediated reaction. 
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4.2 Introduction 
Nevirapine (Figure 4.1) is an anti-retroviral drug used in the treatment of human 
immunodeficiency virus 1 (HIV-1) infected patients. Commercialized as Viramune®, it 
is part of the non-nucleoside reverse transcriptase inhibitor (NNRTI) type of anti-
retroviral drugs [138]. Listed in the WHO Model List of Essential Medicines containing 
essential drugs needed for any basic health-care system [139], nevirapine has been shown 
to have long-term effectiveness [140] and prevent vertical transmission [141]. It is 
administered in highly active antiretroviral therapy (HAART) regimens, consisting of a 
combination of three or more drugs. These regimens are intended to control the disease 
by providing a sustained suppression of HIV-1 replication, lowering viral load and 
increasing CD4+ T-cell levels [142]. 
After invading a host cell, HIV and other single-strand RNA retroviruses use the 
reverse transcriptase (RT) enzyme to reverse-transcribe its RNA genome into double-
stranded DNA, which is then integrated into the host cell DNA in the nucleus, allowing 
the virus to use the cell machinery for its replication. Nevirapine inhibits RT by an 
allosteric binding to the hydrophobic pocket of its p66 subunit, close to the catalytic site 
[143]. Figure 4.2 shows interaction of HIV-1 RT with a representative NNRTI (UC781), 
to exemplify nevirapine mechanism of action [144]. 
 
 
Figure 4.1: Nevirapine 2D (A) and 3D (B) chemical. 
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Figure 4.2: A model for the interaction of HIV-1 RT with a representative NNRTI (UC781), to 
exemplify the functional interaction of HIV-1 RT and nevirapine. The hydrogen bond with K101, 
and the two methyl-group-aromatic-ring interactions are shown explicitly. Other main 
hydrophobic contacts are shown with bold lines; minor ones are shown with faint lines [144]. 
 
In Sub-Saharan Africa, a region with the highest worldwide incidence of HIV [145], 
nevirapine-based regimens have been a therapy of choice for fighting against the virus 
due to its lower cost in comparison to other anti-retroviral drugs with comparable efficacy 
[146], and to its ability to prevent vertical transmission, reducing the prevalence of HIV 
in the next generations [147]. A meta-analysis of randomized trials for HIV-1 anti-
retroviral drugs had shown that the efficacy of nevirapine regimens is similar compared 
to non-nevirapine regimens [148]. However, nevirapine has showed a higher risk for 
discontinuation of treatment due to adverse drug reactions when compared to other anti-
retroviral drug types, such as ritonavir-boosted protease inhibitors [149]. Long-term 
adherence to the treatment is crucial for the success of the treatment regimen, thus it is 
important that adverse reactions are minimised to avoid treatment discontinuation [138]. 
Generally, ADRs are classified as ‘on target’ type A and ‘off target’ or ‘idiosyncratic’ 
type B. The latter have unpredictable nature with unclear relation to the drug’s 
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pharmacological mechanism, differing than more predictable dose-dependent type A 
reactions displaying symptoms related to the drug’s known pharmacological mechanism 
[150]. Most nevirapine-induced ADRs are skin hypersensitivity and hepatic reactions 
belonging to a type B subcategory. This subtype of reaction is characterized by delayed-
type hypersensitivity reactions mediated by T cell response, which can be systemic or 
organ specific [151]. Mild and severe hepatic reactions known as drug-induced liver injury 
(DILI) accounts for around 4% of nevirapine-induced ADRs [152], manifesting as 
hepatocellular injury or cholestasis (obstruction of normal bile flow) that can progress to 
fulminant hepatic failure [153]. 
Skin hypersensitivity configures as systemic reactions accounting for most nevirapine 
ADRs, where clinical trials reported 17% of the patients developing skin rashes, with 
0.3% showing severe skin reactions, such as Steven Johnson Syndrome (SJS) and Toxic 
Epidermal Necrolysis (TEN) [150]. SJS and TEN are the most severe bullous skin ADR, 
characterized by a macular purple-red exanthema that can be painful, and it can develop 
quickly after its establishment. They usually appear during the first 6 weeks of treatment 
and stopping the treatment may not improve the symptoms, but only prevent them from 
continuing to develop. Currently SJS and TEN are considered to be the milder form and 
the more severe form of the same disease, respectively, where SJS is defined by less than 
10% of skin detachment while TEN defines more than 30% of skin detachment. 
Intermediate forms between 10-30% of skin detachment are considered SJS/TEN 
overlap [154]. SJS has 13% mortality rate and TEN has a 39% mortality rate, while 
SJS/TEN has a 21% mortality rate [155]. 
Although the functional mechanisms of those ADRs are not yet fully understood, 
genetic variability in patients has been observed to influence their incidence in different 
geographical regions with distinct ethnic makeup [156]. Probably due to T cell 
involvement in those reactions, several HLA polymorphisms have been found associated 
with type IV ADRs from various drug classes [52]. 
Nevirapine-induced hypersensitivity reactions have been associated with many class 
I and class II alleles in different populations, but HLA-C*04:01 seems to be a risk factor 
common to populations with different ethnicities [157]. Nevirapine-induced SJS/TEN 
has been found associated with HLA-C*04:01 in genome-wide association studies 
(GWAS) using a Malawian discovery cohort and a replication cohort from three countries 
(Malawi, Uganda and Mozambique) [158,159]. Other HLA and ADR associations include 
98 
 
the well known associations of HLA-B*57:01 and hypersensitivity to abacavir anti-RT 
drug, HLA-B*15:02 and carbamazepine-induced SJS/TEN and HLA-B*58:01 and 
allopurinol hypersensitivities [160]. 
To understand the mechanisms of those associations on a structural level, 
computational methods such as molecular docking have been applied to predict the 
binding mode and affinity between drugs (or metabolites) and HLA molecules. This 
method contributed to a thorough characterization of the interaction between abacavir 
and HLA-B*57:01, revealing a strong binding of abacavir to the peptide binding groove 
of the HLA molecule resulting in presentation of a modified peptide repertoire [161]. 
Regarding the underlying mechanism of HLA associations with adverse drug 
reactions, three main hypotheses have been suggested: the hapten, the p-i concept and 
the altered peptide repertoire. The hapten model states that drugs can covalently bind to 
proteins (hapten-carrier complexes) which undergo antigen processing and presentation, 
being able induce a novel immune response. The p-i concept (or pharmacological 
interaction of a drug with immune receptors) postulates that a drug might directly bind 
to TCR and stimulate the T cell. The altered peptide repertoire model (demonstrated for 
abacavir interaction with B*57:01) results from a non-covalent binding of the drug within 
the HLA antigen-binding cleft, modifying the shape of the antigen-binding cleft leading 
to a consequent altering of the presented peptide repertoire [155,162]. The peptides 
presented are thus not recognised as “self”, giving rise to an auto-immune like reaction. 
Given that the altered peptide repertoire model is the only one currently supported by 
structural data, the research presented in this chapter is working under the assumption 
that the altered peptide repertoire is also likely to be the mechanism of action underlying 
adverse reactions to nevirapine. 
In the aforementioned GWAS of nevirapine treated Malawian patients, the SNP 
(rs1050409) found associated encodes for a substitution of alanine to glutamic acid at 
residue 73 of the full length HLA-C*04:01 sequence (corresponds to position 49 when 
excluding the signal peptide). Additionally, this substitution is nearly unique to HLA-C*04 
alleles, suggesting a putative role in nevirapine-induced ADR mechanisms. Since HLA 
protein sequences found in relevant immunogenetic and protein databases consider the 
polypeptide of the mature protein for sequence positions, i.e. excluding the signal peptide, 
position 49 instead of 73 is going to be used throughout this chapter to indicate the 
substitution. 
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In collaboration with Prof Munir Pirmohamed’s research group at the University of 
Liverpool, the present chapter describes the investigation of the structural basis of 
association of HLA-C*04:01 with nevirapine-induced ADRs using molecular docking 
methods. The putative role of Glu49 residue in HLA-C*04:01 (and other Glu49 HLA-
C*04 alleles) in inducing ADRs in patients under nevirapine treatment was a starting point 
for the present investigations. Docking analyses were also performed using a the 12-
hydroxy-nevirapine (a breakdown metabolite derived from nevirapine) since studies using 
in rats suggest that nevirapine-induced skin rash is associated to its metabolite 12-
hydroxy-nevirapine [163]. 
The research described in this chapter has been published as part of a larger study 
regarding genetic associations with nevirapine hypersensitivity in the Journal of 
Antimicrobial Chemotherapy (2017) [159], corresponding to my contribution in the 
manuscript (Appendix A). 
 
4.3 Methods 
 
4.3.1 HLA-C*04:01 crystal structure 
A search for the crystal structure of HLA-C*04:01 or other closer alleles was 
performed by querying UNIPROT database (http://www.uniprot.org/) [164] for “hla-
c” AND organism: “Homo sapiens (Human) [9606]”, resulting in 42 reviewed hits. The 
‘P30504’ UNIPROT ID, described as HLA Cw-4 alpha chain (MHC class I antigen 
Cw*4), was queried in Protein Data Bank (PDB) (http://www.rcsb.org/pdb) [165], 
retrieving the 1QQD PDB crystal structure [166], described as HLA-Cw4, which is a 
nomenclature referring to the antigenic classification. By mapping its protein sequence 
with HLA protein sequences in IMGT/HLA database [107], 1QQD was identified as 
HLA-C*04:01 crystal structure. 
 
4.3.2 Choice of control HLA molecules 
Assuming residue Glu49 as a putative binding site for nevirapine in C*04:01, a control 
molecule for comparison of binding affinity should have an alternative residue at 49 
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position. To choose the most similar molecule to C*04:01, but containing other residue 
than a glutamic acid in position 49, the following steps were performed: i) HLA-C protein 
sequences were extracted from IMGT/HLA database, selecting only protein sequences 
containing a residue other than glutamic acid in position 49, ii) makeblastdb application, 
which is part of the blast+ package from NCBI 
(ftp://ftp.ncbi.nlm.nih.gov/blast/executables/blast+/LATEST/) [167] was used to 
build a blast database containing only the selected sequences, iii) the C*04:01 FASTA 
sequence from 1QQD PDB entry was queried against the built database using blastp 
application, also part of blast+ package. C*04:07 was the top hit in blastp results, containing 
only one residue change as an alanine in position 49 (Ala49), thus selected as a control 
molecule. The next hit belonging to the C*04 allele group was C*04:03, which was also 
included as control molecule, containing six residue changes compared to C*04:01 
(Tables 4.1 and 4.2). The next highest frequency HLA-C allele in the Malawi cohort 
(C*02:10) was also selected as a control molecule, under the assumption the genetic data 
indicated that allele was not associated with a nevirapine-ADR. To assess if Glu49 is a 
key residue for binding nevirapine independent of other residue differences in C*04:01 
with other alleles, C*04:04 and C*04:16 were selected for nevirapine docking, as they have 
the same residue as C*04:01 in position 49 (Glu49) and are not rare alleles in world 
populations [58]. For another hypothesis that the binding site is located elsewhere, other 
HLA-C alleles present in Malawi cohort were selected as control molecules (C*02:02, 
C*03:02, C*03:03, C*03:04, C*06:02, C*07:01, C*07:02, C*07:04, C*08:02, C*12:03, 
C*14:02, C*15:05, C*16:01, C*17:01, C*18:01). 
 
4.3.3 Modelling of control HLA molecules 
Since protein crystal structures for control HLA molecules were not available at PDB, 
homology modelling was performed to generate their structures using two applications 
from Rosetta modelling software (version 2015.05). First, comparative modelling of HLA 
alleles using C*04:01 as a template was performed using the RosettaCM application [168]. 
This application uses two input files: the FASTA sequence of the molecule to be modelled 
and an alignment with the template sequence. Alignments were in HHR format, which 
were generated using hhalign application from HHsuite version 2.0 [169]. Another Rosetta 
application named relax [170] was also used to generate structure models of HLA alleles. 
This application uses an edited PDB file as an input file. In the present study, edited 
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versions of 1QQD PDB file were used for each HLA molecules to be modelled, where 
residue changes were manually altered by changing the residue names and removing 
atoms other than N, C, CA and O. The relax application reads the edited PDB files and 
autocomplete the specified residues and changes the structure configuration accordingly. 
For each molecule and each method, ten models were generated. 
 
4.3.4 Nevirapine Docking 
The preparation of molecules for docking, i.e. generation of PDBQT files, was 
performed using AutoDock Tools (ADT) applications from MGL Tools version 1.5.6 
[171], both Graphical User Interface (GUI) and python scripts for batch generation of 
PDBQT files (prepare_receptor4.py for rigid molecule and prepare_flexreceptor4.py for 
flexible molecules). This pre-docking step is performed to ensure that atoms are in the 
correct format for docking, by adding partial charges, merging non-polar hydrogens and 
detecting aromatic carbons. The PDBQT format is ‘PDB’ from the original format plus 
‘Q’ for partial charges and ‘T’ for AutoDock atom type. For the ligand, it also defines its 
flexible bonds (torsions) which allows for testing different conformations of the ligand 
to fit in the receptor. ADT has identified only one torsion in nevirapine, since most of 
the molecule is composed by aromatic rings, which are not flexible (Figure 4.1). Docking 
was performed using both rigid receptor and flexible receptor. A flexible receptor 
PDBQT file contains information of selected residues defined as flexible, i.e. their side 
chains can present different conformations, providing different shapes of binding sites to 
which the ligand can bind to. To determine which residues are flexible, all the models 
generated for each HLA molecule by Rosetta were superimposed in PyMOL  Molecular 
Graphics System (www.pymol.org) [172]. Residues showing alternate side chains 
positions when comparing all the models were defined as flexible. This information was 
then used in ADT to generate a flexible residues PDBQT file. Autodock VINA [173] was 
used to perform nevirapine docking in HLA molecules for both rigid and flexible docking 
using the following parameters: a search space, i.e. the receptor area to search for likely 
binding sites, of 42 x 50 x 50 Å and exhaustiveness = 30. Visualisation and figures were 
produced in PyMOL and graphs were produced in the R programming language [89]. 
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Table 4.1: HLA polymorphisms selected for nevirapine docking, including the C*04:01 and other HLA control molecules. 
Allele Description 
C*04:01 Associated with nevirapine-induced adverse drug reaction in the Malawi cohort, 
including a SNP within the peptide sequence encoding a Glu49 substitution [158,159] 
C*04:07, C*04:03 C*04 top hits on blastp of C*04:01 against other HLA-C alleles non-Glu49. C*04:07 
is also present in the Malawi cohort.  
C*04:04, C*04:16 Frequent alleles containing Glu49 but differing in other residues from C*04:01 
C*02:02, C*02:10, C*03:02, C*03:03, C*03:04, C*06:02, C*07:01, C*07:02, 
C*07:04, C*08:02, C*12:03, C*14:02, C*15:05, C*16:01, C*17:01, C*18:01 
Other HLA-C alleles present in Malawi cohort 
 
Table 4.2: Polymorphic residue difference between C*04:01 and chosen control alleles within the peptide binding region protein sequence. 
Allele 1 9 11
 
14
 
16
 
21
 
24
 
35
 
49
 
66
 
73
 
77
 
80
 
90
 
91
 
94
 
95
 
97
 
99
 
10
3 
11
3 
11
4 
11
6 
13
8 
14
3 
14
7 
15
2 
15
6 
16
3 
17
0 
17
3 
17
7 
C*04:01 G S S W G R A R E K A N K D G T L R F L Y N F T T W E R T R E E 
C*04:07 * - - - - - - - A - - - - - - - - - - - - - - - - - - - - - - - 
C*04:03 * Y A R S H - - A - - - - - - - - - - - - - - - - - - - - - - - 
C*04:04 * - - - - - - - - - - - - - - - - - - - - - - - - - - L - - - - 
C*04:16 - Y A R - H - - - - - - - - - - - - - - - - - - - - - - - - - - 
C*02:10 C Y A R S H - - A - T - - A - - - - Y - - D S - - - - W E - - - 
C*02:02 C Y A R S H - - A - T - - A - - - - Y - - D S - - - - W E - - - 
C*03:02 - Y A R - H - - A - T S N A - I - - Y V - D S - - - - L L - K - 
C*03:03 - Y A R - H - - A - T S N A R I I - Y V - D Y - - - - L L - K - 
C*03:04 - Y A R - H - - A - T S N A - I I - Y V - D Y - - - - L L - K - 
C*06:02 C D A R - - S - A - - - - - - - - W Y - - D S - - - - W - - - - 
C*07:01 C D A R - - S - A N - S N - - - - - Y - - D S - - L A L - - - - 
C*07:02 C D A R - - S - A - - S N - - - - - S - - D S - - L A L - - - - 
C*07:04 C D A R - - S - A - - S N - - - F - Y - - D - - - L A D - - - K 
C*08:02 C Y A R - - - Q A - T S N A - - - - Y - - - - K - - - - - - - K 
C*12:03 C Y A R - - - - A - - S N A - - - W Y - - D S - - - - W - - - - 
C*14:02 C - - R - - - - A - T S N A - - - W - - - D S - - - - - - - - - 
C*15:05 C Y A R - H - - A N T - - A - I I - Y - H D - - - - - L - - - - 
C*16:01 C Y A R - - - - A - T S N A - - - W Y - - D S - - - A Q - - - - 
C*17:01 - Y A R - - - - A - - - - A - - I - Y - - - - - S L - L E G - - 
C*18:01 C D A R - - S - A - - - - - - - - - - - - - - - - - - - - - - - 
‘-‘ = Same residue as reference sequence C*04:01. ‘*’ = Residue has not been sequenced. 
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4.4 Results and Discussion 
A collaborating research group under the leadership of Prof Munir Pirmohammed 
performed a GWAS in a Malawi cohort of patients being treated with nevirapine, finding 
an association of nevirapine-induced ADR with a SNP encoding for glutamic acid in 
position 49 of the HLA-C*04:01 allele [159]. This residue is present in almost all C*04 
alleles and seldom observed in other HLA-C alleles, and it has been suggested to have a 
structural involvement in the mechanism of nevirapine-induced ADR associated with 
C*04:01. It has also been suggested that not only C*04:01, but all other C*04 alleles 
containing glutamic acid in position 49 (corresponding to the majority of C*04 alleles) 
would be also associated to ADRs. Table 4.3 summarises results found by the mentioned 
research group, showing a highly significant association of C*04:01 and nevirapine-
induced SJS/TEN. 
 
Table 4.3: Comparison of HLA-C allele frequencies between controls and SJS/TEN patients in 
the Malawi cohort. 
HLA Allele Controls (%) SJS/TEN (%) OR CI (95%) P-Value 
C*04:01 0.25 (39) 0.64 (23) 5.12 2.24 - 12.16 2.25 x 10-5 
C*02:10 0.24 (37) 0.11 (4) 0.39 0.09 - 1.22 ns 
C*03:02 0.05 (8) 0.03 (1) 0.52 0.01 - 4.09 ns 
C*03:03 0.04 (6) 0.03 (1) 0.70 0.01 - 6.07 ns 
C*03:04 0.08 (12) 0.14 (5) 1.89 0.49 - 6.29 ns 
C*06:02 0.24 (36) 0.08 (3) 0.3 0.06 - 1.04 0.04 
C*07:01 0.16 (24) 0.25 (9) 1.79 0.66 - 4.55 ns 
C*07:02 0.08 (13) 0.06 (2) 0.63 0.07 - 3.01 ns 
C*07:04 0.05 (7) 0.06 (2) 1.23 0.12 - 6.83 ns 
C*08:02 0.13 (20) 0.11 (4) 0.83 0.19 - 2.73 ns 
C*12:03 0.04 (6) 0.06 (2) 1.44 0.14 - 8.50 ns 
C*16:01 0.1 (15) 0.08 (3) 0.84 0.15 - 3.21 ns 
C*17:01 0.21 (32) 0.19 (7) 0.91 0.31 - 2.39 ns 
C*18:01 0.14 (22) 0.08 (3) 0.54 0.1 - 1.98 ns 
‘HLA genotyping’ refers to individuals from Malawi cohort whose HLA type has been confirmed by 
histogenetics, while ‘Imputed HLA Alleles’ comprises all individuals in the Malawi cohort whose HLA type 
has been estimated by imputation. HLA genotyping sample size: controls = 35, cases = 81; Imputed HLA 
Alleles sample size: controls = 182; cases = 151.  
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Figure 4.3: Comparison of C*04:01 frequencies observed in cases and controls from the Malawian 
cohort with frequencies from worldwide healthy populations from AFND (‘World’, ‘Sub-
Saharan’, ‘Black’) [58].  
 
Figure 4.3 shows that HLA-C*04:01 frequency from controls is similar to most 
frequencies observed in world populations, especially Sub-Saharan and populations 
defined as having ‘Black’ ethnicity. In contrast, frequency of this allele observed in 
patients fall out of the range observed for all healthy population, except from some 
outliers. This comparison reinforces the HLA-C*04:01 association with nevirapine-
induced ADRs, highlighting that the chance of its frequency value to occur by chance in 
any world population is very low. 
Computational docking of nevirapine in the HLA-C*04:01 peptide binding region 
was performed to predict the binding site of nevirapine where the total molecular area of 
the α1 and α2 regions was used as a search space. Figure 4.4 shows a total of 20 
conformations predicted to bind C*04:01. Most of the conformations are within the 
peptide binding region, while others are restricted to a specific loop outside the peptide 
binding region. Glutamic acid in position 49 is highlighted in Figure 4.4, showing that no 
predicted conformations of nevirapine docking were able to contact this residue. The 
identification of the residues within a 4 Å radius of all the conformations predicted does 
not include position 49 within this area. 
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The same analysis was performed using 12-hydroxy-nevirapine as a ligand, which is a 
breakdown metabolite derived from nevirapine and suggested to be associated with ADR 
in comparison to other metabolites. Figure 4.5 shows 20 predicted conformations of 12-
hydroxy-nevirapine binding C*04:01. In this case all conformations are within the peptide 
binding groove. Similar to nevirapine, no predicted conformation was able to contact 
glutamic acid in position 49. The region containing residue 49 does not seem to be 
reachable by nevirapine, since it is located in the bottom of the α1 and α2 molecular 
structure, far from the regions where nevirapine has been predicted to bind, which are 
the peptide binding groove (for both nevirapine and 12-hydroxy-nevirapine) and a cavity 
located at the top of the molecule outside near residue 14 (nevirapine only). 
To identify the putative binding site of nevirapine or 12-hydroxy-nevirapine, residues 
around 4 Å of all the predicted modes were analyzed using PyMOL (Figure 4.6). From 
all residues identified within this radius area, positions where residues are polymorphic 
among the alleles in the Malawi cohort, where at least 50% of the alleles have a residue 
different than C*04:01 were selected as potential candidates (green columns in Table 4.4). 
By analyzing residue differences in those positions between alleles, candidates for ligand 
binding site can be identified. The three top positions where most of the other alleles in 
the cohort have different residues from C*04:01 are position 14, 9 and 99. Position 14 in 
C*04:01 shares the same residue only with C*04:07. Position 9 shares the same residue 
with C*04:07 and C*14:02. Position 99 shares the same residue with the same alleles as 
position 9 plus C*18:01. Other positions share residues with four or more alleles. 
Predominance of C*04:01 residues in those specific positions in comparison to other 
alleles in the cohort suggests their putative role in interaction with nevirapine or its 
metabolites. 
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Figure 4.4: Docking of nevirapine to HLA-C*04:01 peptide binding region, where a total of 20 conformation modes were produced. ‘A’ shows the top view 
of the molecule, while ‘B’ shows a side view of the molecule. Although SNPs coding for residue position 49 in the molecule are strongly associated with 
ADR, no predicted conformation binds that position in the molecule. Areas coloured in darker blue are contain polymorphic residues contacting nevirapine 
conformations. 
107 
 
 
Figure 4.5: Docking of 12-hydroxy-nevirapine to HLA-C*04:01 peptide binding region, where a total of 20 conformation modes were produced. ‘A’ shows 
the top view of the molecule, while ‘B’ shows a side view of the molecule. 12-hydroxy-nevirapine is a nevirapine metabolite, which has been shown to be 
associated to ADR in comparison to other nevirapine metabolites. Although SNPs coding for residue position 49 in the molecule are strongly associated 
with ADR, no predicted conformation binds that position in the molecule. Areas coloured in darker blue are contain polymorphic residues contacting 12-
hydroxy-nevirapine conformations. 
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Docking results also show that predicted conformations form clusters (3 clusters for 
nevirapine and 2 clusters for 12-hydroxy-nevirapine) which may be indicating the possible 
binding sites. While for nevirapine the conformations within each cluster are more spread 
and present variable orientations, for 12-hydroxy-nevirapine, the conformations seem to 
be limited to a smaller molecular area and follow a similar orientation. Figure 4.6 shows 
that for both nevirapine and 12-hydroxy-nevirapine one cluster is limited to a region that 
includes residues 9 and 99, and the other cluster interacts with several other 
polymorphisms where residue 156 contains more amino acid differences in other alleles 
not C*04:01. Another cluster specific to nevirapine analysis contacts position 14. 
Although this region is outside the peptide binding groove, position 14 is accessible for 
interaction with other proteins, since it is situated in the top of the α1 and α2 molecular 
structure. 
Position 14 is also unique to C*04:01, with exception of C*04:07. In the Malawi 
cohort only one individual (patient) was typed for C*04:07 and the highest frequency that 
has been observed in Sub-Saharan African populations is 4% (Figure 4.9). Furthermore, 
most studies use low resolution HLA typing, where both C*04:01 and C*04:07 are part 
of Cw4 classification. Additionally, position 49 is the only residue difference between 
C*04:01 and C*04:07 mature protein sequences, which is unlikely to be a binding site for 
nevirapine and its metabolites, or to interact with other molecules of the immune system. 
Each predicted conformation is assigned a score representing the energy of the 
docking between ligand and molecule for that conformation. The lowest scores are 
assumed to be the best conformations to fit the molecule, having the lowest free energy. 
However docking scores have been shown to be poor predictors of the best 
conformation [174]. Figure 4.7 shows the first poses (conformations with the lowest 
scores) from docking of nevirapine and 12-hydroxy-nevirapine and the contacting 
residues (conserved and polymorphic among alleles in Malawi cohort). Both are within 
the peptide binding region, but are in contact with different set of residues. Taking into 
account the polymorphic positions which are predominantly different than C*04:01 in 
comparison with other alleles in the Malawi cohort (Table 4.4), nevirapine binding site 
includes two positions nearly unique to C*04:01 (residues 9 and 99), while for 12-hydroxy-
nevirapine first docked mode the position which has more differences from C*04:01 
among Malawi cohort alleles is 156 (four alleles have the same residue as C*04:01 from 
17 alleles). 
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Figure 4.6: HLA-C*04:01 residues contacting all nevirapine (A) and 12-hydroxy-nevirapine (B) modes predicted by docking. Residues in magenta are 
polymorphic residues among the alleles present in Malawi cohort, for which more than 50% of the alleles are different than C*04:01, while residues in gold 
are all other residues contacting the predicted modes. This figure shows the same docking results as figures 4.4 and 4.5, but details all residues contacting 
the 20 conformations predicted for each ligand.
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Table 4.4: Polymorphic residues among the alleles present in Malawi cohort for which more than 
50% of the alleles are different than C*04:01 and their HLA carrier frequencies. 
 Amino Acid Positions 
HLA Allele 1 9 11 14a 49 73a 77 80 90 99 114 116 156 219 275 303 
C*04:01 G S S W E A N K D F N F R W K M 
C*02:10 C Y A R A T - - A Y D S W R E V 
C*03:02 - Y A R A T S N A Y D S L - E V 
C*03:03 - Y A R A T S N A Y D Y L - E V 
C*03:04 - Y A R A T S N A Y D Y L - E V 
C*06:02 C D A R A - - - - Y D S W R E V 
C*07:01 C D A R A - S N - Y D S L R E V 
C*07:02 C D A R A - S N - S D S L R E V 
C*07:04 C D A R A - S N - Y D - D R E V 
C*08:02 C Y A R A T S N A Y - - - R G V 
C*12:03 C Y A R A - S N A Y D S W R E V 
C*16:01 C Y A R A T S N A Y D S Q R E V 
C*17:01 - Y A R A - - - A Y - - L R - V 
C*18:01 C D A R A - - - - - - - - - - V 
‘-‘ = Same as C*04:01 sequence. Columns in green represent residues contacting one or more conformation 
modes. a Positions 14 and 73 contact nevirapine, but not 12-hydroxy-nevirapine modes. Columns with a 
red outline are the top 3 residues containing more differences when comparing other alleles to C*04:01. 
For position 14 only C*04:07 has the same residue. For position 9, C*04:07 and C*14:02 have the same 
residue, and for position 99, C*04:07 and C*14:02 and C*18:01 have the same residue. 
 
Thus, docking results have been capable to identify three possible binding sites for 
nevirapine, and two possible binding sites for 12-hydroxy-nevirapine. Each of those 
molecular sites has specific polymorphic positions with the potential to be key interactors 
with nevirapine in C*04:01 due to low replication of the amino acids in those positions 
in other alleles, especially the alleles found in the Malawi cohort where the nevirapine-
induced ADR association with C*04:01 has been found. The next sections detail the 
configuration of those putative binding sites and the likely mechanisms leading to ADR. 
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Figure 4.7: Nevirapine (A) and 12-hydroxy-nevirapine (B) first pose docked to HLA-C*04:01, highlighting the contacting residues. Residues in magenta are 
polymorphic residues among the alleles present in Malawi cohort, while residues in gold are all other residues contacting the predicted mode. Position 49 is 
the only residue shown in detail in nevirapine (A) that does not contact the predicted conformation. 
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4.4.1 Putative drug interaction with position 9 and 99 
(NVP2) 
Docking results suggest a putative binding site that comprises residues S9 and F99 
for both nevirapine and 12-hydroxy-nevirapine (Figure 4.8). For nevirapine docking, this 
binding site appears as the first conformation, i.e. the most likely conformation according 
to docking scoring system. For 12-hydroxy-nevirapine docking, it appears as the second 
conformation according to docking scores. From the 20 conformations generated for 
both ligands, 11 nevirapine conformations were predicted to bind this site in comparison 
to 9 12-hydroxy-nevirapine conformations. 
Residues S9 and F99 have the potential to be key interactors with nevirapine or 12-
hydroxy-nevirapine as they are strongly differentiated in other alleles present in the 
Malawi cohort in comparison to C*04:01 (Table 4.4). Excluding HLA-C*04:07, the only 
allele containing S9 is C*14:02 and F99 is present in C*14:02 and C*18:01. By analysing 
all HLA-C alleles which have been described so far it can be observed that the S9 and 
F99 in combination are only found in C*04 and C*14 alleles. This exclusivity of those 
residues to these two low resolution specificities suggests this molecular region as strong 
candidates for the actual binding site of both nevirapine and 12-hydroy-nevirapine, since 
C*14 and C*14:02 allele frequencies, both in world populations and restricting by sub-
Saharan populations, are lower than C*04 (Figure 4.9), where larger sample sizes are 
required for finding significant associations. 
Those two residues are also known constituent residues of some of the six pockets 
which are part of the HLA peptide binding groove. Residue S9 is part of two pockets, B 
and C, which accommodate peptide residues 2 and 6, respectively. Residue F99 is part of 
three pockets, being the residue with the higher participation in HLA pockets. It is part 
of pockets A, B and D, which accommodate peptide residues 1, 2 and 3 respectively [36]. 
Although there is little information regarding the mechanisms of HLA associations 
with ADRs, those residues have vital importance on the accommodation of the peptide 
in the peptide binding groove, determining their final conformation to be presented to 
T-cells. Recently, the mechanism of an association of B*57:01 and abacavir-induced ADR 
has been described, which is also linked to specific residues within the peptide binding 
groove. Asp114 and Ser116, where the first is part of pockets D and E, enable the binding 
of abacavir to the peptide binding groove, changing its conformation and chemical 
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properties, resulting in an alteration of the peptide repertoire binding this allele. 
Therefore, new endogenous peptides which were not previously identified as self-
peptides during T-cell maturation start being exposed by B*57:01, leading to activation 
of circulating T-cells specific for those new peptides. Since S9 and F99 are also within the 
peptide-binding region and both are constituents of HLA pockets, a similar mechanism 
is likely to be the case in nevirapine scenario. 
 
 
Figure 4.8: List of all contacting residues of predicted conformations of nevirapine and 12-
hydroxy-nevirapine in C*04:01, separately for each ligand cluster referring to a putative binding 
site. (A) and (B) are references for the cluster names, and (C) details all residues contacting each 
cluster. * Polymorphic residues among the alleles present in Malawi cohort, for which more than 
50% of the alleles are different than C*04:01. ‘Aa. Pos.’ = Amino acid position; ‘Aa. Res.’ = 
Amino acid residue; ‘Polymorphism (%)’ = Percentage of polymorphic differences in alleles 
found in Malawi cohort compared to C*04:01 (for this analysis, C*04:07 was excluded, since its 
only residue difference is position 49, which was shown in the present study unlikely to be the 
binding site for nevirapine or its metabolites). White (blank) squares are residues not contacting 
the predicted modes in each given cluster. 
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Figure 4.9: World distribution of allele frequencies of HLA-C alleles present in the Malawi cohort. Distributions are grouped by worldwide populations (left 
side) or restricted to sub-Saharan populations (right side) [58]. 
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4.4.2 Putative drug interaction with position 14 
Docking results show three regions in the C*04:01 where nevirapine can putatively 
bind (Figure 4.8). One of these regions is situated outside the peptide-binding region, but 
still on the top surface, close to residues within the peptide-binding region. The predicted 
nevirapine modes contact the residue Trp14, which is unique to C*04 (except for seven 
non-C*04 rare alleles). The fact that this region is also close to peptide-binding region, it 
is possible that the binding of nevirapine in this region could affect antigen presentation 
in different ways, by changing the chemical structure of the HLA-C molecule or the 
peptide resulting in different structures recognizable by T-cells as non-self, or by 
disturbing regions specific to NK cell recognition. 
HLA-C*04:01, as other HLA-C alleles, are capable of interacting with KIR receptors, 
which are present on the surface of NK cells (Figure 4.10). This interaction results in 
signals that can be inhibitory or activating, depending on the KIR receptor type. NK cells 
will then be activated if there are enough activating signals to initiate a cytolytic response. 
HLA-C alleles are divided in C1 and C2 ligand groups. HLA-C1 ligands contain an 
asparagine in position 80, binding to KIR2DL2 and KIR2DL3 while HLA-C2 ligands 
contain lysine at position 80, binding to KIR2DL1 (C*04:01 allele is a C2 ligand). Most 
of the KIR receptors binding to HLA ligands are inhibitory receptors (including 
KIR2DL1), so when HLA class I molecules are downregulated or impaired, a response 
from NK cells is elicited due to the absence MHC class I interactions with inhibitory 
KIRs, and therefore absence of inhibitory signals. This ‘missing-self’ mechanism is and 
evolutionary development that provides an alternative defence against pathogens and 
tumours that reduce HLA class I molecule expression to avoid their antigen presentation 
to T-cells. 
The main residue involved in HLA-C2 ligand interaction to inhibitory KIR2DL1 is 
Lys80 in HLA and Glu44 in KIR2DL1, but the molecular interface also includes other 
residues. In HLA-C*04:01, residue 14 is within a loop known to influence KIR 
interaction. Trp14 residue in HLA-C*04 has been determined as crucial for binding of 
KIR2DS4, by altering the conformation of the loop comprising residues 14 and 19, which 
is located close the KIR-HLA interaction site. Residue 19 is situated below Arg75, a 
residue that participates in the KIR2DL1 interaction with HLA-C2 ligands [175]. 
Although KIR2DS4 is an activating receptor, its interaction with C*04 alleles is weaker 
than KIR2DL1-C*04 interaction [176], thus the function of KIR2DS4 interaction has 
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not been yet clarified. The 14R>W substitution in HLA-C*04 may facilitate nevirapine 
binding on this site, resulting in an impairment of KIR2DL1 interaction, turning NK cells 
more prone to activate, resulting in a cytolytic response against cells containing HLA-
nevirapine complexes. Both KIR2DL1 and KIR2DS4 have high worldwide frequencies 
[58]. NK and NKT cells are usually found in SJS/TEN blisters together with CD8+ T-
cells. Despite it having been suggested that the inflammatory response in SJS/TEN is 
initiated by T-cells, it has also been argued that the quantity of T-cells found in those 
blisters is too low to generate the extensive inflammatory responses observed in this 
adverse drug reaction. Therefore, an immune response of NK cells due to its failure to 
recognize C*04 ligand through inhibitory KIR2DL1 as a result from the binding of 
nevirapine nearby Trp14 is possible, but it is unlikely to be the only mechanism leading 
to SJS/TEN. 
 
4.4.3 Putative drug interaction with residue Phe116 and 
Arg156 
Another predicted C*04:01 binding site for nevirapine and 12-hydroxi-nevirapine 
comprises residues Phe116 and Arg156 located within the peptide-binding region (Figure 
4.8). In the Malawian cohort, both residues are also present in C*08:02 and C*18:01 
alleles. C*08 has been previously associated with nevirapine-induced ADR in Asian and 
Caucasian populations, however none of those alleles were significantly associated with 
SJS/TEN in the Malawian cohort. C*08:02 was present in 13% of controls and 11% of 
SJS/TEN cases, while C*18:01 was present in 14% of controls and 8% of SJS/TEN 
cases. Despite there being no trend in the Malawian cohort for an association of C*08 
and C*18 to SJS/TEN, C*08 and C*18 frequencies are considerably lower than C*04 in 
sub-Saharan populations (C*08 mean = 0.05, SD = 0.035; C*18 mean = 0.02, SD = 0.025; 
compared to C*04 mean = 0.19, SD = 0.088), and consequently C*04 frequency in the 
Malawian cohort is higher than other alleles, thus giving more support for discovery of 
disease associations. Furthermore, these positions have been previously described in one 
of the few studies detailing HLA binding sites for drugs causing ADRs. Residue Ser116 
have been found to be crucial for binding of abacavir on HLA-B*57:01, while residue 
Trp156 has been related to binding of carbamazepine on HLA-B*15:02, both consisting 
of hypersensitivity mechanisms. 
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Figure 4.10: In silico nevirapine binding to the crystallographic structure of the interaction between HLA-C*04:01 and KIR2DL1, highlighting the residues 
in both molecules contacting nevirapine. 
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4.4.4 Critical evaluation of using docking tools for ADRs 
associated with HLA 
The variability in the predicted binding sites and modes, in conjunction with their 
associated scores reported in this chapter, raises questions regarding the reliability of 
molecular docking tools and the significance of generated scores. Furthermore, since the 
PBG on the top of the HLA molecule comprised a cavity with optimal dimensions to fit 
small molecules such as drugs, one can assume that any molecule within a dimension 
range would be predicted to bind somewhere within the PBG, even if biologically they 
do not bind HLA molecules. Our group has subsequently followed up on these questions, 
in an attempt to optimise protocols and understand the pitfalls of docking [177].  
Using drug-HLA associations with known binding sites as models, such as abacavir 
and carbamazepine, several molecular docking tools were benchmarked regarding their 
capability of predicting the binding site of a drug to their respective risk HLA alleles. The 
same analysis was also performed using control alleles with alternative residues in the 
binding sites to investigate if that changes the predicted binding sites. Results from those 
analyses showed that most docking tools were able to predict the correct binding site, and 
were also able to differentiate between risk and control alleles, where best scoring poses 
for control alleles were positioned further from the known binding site. However, several 
factors from variations in proteins generated by homology modelling, determination of 
flexible residues and adjustment of parameters were shown to have some influence on 
docking results. 
Molecular docking tools should be used with caution, as they are not able to confirm 
that in reality a molecule binds their predicted binding sites. Nevertheless, they are 
certainly helpful tools to guide researchers regarding mechanisms involved in ADRs 
associated with HLA, and should be used in tandem with association studies and 
experimental evidence. 
 
4.5 Conclusion 
An association of a SNP encoding a Glu49 substitution in HLA-C*04:01 with 
nevirapine-induce hypersensitivity led to an initial consideration of its putative 
involvement in the ADR provoking mechanism, since it is nearly absent in non-C*04 
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alleles. While the GWAS study using a replication cohort added further weight to existing 
evidence of association of HLA-C*04:01 with nevirapine-induce hypersensitivity, 
molecular docking of nevirapine with this polymorphism shows no evidence of the 
involvement of this residue in nevirapine hypersensitivity. The docking analysis presented 
in this chapter, as well as analysis of HLA sequences and allele frequencies, has led to 
other HLA-C residues being identified as possible candidates to be influencing nevirapine 
interactions with HLA molecule for further investigations. It is acknowledged that there 
are some limitations to this work. First, it is known that docking can produce false 
positives, and the prediction of docking does not prove a given binding mechanism. 
Second, the work assumes that direct binding of nevirapine to the HLA molecule is the 
mechanism by which the ADR is induced. Given the strength of evidence supporting this 
mechanism with abacavir, this appears a reasonable assumption, however there is still 
controversy and discussion in the field. Despite these limitations, the work presented in 
this chapter has made steps towards suggesting strongly plausible hypotheses by which 
the ADR could be occurring, which can be followed up in new studies. 
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Chapter 5  
Discussion, general conclusions and 
future work 
 
The research described in this thesis is in the context of precision /personalised 
medicine, which is a growing field of clinical science and healthcare that incorporates 
comprehensive knowledge of inter-individual genetic, environmental and lifestyle 
variability to optimize clinical care. The distinctive complexity and clinical impact of 
immune genes and their related mechanisms makes them obvious targets for advances in 
this field. 
Computational and informatics developments are central to integrate data needed to 
deliver tailored healthcare, and are essential for dealing with the continuous growth of 
diseases associations with immune genes, the development of better strategies for HLA 
matching for transplantation, and in uncovering immune mechanisms inducing HLA-
linked hypersensitivity. The developments here described provide informatics resources 
for analysis of immunogenetic variability in diseases and transplantation and gives insights 
on how this variability shapes individual health. It also adds to the understanding of 
molecular mechanisms underlying nevirapine-induced hypersensitivity associated with 
HLA. 
The development of a public database storing KIR and disease association studies 
(KIR and Diseases Database – KDDB) as part of a major immunogenetic database (Allele 
Frequency Net Database – AFND) integrates population gene frequency data with 
susceptibility to diseases, providing a tool for helping researchers in the field to better 
understand the role of those genes in modulating different disease types. A form of meta-
analysis covering the curated data showed a relationship of KIR gene function and the 
type of disease investigated, where an enrichment of reported associations of activating 
KIR genes with autoimmune diseases, cancer and pregnancy complications was found. 
As in a more traditional meta-analysis, publication bias is potentially a limiting factor on 
this analysis. 
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Future work for the field of disease associations with immune genes should involve 
continuous gathering of KIR-disease associations and development of a database storing 
HLA and disease associations that could also be integrated with KDDB. For a better 
understanding of KIR interplay in influencing response to with diseases, further 
systematic analyses are needed. KIR and disease investigations would also benefit from 
further structural knowledge of the interaction of KIRs with ligands, with improved 
definitions of consequences of variable strength affinity in those interactions and 
influence of peptides presented by HLA molecules in the behaviour of those receptors. 
HLA epitope frequencies database (EpFreq-DB) is another resource developed as 
part of AFND, which translates HLA allele data into HLA epitope data regarding 
population frequencies. With the increasing research towards structural approaches in 
transplantation matching making use of HLA epitopes, EpFreq-DB provides a tool for 
assessing the implementation of these methods in worldwide populations. Analysis of 
HLA epitope frequencies in several populations show that epitopes have distinct patterns 
of variability across populations, some being present in almost all individuals while others 
are almost never present. Epitopes showing higher population variability may be more 
relevant to be considered for donor-search strategies. 
An explorative analysis of the HLA epitope matching was performed based on 
alloreactivity profiles from single-antigen bead (SAB) assays containing information 
regarding the presence of alloantibodies that can recognize HLA antigens present in those 
beads. Results from this analysis suggest that HLA antigens in SAB assays – comprising 
only a subset of existing polymorphisms – may not sufficiently cover variability in some 
populations. Since epitopes are shared across different alleles and loci, their application 
has the potential to improve granularity from SAB assay results. However, a better 
understanding of HLA epitopes is required, since most of the epitopes currently defined 
are originated from in silico analysis. 
HLA polymorphisms have been also widely associated to hypersensitivity to several 
drugs. Recently, a strong association of HLA-C*04:01 with nevirapine-induced 
hypersensitivity has been reported. To investigate molecular aspects of this association, 
in silico docking analysis was performed for the interaction of nevirapine and a related 
metabolite with HLA-C*-04:01. Since a SNP substitution (Glu49) in C*04:01 was found 
associated with nevirapine-induced hypersensitivity, a mechanism role of this residue 
nearly unique to all C*04 alleles was initially hypothesized. Results from molecular 
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docking analysis showed no interaction of nevirapine with this position, but it identified 
other possible candidate residues to be involved in the nevirapine hypersensitivity 
mechanism. 
Future generation of the crystallographic structure of nevirapine binding to C*04:01 
is needed to verify those interactions. Additionally, following a rationale that nevirapine 
binds to residues within the HLA peptide-binding region and could be altering the 
peptide repertoire presented by C*04:01 molecules, further data of the peptides generated 
by C*04:01 and closely related alleles would also benefit the understanding of this 
mechanism. 
Achievements from this thesis consist of steps towards a better understanding of 
mechanisms of immune variability in generating distinct outcomes in individual health, 
contributing to necessary knowledge regarding the predictive and preventive aspects for 
tailored healthcare. 
  
123 
 
Appendix A 
 
This appendix outline the publications resulting from this work in the next pages. 
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Appendix B 
 
The following table contains a subset of the KIR and disease associations used in the 
analysis presented in Chapter 2. 
PMID Country KIR Association Disease Class Disease Name 
24185760 Canada 2DL2 Susceptibility Autoimmune Arthritis, Psoriatic 
24185760 Canada 2DS2 Susceptibility Autoimmune Arthritis, Psoriatic 
17882223 Poland 2DL1 Susceptibility Autoimmune Arthritis, Rheumatoid 
26658904 Iran 2DL1 Susceptibility Autoimmune Arthritis, Rheumatoid 
26658904 Iran 2DL2 Protection Autoimmune Arthritis, Rheumatoid 
24912006 India 2DL2 Protection Autoimmune Arthritis, Rheumatoid 
16641046 Taiwan 2DL2 Susceptibility Autoimmune Arthritis, Rheumatoid 
22960345 Mexico 2DL2 Susceptibility Autoimmune Arthritis, Rheumatoid 
27251940 Mexico 2DL2 Susceptibility Autoimmune Arthritis, Rheumatoid 
22960345 Mexico 2DL3 Protection Autoimmune Arthritis, Rheumatoid 
24912006 India 2DL3 Protection Autoimmune Arthritis, Rheumatoid 
17882223 Poland 2DL3 Susceptibility Autoimmune Arthritis, Rheumatoid 
26658904 Iran 2DL5 Protection Autoimmune Arthritis, Rheumatoid 
24912006 India 2DP1 Protection Autoimmune Arthritis, Rheumatoid 
26658904 Iran 2DP1 Susceptibility Autoimmune Arthritis, Rheumatoid 
17882223 Poland 2DS2 Protection Autoimmune Arthritis, Rheumatoid 
26658904 Iran 2DS2 Protection Autoimmune Arthritis, Rheumatoid 
16641046 Taiwan 2DS2 Susceptibility Autoimmune Arthritis, Rheumatoid 
22960345 Mexico 2DS2 Susceptibility Autoimmune Arthritis, Rheumatoid 
24912006 India 2DS2 Susceptibility Autoimmune Arthritis, Rheumatoid 
26658904 Iran 2DS4 Susceptibility Autoimmune Arthritis, Rheumatoid 
26658904 Iran 2DS5 Protection Autoimmune Arthritis, Rheumatoid 
24912006 India 3DL1 Protection Autoimmune Arthritis, Rheumatoid 
26658904 Iran 3DL1 Susceptibility Autoimmune Arthritis, Rheumatoid 
26658904 Iran 3DP1 Susceptibility Autoimmune Arthritis, Rheumatoid 
26658904 Iran 3DS1 Protection Autoimmune Arthritis, Rheumatoid 
24912006 India 3DS1 Susceptibility Autoimmune Arthritis, Rheumatoid 
26334461 Turkey 2DL2 Protection Autoimmune Celiac Disease 
22180175 Italy 2DL2 Susceptibility Autoimmune Celiac Disease 
26334461 Turkey 2DP1 Protection Autoimmune Celiac Disease 
26334461 Turkey 2DS2 Protection Autoimmune Celiac Disease 
22180175 Italy 2DS2 Susceptibility Autoimmune Celiac Disease 
26334461 Turkey 2DS4 Protection Autoimmune Celiac Disease 
26334461 Turkey 2DS5 Susceptibility Autoimmune Celiac Disease 
22180175 Italy 3DL1 Protection Autoimmune Celiac Disease 
26334461 Turkey 3DL1 Protection Autoimmune Celiac Disease 
22180175 Italy 3DL2 Protection Autoimmune Celiac Disease 
26334461 Turkey 3DS1 Protection Autoimmune Celiac Disease 
26334461 Turkey 3DS1 Susceptibility Autoimmune Celiac Disease 
20036705 Brazil 2DL2 Protection Autoimmune Colitis, Ulcerative 
16929347 
United 
Kingdom 2DL2 Susceptibility Autoimmune Colitis, Ulcerative 
16929347 
United 
Kingdom 2DS2 Susceptibility Autoimmune Colitis, Ulcerative 
19789864 United States 2DL2 Protection Autoimmune Crohn Disease 
26542067 Spain 2DL2 Protection Autoimmune Crohn Disease 
26542067 Spain 2DL3 Susceptibility Autoimmune Crohn Disease 
26542067 Spain 2DS2 Protection Autoimmune Crohn Disease 
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15699512 Latvia 2DL1 Protection Autoimmune Diabetes Mellitus, Type 1 
14514651 Netherlands 2DL1 Protection Autoimmune Diabetes Mellitus, Type 1 
22069276 China 2DL1 Protection Autoimmune Diabetes Mellitus, Type 1 
21909837 
United 
Kingdom 2DL1 Protection Autoimmune Diabetes Mellitus, Type 1 
20580654 Brazil 2DL1 Protection Autoimmune Diabetes Mellitus, Type 1 
17174747 Finland 2DL1 Susceptibility Autoimmune Diabetes Mellitus, Type 1 
21909837 
United 
Kingdom 2DL1 Susceptibility Autoimmune Diabetes Mellitus, Type 1 
17445178 Netherlands 2DL2 Susceptibility Autoimmune Diabetes Mellitus, Type 1 
20580654 Brazil 2DL2 Susceptibility Autoimmune Diabetes Mellitus, Type 1 
26031759 India 2DL2 Susceptibility Autoimmune Diabetes Mellitus, Type 1 
17445178 Netherlands 2DL3 Protection Autoimmune Diabetes Mellitus, Type 1 
22069276 China 2DL3 Protection Autoimmune Diabetes Mellitus, Type 1 
21909837 
United 
Kingdom 2DL3 Protection Autoimmune Diabetes Mellitus, Type 1 
26031759 India 2DL3 Protection Autoimmune Diabetes Mellitus, Type 1 
17445178 Netherlands 2DL3 Susceptibility Autoimmune Diabetes Mellitus, Type 1 
22069276 China 2DL3 Susceptibility Autoimmune Diabetes Mellitus, Type 1 
21909837 
United 
Kingdom 2DL3 Susceptibility Autoimmune Diabetes Mellitus, Type 1 
26031759 India 2DL3 Susceptibility Autoimmune Diabetes Mellitus, Type 1 
19046302 Latvia 2DL5 Susceptibility Autoimmune Diabetes Mellitus, Type 1 
17445178 Netherlands 2DL5 Susceptibility Autoimmune Diabetes Mellitus, Type 1 
21909837 
United 
Kingdom 2DS1 Protection Autoimmune Diabetes Mellitus, Type 1 
19046302 Latvia 2DS1 Susceptibility Autoimmune Diabetes Mellitus, Type 1 
17445178 Netherlands 2DS1 Susceptibility Autoimmune Diabetes Mellitus, Type 1 
21909837 
United 
Kingdom 2DS1 Susceptibility Autoimmune Diabetes Mellitus, Type 1 
19046302 Latvia 2DS2 Susceptibility Autoimmune Diabetes Mellitus, Type 1 
17445178 Netherlands 2DS2 Susceptibility Autoimmune Diabetes Mellitus, Type 1 
26031759 India 2DS2 Susceptibility Autoimmune Diabetes Mellitus, Type 1 
19046302 Latvia 2DS3 Susceptibility Autoimmune Diabetes Mellitus, Type 1 
17445178 Netherlands 2DS3 Susceptibility Autoimmune Diabetes Mellitus, Type 1 
17174747 Finland 2DS4 Susceptibility Autoimmune Diabetes Mellitus, Type 1 
26031759 India 2DS4 Susceptibility Autoimmune Diabetes Mellitus, Type 1 
14514651 Netherlands 3DL1 Protection Autoimmune Diabetes Mellitus, Type 1 
15699512 Latvia 3DS1 Susceptibility Autoimmune Diabetes Mellitus, Type 1 
19046302 Latvia 3DS1 Susceptibility Autoimmune Diabetes Mellitus, Type 1 
17445178 Netherlands 3DS1 Susceptibility Autoimmune Diabetes Mellitus, Type 1 
20580654 Brazil 3DS1 Susceptibility Autoimmune Diabetes Mellitus, Type 1 
19309280 Lebanon 2DP1 Protection Autoimmune 
Familial Mediterranean 
Fever 
26574972 Turkey 2DS2 Susceptibility Autoimmune 
Familial Mediterranean 
Fever 
24367901 Australia 2DL1 Susceptibility Autoimmune Guillain Barre Syndrome 
27797112 Spain 2DL5 Susceptibility Autoimmune 
Inflammatory Bowel 
Diseases 
27797112 Spain 2DS1 Susceptibility Autoimmune 
Inflammatory Bowel 
Diseases 
27797112 Spain 2DS5 Susceptibility Autoimmune 
Inflammatory Bowel 
Diseases 
27797112 Spain 3DS1 Susceptibility Autoimmune 
Inflammatory Bowel 
Diseases 
19120281  2DL1 Susceptibility Autoimmune 
Latent Autoimmune 
Diabetes in Adults 
19120281  2DL2 Protection Autoimmune 
Latent Autoimmune 
Diabetes in Adults 
19120281  2DL2 Susceptibility Autoimmune 
Latent Autoimmune 
Diabetes in Adults 
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19120281  2DL5 Susceptibility Autoimmune 
Latent Autoimmune 
Diabetes in Adults 
19120281  2DS1 Protection Autoimmune 
Latent Autoimmune 
Diabetes in Adults 
19120281  2DS2 Susceptibility Autoimmune 
Latent Autoimmune 
Diabetes in Adults 
19120281  2DS3 Protection Autoimmune 
Latent Autoimmune 
Diabetes in Adults 
19120281  2DS4 Susceptibility Autoimmune 
Latent Autoimmune 
Diabetes in Adults 
19120281  2DS5 Protection Autoimmune 
Latent Autoimmune 
Diabetes in Adults 
19120281  3DL1 Susceptibility Autoimmune 
Latent Autoimmune 
Diabetes in Adults 
19926642 China 2DL2 Susceptibility Autoimmune 
Lupus Erythematosus, 
Systemic 
20371502 Japan 2DL5 Protection Autoimmune 
Lupus Erythematosus, 
Systemic 
17445179 Canada 2DS1 Susceptibility Autoimmune 
Lupus Erythematosus, 
Systemic 
20371502 Japan 2DS1 Susceptibility Autoimmune 
Lupus Erythematosus, 
Systemic 
19926642 China 2DS1 Susceptibility Autoimmune 
Lupus Erythematosus, 
Systemic 
25581336 China 2DS1 Susceptibility Autoimmune 
Lupus Erythematosus, 
Systemic 
26989167 Iran 3DP1 Susceptibility Autoimmune 
Lupus Erythematosus, 
Systemic 
16508981 Japan 2DS3 Protection Autoimmune Microscopic Polyangiitis 
19630074 Norway 2DL1 Protection Autoimmune Multiple Sclerosis 
22185807 Germany 2DL2 Susceptibility Autoimmune Multiple Sclerosis 
24735502 Tunisia 2DL2 Susceptibility Autoimmune Multiple Sclerosis 
22185807 Germany 2DL3 Protection Autoimmune Multiple Sclerosis 
21665278 Spain 2DL5 Susceptibility Autoimmune Multiple Sclerosis 
19630074 Norway 2DS1 Protection Autoimmune Multiple Sclerosis 
24529855 Portugal 2DS1 Protection Autoimmune Multiple Sclerosis 
22185807 Germany 2DS2 Susceptibility Autoimmune Multiple Sclerosis 
19630074 Norway 2DS4 Susceptibility Autoimmune Multiple Sclerosis 
19630074 Norway 3DL1 Susceptibility Autoimmune Multiple Sclerosis 
21665278 Spain 3DS1 Susceptibility Autoimmune Multiple Sclerosis 
22768326 Brazil 2DL5 Protection Autoimmune Pemphigus Foliaceus 
22768326 Brazil 2DS1 Protection Autoimmune Pemphigus Foliaceus 
22768326 Brazil 2DS3 Protection Autoimmune Pemphigus Foliaceus 
25867094 Brazil 3DL2 Susceptibility Autoimmune Pemphigus Foliaceus 
22768326 Brazil 3DS1 Protection Autoimmune Pemphigus Foliaceus 
26198918 
Australia 3DL1 Susceptibility Autoimmune 
Polyradiculoneuropathy, 
Chronic Inflammatory 
Demyelinating 
15140215 Japan 2DL5 Susceptibility Autoimmune Psoriasis 
18643961 Brazil 2DS1 Susceptibility Autoimmune Psoriasis 
16829306 Poland 2DS1 Susceptibility Autoimmune Psoriasis 
16185272 Sweden 2DS1 Susceptibility Autoimmune Psoriasis 
15140215 Japan 2DS1 Susceptibility Autoimmune Psoriasis 
22024796 
Australia 2DL2 Susceptibility Autoimmune 
Purpura, 
Thrombocytopenic, 
Idiopathic 
24571473 
Australia 2DL2 Susceptibility Autoimmune 
Purpura, 
Thrombocytopenic, 
Idiopathic 
24571473 
Australia 2DL5 Protection Autoimmune 
Purpura, 
Thrombocytopenic, 
Idiopathic 
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22024796 
Australia 2DS2 Susceptibility Autoimmune 
Purpura, 
Thrombocytopenic, 
Idiopathic 
24571473 
Australia 2DS2 Susceptibility Autoimmune 
Purpura, 
Thrombocytopenic, 
Idiopathic 
24571473 
Australia 2DS3 Susceptibility Autoimmune 
Purpura, 
Thrombocytopenic, 
Idiopathic 
24571473 
Australia 2DS5 Protection Autoimmune 
Purpura, 
Thrombocytopenic, 
Idiopathic 
20082621 Brazil 2DL2 Protection Autoimmune Scleroderma, Systemic 
17445179 Canada 2DL2 Susceptibility Autoimmune Scleroderma, Systemic 
17445179 Canada 2DS1 Protection Autoimmune Scleroderma, Systemic 
17445179 Canada 2DS1 Susceptibility Autoimmune Scleroderma, Systemic 
26996109 Iran 2DL1 Protection Autoimmune Spondylitis, Ankylosing 
20652381 China 2DL1 Susceptibility Autoimmune Spondylitis, Ankylosing 
26996109 Iran 2DL1 Susceptibility Autoimmune Spondylitis, Ankylosing 
26996109 Iran 2DL2 Protection Autoimmune Spondylitis, Ankylosing 
26996109 Iran 2DL3 Susceptibility Autoimmune Spondylitis, Ankylosing 
26996109 Iran 2DL5 Protection Autoimmune Spondylitis, Ankylosing 
21797986 Iran 2DL5 Susceptibility Autoimmune Spondylitis, Ankylosing 
20652381 China 2DL5 Susceptibility Autoimmune Spondylitis, Ankylosing 
26996109 Iran 2DS1 Protection Autoimmune Spondylitis, Ankylosing 
21797986 Iran 2DS1 Susceptibility Autoimmune Spondylitis, Ankylosing 
25491925 Spain 2DS1 Susceptibility Autoimmune Spondylitis, Ankylosing 
26996109 Iran 2DS1 Susceptibility Autoimmune Spondylitis, Ankylosing 
26996109 Iran 2DS2 Protection Autoimmune Spondylitis, Ankylosing 
21797986 Iran 3DL1 Protection Autoimmune Spondylitis, Ankylosing 
20574122 Iran 3DL1 Protection Autoimmune Spondylitis, Ankylosing 
22744805 China 3DS1 Susceptibility Autoimmune Spondylitis, Ankylosing 
21797986 Iran 3DS1 Susceptibility Autoimmune Spondylitis, Ankylosing 
25491925 Spain 3DS1 Susceptibility Autoimmune Spondylitis, Ankylosing 
27490240 Japan 2DL2 Protection Autoimmune 
Uveomeningoencephalitic 
Syndrome 
19897003 Japan 2DS1 Susceptibility Autoimmune 
Uveomeningoencephalitic 
Syndrome 
19897003 Japan 2DS2 Protection Autoimmune 
Uveomeningoencephalitic 
Syndrome 
27490240 Japan 2DS2 Protection Autoimmune 
Uveomeningoencephalitic 
Syndrome 
27490240 Japan 2DS3 Protection Autoimmune 
Uveomeningoencephalitic 
Syndrome 
22219647 Saudi Arabia 2DS3 Susceptibility Autoimmune 
Uveomeningoencephalitic 
Syndrome 
19897003 Japan 2DS5 Susceptibility Autoimmune 
Uveomeningoencephalitic 
Syndrome 
19897003 Japan 3DL1 Protection Autoimmune 
Uveomeningoencephalitic 
Syndrome 
27490240 Japan 3DL1 Protection Autoimmune 
Uveomeningoencephalitic 
Syndrome 
21479698 Turkey 2DL1 Protection Cancer Breast Neoplasms 
27631728 Saudi Arabia 2DL1 Protection Cancer Breast Neoplasms 
27631728 Saudi Arabia 2DL1 Susceptibility Cancer Breast Neoplasms 
27631728 Saudi Arabia 2DL2 Protection Cancer Breast Neoplasms 
23792055 Brazil 2DL2 Susceptibility Cancer Breast Neoplasms 
27631728 Saudi Arabia 2DL3 Protection Cancer Breast Neoplasms 
27631728 Saudi Arabia 2DL5 Protection Cancer Breast Neoplasms 
21479698 Turkey 2DS1 Susceptibility Cancer Breast Neoplasms 
27631728 Saudi Arabia 2DS2 Protection Cancer Breast Neoplasms 
27631728 Saudi Arabia 2DS3 Protection Cancer Breast Neoplasms 
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25700262 Italy 2DS4 Susceptibility Cancer Carcinoma, Hepatocellular 
25700262 Italy 3DL1 Susceptibility Cancer Carcinoma, Hepatocellular 
24011088 Australia 2DL2 Protection Cancer 
Cervical Intraepithelial 
Neoplasia 
24011088 Australia 2DS2 Protection Cancer 
Cervical Intraepithelial 
Neoplasia 
26181663 Turkey 2DL1 Protection Cancer Colorectal Neoplasms 
28088355 Brazil 2DL1 Protection Cancer Colorectal Neoplasms 
27519478 Italy 2DL2 Protection Cancer Colorectal Neoplasms 
26181663 Turkey 2DL2 Susceptibility Cancer Colorectal Neoplasms 
26383988 Saudi Arabia 2DL3 Susceptibility Cancer Colorectal Neoplasms 
26383988 Saudi Arabia 2DS1 Susceptibility Cancer Colorectal Neoplasms 
26383988 Saudi Arabia 2DS2 Susceptibility Cancer Colorectal Neoplasms 
26383988 Saudi Arabia 2DS3 Susceptibility Cancer Colorectal Neoplasms 
28088355 Brazil 2DS4 Protection Cancer Colorectal Neoplasms 
24998207 South Korea 2DS5 Susceptibility Cancer Colorectal Neoplasms 
26383988 Saudi Arabia 2DS5 Susceptibility Cancer Colorectal Neoplasms 
24755352 Thailand 3DL1 Protection Cancer 
Diffuse Large B-cell 
Lymphoma 
24755350 Poland 2DL1 Protection Cancer Epithelial Ovarian Cancer 
24755350 Poland 2DL3 Susceptibility Cancer Epithelial Ovarian Cancer 
26495028 Mexico 2DL2 Susceptibility Cancer 
Haematological 
Malignancies 
26983546 Italy 3DL1 Susceptibility Cancer Hodgkin Disease 
26983546 Italy 3DS1 Susceptibility Cancer Hodgkin Disease 
21726204 Poland 3DL1 Protection Cancer 
Leukemia, Lymphocytic, 
Chronic, B-Cell 
21726204 Poland 3DS1 Protection Cancer 
Leukemia, Lymphocytic, 
Chronic, B-Cell 
26472014 India 2DL1 Protection Cancer 
Lymphoblastic Leukemia, 
Acute 
26472014 India 2DL2 Protection Cancer 
Lymphoblastic Leukemia, 
Acute 
26472014 India 2DL3 Protection Cancer 
Lymphoblastic Leukemia, 
Acute 
26472014 India 2DL5 Protection Cancer 
Lymphoblastic Leukemia, 
Acute 
25281696 United States 2DL5 Susceptibility Cancer 
Lymphoblastic Leukemia, 
Acute 
26472014 India 2DS1 Susceptibility Cancer 
Lymphoblastic Leukemia, 
Acute 
25281696 United States 2DS1 Susceptibility Cancer 
Lymphoblastic Leukemia, 
Acute 
26472014 India 2DS2 Susceptibility Cancer 
Lymphoblastic Leukemia, 
Acute 
26472014 India 2DS3 Susceptibility Cancer 
Lymphoblastic Leukemia, 
Acute 
25281696 United States 2DS3 Susceptibility Cancer 
Lymphoblastic Leukemia, 
Acute 
26472014 India 2DS4 Susceptibility Cancer 
Lymphoblastic Leukemia, 
Acute 
26472014 India 2DS5 Susceptibility Cancer 
Lymphoblastic Leukemia, 
Acute 
26472014 India 3DL1 Protection Cancer 
Lymphoblastic Leukemia, 
Acute 
24518758 United States 3DL1 Susceptibility Cancer 
Lymphoblastic Leukemia, 
Acute 
26472014 India 3DS1 Susceptibility Cancer 
Lymphoblastic Leukemia, 
Acute 
24518758 United States 3DS1 Susceptibility Cancer 
Lymphoblastic Leukemia, 
Acute 
25699652 Turkey 2DS1 Susceptibility Cancer Lymphoma, Non-Hodgkin 
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25699652 Turkey 3DL1 Susceptibility Cancer Lymphoma, Non-Hodgkin 
25699652 Turkey 3DS1 Protection Cancer Lymphoma, Non-Hodgkin 
27141379 Spain 2DL1 Protection Cancer Multiple Myeloma 
27141379 Spain 2DL3 Protection Cancer Multiple Myeloma 
27141379 Spain 2DS4 Protection Cancer Multiple Myeloma 
27141379 Spain 3DL1 Protection Cancer Multiple Myeloma 
26202659 Ireland 2DL2 Susceptibility Cancer Neuroblastoma 
26202659 Ireland 2DS2 Susceptibility Cancer Neuroblastoma 
24818561 India 2DL3 Protection Cancer 
Oral Squamous Cell 
Carcinoma 
26268853 Italy 3DS1 Susceptibility Cancer Sarcoma, Kaposi 
25978047 Brazil 2DL2 Protection Infectious Chagas Disease 
25978047 Brazil 3DL2 Protection Infectious Chagas Disease 
24737799 Italy 2DS2 Protection Infectious 
Cytomegalovirus 
Infections 
24498996 Brazil 2DL5 Susceptibility Infectious Dengue 
26385514 India 3DL1 Susceptibility Infectious Dengue 
25966757 China 2DL2 Susceptibility Infectious 
Epstein-Barr Virus 
Infections 
25966757 China 2DL5 Susceptibility Infectious 
Epstein-Barr Virus 
Infections 
25966757 China 2DS2 Susceptibility Infectious 
Epstein-Barr Virus 
Infections 
25966757 China 2DS4 Susceptibility Infectious 
Epstein-Barr Virus 
Infections 
25966757 China 3DS1 Protection Infectious 
Epstein-Barr Virus 
Infections 
20878400 Gabon 2DS1 Susceptibility Infectious Hemorrhagic Fever, Ebola 
20878400 Gabon 2DS3 Protection Infectious Hemorrhagic Fever, Ebola 
20878400 Gabon 2DS3 Susceptibility Infectious Hemorrhagic Fever, Ebola 
20878400 Gabon 2DS4 Protection Infectious Hemorrhagic Fever, Ebola 
24407110 Turkey 2DL3 Protection Infectious Hepatitis B 
18074414 China 2DL5 Protection Infectious Hepatitis B 
18074414 China 2DL5 Susceptibility Infectious Hepatitis B 
18074414 China 2DS1 Protection Infectious Hepatitis B 
18074414 China 2DS2 Susceptibility Infectious Hepatitis B 
18074414 China 2DS3 Susceptibility Infectious Hepatitis B 
27019428 India 2DS5 Protection Infectious Hepatitis B 
18074414 China 2DS5 Susceptibility Infectious Hepatitis B 
18074414 China 3DS1 Protection Infectious Hepatitis B 
24407110 Turkey 3DS1 Protection Infectious Hepatitis B 
26945896 Netherlands 2DL2 Protection Infectious Hepatitis B, Chronic 
26945896 Netherlands 2DL3 Susceptibility Infectious Hepatitis B, Chronic 
20643584 China 2DL1 Susceptibility Infectious Hepatitis C 
16571411 Spain 2DL2 Protection Infectious Hepatitis C 
17445180 Argentina 2DL2 Protection Infectious Hepatitis C 
21931540 Australia 2DL2 Protection Infectious Hepatitis C 
17445180 Argentina 2DL2 Susceptibility Infectious Hepatitis C 
19846535 Spain 2DL2 Susceptibility Infectious Hepatitis C 
23569404 Brazil 2DL2 Susceptibility Infectious Hepatitis C 
20077564 
United 
Kingdom 2DL3 Protection Infectious Hepatitis C 
19846535 Spain 2DL3 Protection Infectious Hepatitis C 
21931540 Australia 2DL3 Protection Infectious Hepatitis C 
20643584 China 2DL3 Protection Infectious Hepatitis C 
18289678 United States 2DL3 Protection Infectious Hepatitis C 
16571411 Spain 2DL3 Susceptibility Infectious Hepatitis C 
21931540 Australia 2DL3 Susceptibility Infectious Hepatitis C 
18289678 United States 2DL3 Susceptibility Infectious Hepatitis C 
20456039 Brazil 2DL5 Susceptibility Infectious Hepatitis C 
21931540 Australia 2DS1 Protection Infectious Hepatitis C 
17445180 Argentina 2DS2 Susceptibility Infectious Hepatitis C 
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23569404 Brazil 2DS2 Susceptibility Infectious Hepatitis C 
17445180 Argentina 2DS3 Susceptibility Infectious Hepatitis C 
21402922 Ireland 2DS3 Susceptibility Infectious Hepatitis C 
23569404 Brazil 2DS3 Susceptibility Infectious Hepatitis C 
17445180 Argentina 2DS4 Protection Infectious Hepatitis C 
19552960 Puerto Rico 2DS4 Protection Infectious Hepatitis C 
17445180 Argentina 2DS5 Susceptibility Infectious Hepatitis C 
20456039 Brazil 2DS5 Susceptibility Infectious Hepatitis C 
17445180 Argentina 3DL1 Protection Infectious Hepatitis C 
15942906 Spain 3DS1 Protection Infectious Hepatitis C 
25636579 Poland 2DS2 Protection Infectious Hepatitis C, Chronic 
17559579 Spain 2DL2 Susceptibility Infectious Herpes Simplex 
17559579 Spain 2DS2 Susceptibility Infectious Herpes Simplex 
27930093 Zimbabwe 2DL2 Protection Infectious HIV Infections 
27148256 China 2DL2 Protection Infectious HIV Infections 
22073315 Italy 2DL3 Protection Infectious HIV Infections 
26888639 Poland 2DL3 Protection Infectious HIV Infections 
26255774 India 2DL3 Protection Infectious HIV Infections 
17082569 Cote d Ivoire 2DL3 Susceptibility Infectious HIV Infections 
27148256 China 2DL5 Protection Infectious HIV Infections 
26888639 Poland 2DL5 Susceptibility Infectious HIV Infections 
22073315 Italy 2DS1 Susceptibility Infectious HIV Infections 
27148256 China 2DS2 Protection Infectious HIV Infections 
27148256 China 2DS4 Protection Infectious HIV Infections 
26255774 India 2DS5 Protection Infectious HIV Infections 
27148256 China 2DS5 Protection Infectious HIV Infections 
15784466 Zambia 3DL1 Protection Infectious HIV Infections 
17082569 Cote d Ivoire 3DL1 Protection Infectious HIV Infections 
26033692 Mexico 3DL1 Protection Infectious HIV Infections 
27148256 China 3DL1 Protection Infectious HIV Infections 
18317000 Canada 3DS1 Protection Infectious HIV Infections 
24877146 India 3DS1 Protection Infectious HIV Infections 
26033692 Mexico 3DS1 Protection Infectious HIV Infections 
18778326 Brazil 2DL1 Protection Infectious Leprosy 
25117794 Brazil 2DL1 Protection Infectious Leprosy 
18778326 Brazil 2DL3 Protection Infectious Leprosy 
25117794 Brazil 2DS2 Susceptibility Infectious Leprosy 
18778326 Brazil 2DS3 Susceptibility Infectious Leprosy 
18778326 Brazil 3DL2 Susceptibility Infectious Leprosy 
22715396 Kenya 2DL1 Susceptibility Infectious Malaria 
22715396 Kenya 2DL2 Protection Infectious Malaria 
22715396 Kenya 2DL2 Susceptibility Infectious Malaria 
22715396 Kenya 2DL3 Protection Infectious Malaria 
22412373 Thailand 2DL3 Susceptibility Infectious Malaria 
22715396 Kenya 2DL3 Susceptibility Infectious Malaria 
24929143 Nigeria 2DL5 Protection Infectious Malaria 
22412373 Thailand 2DS1 Protection Infectious Malaria 
22412373 Thailand 2DS1 Susceptibility Infectious Malaria 
24929143 Nigeria 2DS3 Protection Infectious Malaria 
24929143 Nigeria 2DS3 Protection Infectious Malaria 
19859704 
Solomon 
Islands 2DS4 Susceptibility Infectious Malaria 
24929143 Nigeria 2DS5 Protection Infectious Malaria 
24929143 Nigeria 2DS5 Protection Infectious Malaria 
19859704 
Solomon 
Islands 3DL1 Susceptibility Infectious Malaria 
21889618 India 3DL1 Susceptibility Infectious Malaria 
25188020 Italy 2DL3 Protection Infectious Papillomavirus Infections 
22958291 china 2DL3 Protection Infectious Syphilis 
22958291 china 2DS3 Susceptibility Infectious Syphilis 
22128817 China 2DS4 Susceptibility Infectious Syphilis 
22958291 china 2DS5 Protection Infectious Syphilis 
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22958291 china 3DS1 Susceptibility Infectious Syphilis 
26077983 Canada 2DL2 Protection Infectious Tuberculosis 
23073291 India 2DL3 Susceptibility Infectious Tuberculosis 
17092251 Mexico 2DS1 Susceptibility Infectious Tuberculosis 
23073291 India 2DS1 Susceptibility Infectious Tuberculosis 
26077983 Canada 2DS2 Protection Infectious Tuberculosis 
23073291 India 2DS5 Susceptibility Infectious Tuberculosis 
23073291 India 3DL1 Susceptibility Infectious Tuberculosis 
22426166 Iran 3DS1 Protection Infectious Tuberculosis 
22862677 China 2DL2 Protection Infectious Tuberculosis, Pulmonary 
22862677 China 2DL2 Susceptibility Infectious Tuberculosis, Pulmonary 
22862677 China 2DL3 Protection Infectious Tuberculosis, Pulmonary 
22862677 China 2DL3 Susceptibility Infectious Tuberculosis, Pulmonary 
22862677 China 2DS1 Susceptibility Infectious Tuberculosis, Pulmonary 
22653583 China 2DS1 Susceptibility Infectious Tuberculosis, Pulmonary 
22862677 China 2DS3 Susceptibility Infectious Tuberculosis, Pulmonary 
22653583 China 2DS3 Susceptibility Infectious Tuberculosis, Pulmonary 
22862677 China 3DS1 Susceptibility Infectious Tuberculosis, Pulmonary 
22653583 China 3DS1 Susceptibility Infectious Tuberculosis, Pulmonary 
22884899 United States 2DL5 Susceptibility Neurological Autism 
22884899 United States 2DS1 Susceptibility Neurological Autism 
24120931 Italy 2DS2 Susceptibility Neurological Autism 
22884899 United States 2DS4 Susceptibility Neurological Autism 
22884899 United States 2DS5 Susceptibility Neurological Autism 
22884899 United States 3DL1 Protection Neurological Autism 
24120931 Italy 3DL1 Protection Neurological Autism 
22884899 United States 3DL1 Susceptibility Neurological Autism 
22884899 United States 3DS1 Susceptibility Neurological Autism 
21159685 India 2DL1 Protection Pregnancy Abortion, Habitual 
19279038 India 2DL1 Protection Pregnancy Abortion, Habitual 
17617375 China 2DL5 Susceptibility Pregnancy Abortion, Habitual 
19279038 India 2DP1 Protection Pregnancy Abortion, Habitual 
17617375 China 2DS1 Susceptibility Pregnancy Abortion, Habitual 
17617375 China 2DS2 Susceptibility Pregnancy Abortion, Habitual 
21159685 India 2DS2 Susceptibility Pregnancy Abortion, Habitual 
19279038 India 2DS2 Susceptibility Pregnancy Abortion, Habitual 
19279038 India 2DS3 Susceptibility Pregnancy Abortion, Habitual 
21159685 India 2DS4 Protection Pregnancy Abortion, Habitual 
19279038 India 2DS4 Protection Pregnancy Abortion, Habitual 
21159685 India 2DS5 Susceptibility Pregnancy Abortion, Habitual 
19279038 India 3DL1 Protection Pregnancy Abortion, Habitual 
19279038 India 3DS1 Susceptibility Pregnancy Abortion, Habitual 
28069185 United States 2DS1 Susceptibility Pregnancy Abortion, Spontaneous 
28069185 United States 2DS5 Susceptibility Pregnancy Abortion, Spontaneous 
28069185 United States 3DS1 Susceptibility Pregnancy Abortion, Spontaneous 
25561558 Uganda 2DL2 Protection Pregnancy Pre-Eclampsia 
26823774 China 2DL4 Protection Pregnancy Pre-Eclampsia 
25561558 Uganda 2DL5 Protection Pregnancy Pre-Eclampsia 
24911933 China 2DS1 Protection Pregnancy Pre-Eclampsia 
25561558 Uganda 2DS5 Protection Pregnancy Pre-Eclampsia 
21561401 United States 2DL1 Protection Undetermined 
Bone Marrow failure 
syndromes 
21561401 United States 2DL3 Protection Undetermined 
Bone Marrow failure 
syndromes 
21561401 United States 3DL1 Protection Undetermined 
Bone Marrow failure 
syndromes 
27665490 United States 2DL3 Susceptibility Undetermined 
Common Variable 
Immunodeficiency 
27665490 United States 2DL5 Susceptibility Undetermined 
Common Variable 
Immunodeficiency 
27665490 United States 2DS1 Susceptibility Undetermined 
Common Variable 
Immunodeficiency 
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27665490 United States 3DL1 Protection Undetermined 
Common Variable 
Immunodeficiency 
27665490 United States 3DS1 Susceptibility Undetermined 
Common Variable 
Immunodeficiency 
26679162  2DL2 Protection Undetermined Cryptorchidism 
26679162  2DS2 Protection Undetermined Cryptorchidism 
23831511 Poland 2DS1 Protection Undetermined Dermatitis, Atopic 
24122895 Italy 2DL2 Susceptibility Undetermined Diabetes Mellitus, Type 2 
24122895 Italy 2DL3 Protection Undetermined Diabetes Mellitus, Type 2 
24122895 Italy 2DS2 Susceptibility Undetermined Diabetes Mellitus, Type 2 
22509813 China 2DS2 Susceptibility Undetermined Dry Eye Syndrome 
25724317 Poland 2DS5 Protection Undetermined Endometriosis 
21468604 Italy 3DL1 Susceptibility Undetermined 
Fatigue Syndrome, 
Chronic 
21468604 Italy 3DS1 Susceptibility Undetermined 
Fatigue Syndrome, 
Chronic 
22803950 Italy 3DL1 Protection Undetermined 
Hemoglobinuria, 
Paroxysmal 
23777934 India 2DL1 Protection Undetermined Renal Disease 
23777934 India 2DL2 Protection Undetermined Renal Disease 
23777934 India 2DP1 Protection Undetermined Renal Disease 
23777934 India 2DS1 Susceptibility Undetermined Renal Disease 
23777934 India 2DS2 Susceptibility Undetermined Renal Disease 
23777934 India 2DS3 Susceptibility Undetermined Renal Disease 
23777934 India 2DS5 Susceptibility Undetermined Renal Disease 
23777934 India 3DL1 Protection Undetermined Renal Disease 
23777934 India 3DS1 Susceptibility Undetermined Renal Disease 
19850842 United States 2DS5 Protection Undetermined Uveitis, Anterior 
19850842 United States 3DL1 Protection Undetermined Uveitis, Anterior 
19850842 United States 3DL1 Susceptibility Undetermined Uveitis, Anterior 
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Appendix C 
 
The following figures complement Figure 3.9 by showing more detailed comparisons 
between HLA epitope frequencies generated from HLA raw data and HLA haplotype 
frequency data in line plots for each population included in the analysis. 
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